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Abstract 
 
Cleft palate is one of the most common structural birth defects in humans. Hoxa2 is the 
most anteriorly expressed gene of the homeobox family that define the anterior-posterior axis 
during embryonic development. Hoxa2 is expressed in the palatal shelves and plays an intrinsic 
role regulating cell proliferation. Hoxa2-/- mice develop cleft palate, albeit many of the cellular and 
molecular mechanisms remain to be explored. In this thesis, I have tested the hypothesis that 
Hoxa2 inhibits osteogenic differentiation of the palatal mesenchyme. I present here evidence that 
loss of Hoxa2 results in increased canonical BMP signaling dependent osteogenic program 
spatially and temporally in the developing Hoxa2-/- palatal shelves in vivo and in Hoxa2-/- palatal 
mesenchymal cells in vitro.  
 In the second part of this thesis, I investigated the role of a serine protease Htra1, a putative 
downstream target of Hoxa2 in osteogenic differentiation of the palatal mesenchyme. The results 
indicate that Htra1 is a positive regulator of osteogenic differentiation and is upregulated in the 
Hoxa2-/- palatal shelves. In addition, I identified that Runx2, a master regulator of osteogenic 
differentiation, binds to the proximal 5’ flanking region region of Htra1 to induce its expression.  
 Collectively, the data reveals that aberrant osteogenic signaling in the Hoxa2-/- palatal 
shelves due to increased osteoprogenitor commitment and proliferation may lead to cleft palate in 
these mice. In addition, I show for the first time that Htra1 is a novel direct downstream target of 
Runx2 during osteogenic differentiation. In summary, this thesis contributes to a better 
understanding of the cellular and molecular mechanisms governing osteogenic differentiation in 
the palatal mesenchyme during normal palate development and in cleft palate pathogenesis.  
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1. GENERAL INTRODUCTION 
The palate forms the upper roof of the mouth separating the oral and nasal structures. Cleft 
palate is one of the most common congenital birth defects in humans with an incidence of 1 in 700 
to 1 in 1000 live births (Dixon et al., 2011). Children born with this error often have issues with 
suckling, feeding and speech. These children often require multiple surgeries, therefore affecting 
the physiological and psychological part of their early life. Thus, understanding the mechanisms 
of proper palate formation and the cleft palate pathogenesis is of critical importance in future 
prevention or therapy for cleft palate.  
Studies using mouse model, which has a high similarity to human palate development, 
helped to identify several key stages and cellular processes during palate formation (Yu et al., 
2017). In humans, secondary palate development occurs from six weeks to nine weeks, while in 
mice, it begins at embryonic day (E) 11.5 and the palatal fusion is complete by E15.5 (Ferguson, 
1988). By E15.5, the developing palatal bones ossify. During palate development, the vertical 
palatal shelves grow downward along both sides of the tongue, elevate above the tongue and then 
contact with each other resulting in subsequent formation and disintegration of the midline 
epithelial seam. Cleft palate can occur due to failure in any of the aforementioned events during 
palatogenesis. While the structural changes during palate development are well defined, there is a 
scarcity of knowledge on the molecular mechanisms governing the patterning of the palate. 
Hox genes play vital roles in defining the anterior-posterior axis during development. 
Hoxa2 is the most anteriorly expressed Hox gene with its anterior limit at the rhombomeres r1/r2 
boundary (Krumlauf, 1993). However, Hoxa2 is not expressed in cranial neural crest cells that 
emigrate from rhombomeres r1/r2 boundary to populate the first pharyngeal arch (Prince and 
Lumsden, 1994), which makes first pharyngeal arch devoid of Hox gene expression (Köntges and 
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Lumsden, 1996). Mutation in the Hoxa2 gene is associated with cleft palate in humans (Alasti et 
al., 2008) and animal models (Gendron-Maguire et al., 1993; Rijli et al., 1993). Previously, cleft 
palate in the Hoxa2-/- mice was attributed to the tongue musculature in these mice, as Hoxa2 is not 
expressed in the cranial neural crest cells of first pharyngeal arch, which give rise to the palate 
(Barrow and Capecchi 1999). However, our group previously demonstrated that Hoxa2 is 
expressed in palatal shelves (Nazarali et al., 2000) and plays a direct role in secondary palate 
development by regulating cell proliferation (Smith et al., 2009; Okello et al., 2017). Hence, Hoxa2 
expression in the migrating cranial neural crest cells from rhombomere 1 and rhombomere 2 does 
not appear to be a pre-requisite for its role in palatogenesis, and tongue musculature is unlikely to 
be the causative for the cleft palate phenotype in the Hoxa2-/- mice (Smith et al., 2009).  
The maxillary region comprises of pairs of premaxilla, maxilla and palatine bones, which 
are all derived from the cranial neural crest cells through intramembranous ossification (Iwata et 
al, 2010). Hoxa2 is a known inhibitor of osteoblast differentiation in the second pharyngeal arch 
(Kanzler et al., 1998), in calvaria (Dobreva et al., 2006), in long bones (Deprez et al., 2012) and 
in ST2 stromal cells (Hu et al., 2011).  However, the mechanism involved in regulation of palate 
development by Hoxa2 is largely unknown.  In this study, I used a combination of in vivo and in 
vitro approaches to study the role of Hoxa2 in osteoblast differentiation of the palatal mesenchyme. 
My results suggest that Hoxa2 plays a crucial role in regulating the spatial and temporal expression 
of osteoblast markers via inhibiting bone morphogenetic protein (BMP) signaling in the 
developing palatal shelves.  
High Temperature Requirement Factor A- HTRA1 and HTRA3 belong to the conserved 
family of serine proteases that mediate proliferation, apoptosis and epithelial-mesenchymal 
transition in cancer as tumor suppressor genes (Chien et al., 2004; Wang et al., 2012; Xia et al., 
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2013). A previous finding from our group showed that HOXA2 acts as a transcriptional repressor 
of Htra family members by binding to the intronic region to inhibit the expression during spinal 
cord development (Yan, 2008). Here, I examined the expression pattern of Htra1 and Htra3 during 
palatogenesis. Htra1 is expressed in osteoblasts (Tocharus et al., 2004) and its role in osteoblast 
differentiation remains elusive. Hence, I investigated the role of Htra1 in osteoblast differentiation 
of mesenchymal cells from the palate. My results support the role of Htra1 as an inducer of 
osteoblast differentiation and the data reveal that Htra1 is a putative direct downstream target of 
Runx2 during osteoblast differentiation.   
1.1 Hypothesis 
Hoxa2 inhibits BMP-dependent osteogenic differentiation of the palatal mesenchyme spatially and 
temporally and its putative downstream target Htra1 is a positive regulator of osteogenic 
differentiation in the palatal mesenchyme induced by Runx2.  
1.2 Objectives 
1) To determine the role of Hoxa2 in osteoblast differentiation of the palatal mesenchyme in vivo 
and in vitro. 
2) To examine the spatiotemporal expression of Htra3 during mouse palate development and to 
determine whether Htra3 plays a role in the degradation of midline epithelial seam for palatal 
fusion using lentiviral aided small interfering-RNA (siRNA). 
3) To determine the role of Htra1 in osteogenic differentiation of mouse embryonic palatal 
mesenchymal cells (MEPM) cells. 
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1.3 Overview of chapters 
Chapter 3 is focussed on the role of Hoxa2 as an inhibitor of osteogenic differentiation in the 
palatal mesenchyme during development. In this chapter, I have used immunohistochemistry 
(IHC), quantitative real-time PCR (qPCR), Western blot to study osteogenic differentiation of the 
palatal mesenchyme before and after palatal fusion in the wild-type and Hoxa2 null embryos. In 
addition, mouse embryonic palatal mesenchymal (MEPM) cells from wild-type and Hoxa2-/- mice 
were differentiated to osteoblasts to determine the role of Hoxa2 in osteogenic differentiation of 
the palatal mesenchyme. The data indicate that loss of Hoxa2 leads to accelerated osteogenic 
differentiation due to enhanced BMP signaling-dependent osteogenic program. This finding was 
published in Frontiers in Physiology in 2017. I designed the study, performed experiments, 
analyzed the data, and wrote the manuscript. Dr. Adil J. Nazarali was the senior author who 
conceived, coordinated the study and after his passing away, I corresponded the manuscript for 
publication. 
Chapter 4 explores the temporal expression pattern of two Htra serine proteases Htra1 and Htra3, 
which are previously identified targets of Hoxa2. Furthermore, Htra1 and Htra3 are known to 
inhibit TGFβ signaling in other systems. Given the importance of TGFβ signaling in cell 
proliferation, osteogenic differentiation, and fusion during palatogenesis, the expression patterns 
of Htra1 and Htra3 during palatogenesis are explored in this chapter using qPCR and Western 
blot. The data indicate that the expressions of Htra1 and Htra3 increase during palatogenesis. IHC 
staining shows that Htra3 is mainly expressed in the palatal epithelia and in the midline epithelial 
seam, which may be indicative that Htra3 might play a significant role in palatal fusion. The 
expression of Htra3 in the osteogenic centers of the palatal mesenchyme may be indicative of the 
role of Htra3 in osteogenic differentiation. These data have not yet been submitted for publication. 
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I designed and performed the experiments in this chapter and analyzed the data. Dr. Adil J. 
Nazarali was the senior author conceived and coordinated the study. 
Chapter 5 deals with the functional role of Htra1 during osteogenic differentiation of the palatal 
mesenchyme. IHC staining indicates that Htra1 is mainly expressed in the osteogenic domains of 
the craniofacial bones during development. The gain of function of Htra1 in MEPM cells results 
in increased matrix deposition and mineralization in vitro. Based on the similarity in the expression 
profile of Htra1 and Runx2, I investigated the molecular interaction between Htra1 and Runx2 
during osteogenic differentiation of the palatal mesenchyme. The data reveal that Htra1 is a direct 
transcriptional target of Runx2. RUNX2 binds to the proximal promoter region of Htra1 to induce 
its expression during osteogenic differentiation. The data from this chapter are written and are 
about to be submitted to the journal Osteoarthritis and Cartilage. I designed, performed 
experiments, analyzed the data and wrote the manuscript. Adil J. Nazarali was the senior author 
who conceived and coordinated the study. Merlin P. Thangaraj assisted in performing the 
luciferase assay and osteogenic arrays, while I performed the experiments. B. Frank Eames was 
involved in the conception of the study and critical analysis of the data and in manuscript revisions.  
 Appendix at the end of the thesis has published papers from this thesis and related work.   
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2. REVIEW OF LITERATURE 
Cleft palate is one of the most common congenital birth defects in humans with both 
environmental and genetic factors playing a crucial role in the pathogenesis (Dixon et al., 2011). 
Palate development requires precise regulation of gene expression changes, morphogenetic 
movements and alterations in cell physiology (Murray and Schutte, 2004). In mice, secondary 
palate arises from the maxillary prominences (Mxp) at E11.5. The palatal shelves grow vertically 
downward on either side of the tongue until E14, during which the palatal shelves elevate to 
reorient above the tongue (Figure 2.1) (Ferguson, 1987). At E14.5, the palatal shelves contact each 
other forming MES. The MES subsequently undergoes rapid degeneration by apoptosis and 
epithelial-mesenchymal transition leading to mesenchymal confluence at E15.5 (Ferguson 1987) 
(Figure 2,1). By E15.5, the anterior palatal mesenchyme begins to ossify leading to the formation 
of the palatal process of maxilla (Nelson et al., 2011), while the palatal process of the palatine 
bone ossifies early at E13.5 (Wu et al., 2008). Cleft palate may result from failure in any of the 
critical events such as vertical growth, elevation and reorientation above the tongue, contact of the 
palatal shelves to form MES, degradation of the MES and consolidation of the mesenchymal 
confluence. In addition, abnormal osteogenic differentiation prior to the elevation of palatal 
shelves has been associated with the manifestation of cleft palate (Fu et al., 2017; Jia et al., 2017a, 
b).  
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Figure 2.1 Schematics showing the stages of palate development in mice. At E12.5, the palatal 
shelves which arose from the Mxp lie on either side of the tongue. At E13.5, the palatal shelves 
grow vertically downward and at E14.0 the palatal shelves elevate above the tongue. At E14.5, the 
palatal shelves grow horizontally and contact each other to form MES. At E15.5, the MES is 
degraded to result in mesenchymal confluence, which ensures that the palatal fusion is complete. 
At this stage the developing palatine bone starts to ossify as well. T, tongue; P, palatal shelf, MES, 
midline epithelial seam.   
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 The developing secondary palate is composed of mesenchymal cells mainly derived from 
cranial neural crest cells (Ito et al., 2003) covered by multilayered epithelia from the facial 
ectoderm (Noden, 1983). Palatal epithelia are heterogeneous, with epithelia on the oral side made 
up of stratified, keratinizing, squamous cells, while the nasal side is of pseudo-stratified, ciliated, 
columnar cells (Ferguson, 1987; Han et al., 2009). Initially, the cranial neural crest cells derived 
mesenchyme was regarded as a homogenous cell population. However, several findings highlight 
the demarcations amongst the mesenchymal cells on the oro-nasal axis. Nasal side mesenchyme 
of the palate is marked by the expression of distal-Less homeobox 5 (Dlx5), fibroblast growth 
factor 7 (Fgf7) and canonical Bmp signaling mediated by pSMAD 1/5/8, whereas the oral side 
mesenchyme is occupied by the expressions of glioma-associated oncogene homolog 1 (Gli1) and 
Fgf10 (Han et al., 2009). In addition, sonic hedgehog (Shh) is expressed on the oral side of the 
palatal epithelia (Han et al., 2009). These signaling molecules demarcate the nasal and oral sides 
of the palate that would form the prospective palatal bones and soft tissues respectively.  
In mammals, the palate tissue can be distinguished into anterior bony hard palate and 
posterior soft palate. Hard palate is required for speech and swallowing, while the soft palate is 
necessary for occlusion (Bush and Jiang, 2012; Smith et al., 2013). Regional heterogeneity at the 
molecular and cellular level along the A-P axis and oral-nasal (dorsal ventral) axis is a hallmark 
of murine secondary palate development (Hilliard et al., 2005; Bush and Jiang, 2012; Smith et al., 
2013). Several networks and signaling pathways have been found to be anterior (Msx1, Bmp4, Shh, 
Bmp2, Fgf10, Fgf7 and Shox2) (Figure 2.2) or posterior specific (Meox2, Mn1, Tbx22 and Barx1) 
(Figure 2.3) in the developing palatal shelves (Hilliard et al., 2005; Bush and Jiang, 2012; Smith 
et al., 2013).  
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2.1 Anterior palate specific gene expressions 
 The anterior palate was initially considered as a signaling center involving multiple 
networks and signaling pathways coordinating proper palate development (Figure 2.2) (Smith et 
al., 2013). Failure in cell proliferation leading to defect in growth or elevation of the palatal shelves 
in the anterior palate would result in a complete cleft palate rather than an anterior palatal cleft 
(Smith et al., 2013). For example, deletion of an anterior palate specific gene Msx1, results in overt 
cleft palate along the A-P axis in Msx1-/- mice (Zhang et al., 2002).  Consistent with the structure 
and function of the anterior palate to form the palatal bones, BMP signaling, and related 
transcription factor networks play vital roles in the anterior palatal morphogenesis. 
2.1.1 Msx1 network 
Msh (Drosophila) homeo box homolog 1 (Msx1) was the first gene reported as expressed 
specifically in the anterior palate. Despite the exclusive expression on the anterior palate (Zhang 
et al., 2002), Msx1-/- mice develop overt cleft palate along A-P axis (Satokata and Maas, 1994; 
Zhang et al., 2002). Msx1 is required for the expression of Bmp4, Shh and Bmp2 in the anterior 
palate to regulate cell proliferation (Figure 2.2). Interestingly, mice expressing a Bmp4 transgene 
could rescue the cleft palate phenotype of Msx1-/- mutants. Also, Bmp4 in turn induces the 
expression of Msx1 in the anterior palate but not in the posterior palate (Zhang et al., 2002). Since 
then numerous findings have explored the role of this network in the anterior palate cell 
proliferation.  
2.1.2 Shh 
Shh is expressed in oral side epithelium of the palatal shelves, which is involved in rugae 
patterning (Rice et al., 2006). Rugae are the epithelial ridges present on the oral side of the palate, 
10 
 
which were initially considered as the signaling centre coordinating several signaling molecules 
to regulate cell proliferation during secondary palate development (Welsh and O’Brien, 2009). 
Transgenic mice with deletion of Shh in the epithelia (K14-Cre; Shhfl/fl) develop cleft palate with 
an incidence of 70-85% (Rice et al., 2004; Lan and Jiang, 2009). SHH in the palatal epithelia 
signals through Smoothened (SMO), a transmembrane protein in the mesenchyme, to induce Fgf10 
expression to positively regulate cell proliferation (Lan and Jiang, 2009). Shh regulates the 
downstream expression of Bmp2 in the palatal mesenchyme for cell proliferation (Figure 2.2) (Rice 
et al., 2004). SHH signaling regulates Forkhead Box (Fox) family of transcription factors Foxf1, 
Foxf2 and Osr2 in the palatal mesenchyme and deletion of Smo gene in the palatal mesenchyme 
(Osr2-IresCre; Smofl/fl) results in downregulation of Foxf1, Foxf2 and Osr2 (Lan et al., 2004). 
Foxf1 is mainly expressed in the mesenchyme along the middle region of the palatal shelves, 
whereas Foxf2 is expressed in the mesenchyme throughout the anterior-posterior axis during 
palatogenesis (Xu et al., 2016). Deletion of Foxf1 (Wnt1-Cre; Foxf1fl/fl) or Foxf2 in the cranial 
neural crest cells (Wnt1-Cre; Foxf2 fl/fl) results in cleft palate manifestation due to reduced cell 
proliferation (Xu et al., 2016). In the Foxf2 mutants (Wnt1-Cre; Foxf2 fl/fl), the expression of Shh 
and Shox2 are downregulated in the very anterior and posterior regions of the palate, in contrast 
Fgf18 mRNA was upregulated in the corresponding regions. In the Foxf1; Foxf2 double mutants 
(Wnt1-Cre; Foxf1 fl/fl Foxf2 fl/fl), there was a significant upregulation of Fgf18 along the anterior-
posterior axis of the palate with concomitant downregulation of Shh with complete lack of rugae 
formation (Xu et al., 2016). These new lines of evidence suggest that Foxf1 and Foxf2 are 
redundant in repressing Fgf18 to regulate Shh expression and cell proliferation downstream of Shh. 
Indeed, some elegant experiments using FGF18 soaked beads on palatal explant cultures 
completely abolished the expression of Shh and rugae formation in the palate (Xu et al., 2016). 
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Wnt1-Cre; Foxf2 fl/fl palatal shelves exhibit reduced TGFβ signaling characterized by pSMAD 2/3 
with the downregulation of TGFβR3. In addition, in the Wnt1-Cre; Foxf2 fl/fl palatal shelves there 
is enhanced activation of non-canonical phospho-p38 signaling, indicating a strong interplay 
between different signaling pathways downstream of SHH in regulating cell proliferation (Nik et 
al., 2016).  
 
Figure 2.2 Schematic representation of the key regulators in the developing anterior palatal 
shelves. Msx1 and Bmp4 function in an autoregulatory loop mechanism in the mesenchyme. Bmp4 
induces Shh expression in the epithelium which signals backs to mesenchyme to positively regulate 
Bmp2 to enhance cell proliferation in the mesenchyme (Zhang et al., 2002). Hoxa2 inhibits Msx1 
expression in early palatal development. Spry2 regulates Fgfs and their receptors for proper 
balance of proliferation and prevention of premature apoptosis in the epithelium. Fgf10 induces 
Shh where as Fgf7 acts as an antagonist. Genes represented in red are restricted to either oral or 
nasal side of the palate, whereas those represented in blue are expressed across the shelf. T, 
Tongue. I drew this figure as part of a review on molecular signaling along the anterior-posterior 
axis during palate development that was published (Smith et al., 2013). 
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2.1.3 Dlx5 
Distal-less homeobox-5 (Dlx5) is expressed in the nasal side (medial) mesenchyme in the 
middle region of the palate in the preosteoblast region at E13.5 (Han et al., 2009). In addition to 
other craniofacial defects, Dlx5-/- mutants develop cleft of the secondary palate with an incidence 
of 88% (Levi et al., 2006). In these mice, the horizontal laminae of the palatal bones are missing 
(Acampora et al., 1999).  Interestingly, deletion of Dlx5 rescues the cleft palate phenotype of Msx1-
/- mice (Dlx5-/- Msx1-/-) (Levi et al., 2006). Although Msx1 and Dlx5 are expressed in anterior 
palatal mesenchyme, their interaction in the network might be indirect, as Msx1 is not altered in 
the Dlx5-/- mutants and vice-versa (Han et al., 2009). In the wild-type mice, Fgf7 expressed in the 
osteogenic front on the nasal side of the palate could inhibit Shh expression and narrow its domain 
to the oral side epithelia to control cell proliferation (Figure 2.2). Hence the decrease in cell 
proliferation due to the diminished Shh expression in the Msx1-/- mutant is rescued by 
downregulated Fgf7 expression in the Dlx5-/- Msx1-/- double mutants (Han et al., 2009). Moreover, 
increased Bmp7 in the palatal epithelia along the A-P axis as well as decreased BMP antagonist 
Follistatin in the posterior palatal epithelia in the double mutants (Dlx5-/- Msx1-/-) may also account 
for the rescue of cell proliferation and cleft palate in the Dlx5-/- Msx1-/- double mutants (Levi et al., 
2006).  
2.1.4 BMP signaling 
BMP signaling plays a critical role in cell proliferation and osteogenic differentiation during 
palatogenesis (Baek et al., 2011). In Nestin-Cre; Bmpr1afl/fl mutants, in which the bone 
morphogenetic protein receptor Bmpr1a expression is removed from the facial primordia, develop 
cleft lip and cleft palate due to decreased cell proliferation in the Mxp mesenchyme at E11.5 (Liu 
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et al., 2005). Surprisingly, in the palatal shelves of these mice, Msx1 expression was not altered. 
However, there was expansion in the expression domain of posterior specific Barx homeobox 1 
(Barx1) towards the anterior side of the palate (Liu et al., 2005).  In addition, Nestin-Cre; Bmp4fl/fl 
mice exhibit isolated unilateral cleft lip (2/9) without any cleft palate, which highlights the 
redundancy of the BMP ligands in lip fusion and palate development (Liu et al., 2005). Bmpr1a is 
expressed prominently in the anterior palate both in mesenchyme and epithelia, whereas its 
expression is mainly concentrated in the epithelia on the posterior side. Similarly, Bmp1b is 
expressed only in the anterior palatal epithelia and mesenchyme (Li et al., 2011). Deletion of 
Bmpr1a in the cranial neural crest cells (Wnt1-Cre; Bmpr1afl/fl) results in a cleft between the 
primary palate and anterior secondary palate. Constitutive activation of Bmpr1b in the Bmpr1a 
mutants failed to rescue the cleft palate phenotype (Li et al., 2011), although the tooth development 
defect was partially rescued. Wnt1-Cre; Bmpr1afl/fl mice exhibit reduced expression of pSMAD 
1/5/8, Msx1, Bmp4, Pax9 and Short stature homeobox 2 (Shox2) leading to decreased cell 
proliferation in the palatal shelves (Li et al., 2011). Furthermore, the role of Bmpr1a specifically 
in palate development was studied using Osr2-Cre; Bmpr1afl/fl mice in which the expression of 
Bmpr1a was deleted only in the palatal mesenchyme (Baek et al., 2011), as Osr2 is exclusively 
expressed in the oral side of the palatal mesenchyme and in the developing molar tooth buds (Lan 
et al., 2004). Similar to Wnt1-Cre; Bmpr1afl/fl mice, these mice exhibit cleft between the primary 
palate and the anterior secondary palate (Baek et al., 2011) due to decreased cell proliferation in 
the anterior, mid and primary palate. Although Msx1 and Fgf10 were downregulated, Bmp4 and 
Bmp2 were surprisingly upregulated in these mutants, underlining the complex signaling involved 
in this pathway.  In addition, these mice exhibit submucous cleft palate with a failure in the 
initiation of osteogenesis in the palatal process of the maxilla and decrease in the size of the palatal 
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process of the palatine bone (Baek et al., 2011). Surprisingly, constitutive activation of Bmpr1a 
(with Gln203 to Asp) in the cranial neural crest cells (Wnt1-Cre; pMes-caBmpr1a) results in 
ectopic cartilage formation in the posterior side leading to cleft palate (Li et al., 2013). Although 
BMP signaling has been known to induce cell proliferation during palatogenesis, constitutive 
Bmpr1a mutants exhibit reduced cell proliferation in the anterior palate. Msx1, Shox2 and pSMAD 
1/5/8 are all ectopically induced in the posterior palate in the area of cartilage formation. In 
addition, pSMAD1/5/8 expression is shifted from nasal side mesenchyme of the palatal shelves to 
the oral side. Non-canonical Bmp signaling via phospho-p38 Mitogen-activated protein kinase 
(MAPK) and phosphorylated c-Jun N-terminal kinase are also activated in the ectopic cartilage 
formation area in the posterior palatal shelves (Li et al., 2013). Constitutive activation of Bmpr1a 
in the epithelia of the palatal shelves (K14-Cre; pMes-caBmpr1a) leads to cleft palate due to fusion 
of the palatal shelves to the mandible (He, et al., 2010). This phenotype is consistent with that of 
Noggin mutants in the epithelia (K14-Cre; Nogfl/fl) in which the palatal shelves fuse with the 
mandible resulting in cleft palate. Noggin mutant mice exhibit increased cell proliferation in 
anterior palatal epithelia, posterior palatal epithelia and decreased proliferation in anterior palatal 
mesenchyme. Ectopic Bmp2 could at least partially account for the ectopic expression of 
pSMAD1/5/8 in the oral epithelia of these Noggin mutant palates. TGFβ3 induced cell death was 
found in the oral side of the palatal shelves instead of the MES leading to fusion of the palatal 
shelves to the mandible. Similar to the Noggin mutant phenotype, epithelial specific deletion of 
heart and neural crest derivatives expressed 2 (Hand2) (Pitx2-Cre; Hand2fl/fl) leads to cleft palate 
due to fusion of the palatal shelves to the mandible at the posterior side (Xiong et al., 2009). There 
is decreased cell proliferation in the anterior palate of these mice consistent with the decrease in 
expression of Bmp2 and Shh, but not Msx1 and Fgf10, showing that Hand2 could be a downstream 
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target of Msx1. Intriguingly, Noggin inhibits the expression of Hand2 in the palatal shelves (Xiong 
et al., 2009). 
2.1.5 Shox2 
Shox2 is another transcription factor expressed specifically in the anterior palate. Deletion 
of Shox2 in the cranial neural crest cells (Wnt-Cre; Shox2fl/fl) results in cleft between the primary 
palate and the anterior secondary palate, with increased apoptosis and decreased cell proliferation 
in the palatal mesenchyme (Yu et al., 2005). Consistent with this, there is an increase in expression 
of Fgf10 and Fibroblast growth factor receptor 2c (Fgfr2c) covering the entire anterior palatal 
mesenchyme. Also, loss of Noggin in the epithelia (Yu et al., 2005; He et al., 2010) or Bmpr1a in 
the cranial neural crest cells result in the reduction of Shox2 expression in the anterior palatal 
mesenchyme (Li et al., 2011). However, exposure of the palatal mesenchyme to BMP4, BMP2 or 
SHH-soaked beads in vitro is not sufficient to induce Shox2 expression. These suggest that BMP 
signaling is not capable of inducing Shox2 expression on its own but is necessary for Shox2 
expression. 
2.1.6 FGF signaling 
FGF10 is expressed in the oral side mesenchyme of the palate and signals through its 
receptor FGFR2B in the oral side epithelia to induce the expression of Shh (Figure 2) (Rice et al., 
2004; Alappat et al., 2005). Similar to the Noggin and Hand2 mutants, Fgf10 mutant palatal 
shelves in the posterior side fuse with the mandible due to the mislocalization of Tgfβ3 expression 
to the oral side epithelia instead of the MEE. Deletion of Fgfr2 (K14Cre-Fgfr2fl/fl) in the epithelia 
in mice results in cleft palate due to reduced cell proliferation in the palatal epithelia. Consistent 
with this, there is a lack of organized rugae formation due to failure in the expression of Shh 
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(Hosokawa et al., 2009). Also, FGFR1B, another FGF receptor is expressed in the mesenchyme 
of the anterior and posterior palate during development. Fgfr1b regulates cell proliferation by 
inhibiting Wnt11 during the growing stages of palate development. In turn, Wnt11 induces 
apoptosis during fusion of the palatal shelves by inhibiting Fgfr1b (Lee et al., 2008). 
Fgf antagonist Sprouty2 (Spry2) is strongly expressed on the nasal and oral sides of anterior 
palatal mesenchyme and epithelia, with negligible expression in the posterior palate (Welsh et al., 
2007). Mice homozygous for an Mb-scale deletion (pie bald deletion) that removes the Spry2 locus 
exhibit cleft palate with an incidence of 83% and cleft lip with an incidence of 27% (Welsh et al., 
2007). In these mice, there is an increase in cell proliferation accompanied with an expansion in 
the expression domain of anterior specific Msx1 and Ets variant 5 into the posterior palate, whereas 
posterior specific Barx1 is expanded into the anterior palate. Also, T-box 22 (Tbx22) domain in 
the posterior palate is reduced. These mice also have disorganized rugae formation due to 
decreased Shh expression. The antagonism on Fgf9 relieved by the loss of Spry2 may account for 
the expanded and ectopic domain of Msx1 (Welsh et al., 2007). These findings highlight the 
necessary control of FGF gradients to maintain the A-P axis during palatogenesis (Figure 2.4). 
Interestingly, Fgf9 is expressed in the nasal side of the palate (Iwata et al., 2012) and Fgf9-/- mice 
develop cleft palate with an incidence of 40% (Colvin et al., 2002). Recently, FGF9 has been 
shown to induce Pitx2 expression, which in turn activates Cyclin D1 (Ccnd1) and Cyclin D3 
(Ccnd3) expression to promote cell proliferation in the palatal shelves of Wnt1-Cre; Tgfbr2fl/fl 
mice.  
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2.2 Posterior palate specific gene expression 
In contrast to signaling in anterior palate, very little information is available on posterior 
palate specific gene expression. Transcription factors such as MEOX2, TBX22 and BARX1 are 
expressed in the posterior palate (Figure 2.3).  
 
Figure 2.3 Schematic representation of the key regulators in the posterior palate. Barx1 and 
Tbx22 induce cell proliferation in the posterior palate. Hoxa2 also controls the expression of Barx1 
in the early stage of palatogenesis. Meningioma 1 (Mn1) positively regulates Tbx22. Mesenchyme 
homeo box 2 (Meox2) plays a role in fusion of the posterior palate. T, Tongue. This figure is 
published in Smith et al., 2013. 
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2.2.1 Meox2 
Mesenchyme homeo box 2 (Meox2) is expressed in the extreme posterior regions of the 
palate. Meox2-/- mice exhibit a low penetrance of cleft palate (35%) (Jin and Ding, 2006). In these 
mice, palatal shelves grow, elevate and fuse but the fusion is weak that the palatal shelves separate 
from each other resulting in cleft of the posterior palate. TGFβ1 mediated Meox2 induces p21 to 
inhibit cell proliferation in mammary epithelial cells (Valcourt et al., 2007). Interestingly, p21 is 
necessary for Smad4 mediated phospho-p38 MAPK signaling for apoptosis and MES degeneration 
during palatal fusion (Xu et al., 2008). However, whether Meox2 promotes p21 expression in the 
palate remains to be tested to identify the network downstream of Meox2 during palatal fusion in 
the posterior palate.  
2.2.2 Tbx22 
T-box transcription factor 22 (Tbx22) is expressed in the posterior part of the developing 
palatal shelves (Herr et al., 2003). Tbx22-/- mice develop submucous cleft palate with a small 
minority (2/30) exhibiting overt cleft palate (Pauws et al., 2009). Palatal shelves of the Tbx22-/- 
mutants have an aberrant rugae pattern in the posterior half of the hard palate and translucency in 
the posterior rugal regions. Beads soaked with BMP4 protein inhibit Tbx22 expression in palatal 
explant cultures in vitro (Fuchs et al., 2010). Ectopic expression of Msx1 in Spry2 piebald mutants 
coincides with the restricted expression pattern of Tbx22 (Welsh et al., 2007). However, in the 
Msx1-/- mutant palatal shelves, Tbx22 expression is not altered. Hence BMP4 could be regulating 
Tbx22 expression in the posterior palatal shelves through Msx1 independent mechanism.  
 Transcription factor MN1 is expressed in the middle to the posterior regions of the palatal 
shelves (Liu et al., 2008). In Mn1-/- palatal shelves, expression of Tbx22 is reduced in the posterior 
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regions. Mn1-/- mice exhibit cleft palate due to reduced cell proliferation in the middle and posterior 
regions of the palate with reduction in the expression of Ccnd2 (Liu et al., 2008). 
2.2.3 Barx1 
Barx1 is expressed in the posterior regions of the palatal shelves. A-P axis characterized by 
the expression of anterior Msx1 and posterior Barx1 is set up in the pharyngeal arch (PA) where 
Msx1 is expressed in the distal region and Barx1 in the proximal region (Barlow et al., 1999). 
Relative gradients of BMP and FGF signaling maintain the A-P axis in the developing palatal 
shelves (Figure 2.4) (Welsh et al., 2007). Consistently, loss of Bmpr1a in the cranial neural crest 
cells leads to expansion in the region of Barx1 expression. Hoxa2 inhibits Barx1 in the developing 
palatal shelves at E12.5, which may partially account for the elevated cell proliferation in the 
Hoxa2 null palatal shelves (Smith et al., 2009).  
2.3 TGFβ signaling pathway in cell proliferation  
The TGFβ signaling pathway plays a critical role in regulating cell proliferation, apoptosis 
and differentiation during embryonic palate development (Chai et al., 2003). Canonical TGFβ 
signaling is mediated by the binding of ligands (TGFβ1 or TGFβ2 or TGFβ3) to the receptor 
TGFBR2, which initiates the heterodimeric binding of TGFBR1. This heterodimerization leads to 
the phosphorylation of TGFBR1, which in turn phosphorylates the receptor associated SMADs 
such as SMAD2 and/or SMAD3 depending on the context (Chai et al., 2003; Iwata et al., 2011). 
The phosphorylated receptor-associated SMADs then cooperate with SMAD4 to translocate into 
the nucleus to regulate the transcription of downstream target genes. Mutants of TGFβ ligands 
TGFβ2-/- (Sanford et al., 1997) and TGFβ3-/- (Kaartinen et al., 1995; Proetzel et al., 1995) develop 
cleft palate with the incidences of 23% and 100%, respectively.  
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The role of TGFβ signaling in the cranial neural crest cells derived palatal mesenchyme 
has been extensively studied using Wnt1-Cre; Tgfbr2fl/fl mice (Ito et al., 2003; Iwata et al., 2012a; 
Iwata et al., 2012b; Iwata et al., 2014). In addition to other craniofacial defects, Wnt1-Cre; 
Tgfbr2fl/fl mice develop overt cleft palate with complete penetrance. In these mice, there is 
decreased cell proliferation at E14.5 along with diminished expression of Ccnd1 (Ito et al., 2003). 
Loss of Tgfbr2 results in an increase in the mRNA expression of Tgfβ2 and Tgfbr3. In the Tgfbr2 
mutants, upregulated TGFβ2 binds and signals through TGFBR3 to activate non-canonical TGFβ 
signaling via p38 MAPK signaling resulting in defective cell proliferation (Iwata et al., 2012a). 
Neutralizing antibodies against TGFβ2 or TGFBR3 rescue cell proliferation in the Tgfbr2 mutant 
palatal explants. More importantly, the cleft palate phenotype of Tgfbr2 mutants is rescued by the 
haploinsufficiency of Tgfβ2 (82.5%) or Tgfbr1 (91.7%) (Iwata et al., 2012a). In addition, activation 
of phospho-p38 MAPK signaling in the Tgfbr2 mutant palatal shelves results in the decreased 
expression of Fgf9 and Pitx2 (Iwata et al., 2012b). Exogenous addition of FGF9 rescued cell 
proliferation in the Tgfbr2 mutant palatal mesenchymal cells (MEPM) (Iwata et al., 2012b). In 
addition, MEPM cells of the Tgfbr2 mutants in culture display spontaneous accumulation of lipid 
droplets due to failed lipolysis (Iwata et al., 2014). In the MEPM cells of the Tgfbr2 mutants, 
exogenous addition of SHH failed to induce Gli1 expression as well as proliferation. As expected, 
phospho-p38 MAPK signaling is responsible for the impaired SHH signaling in the Tgfbr2 palatal 
shelves. Interestingly, telmisartan (a clinical angiotensin II receptor blocker) rescued the aberrant 
phospho-p38 MAPK signaling, lipid metabolic activity and cell proliferation in the Tgfbr2 mutant 
palatal shelves. More importantly, oral administration of telmisartan (20mg/kg body weight per 
day) to the pregnant dams from E11.5 to E15.5 rescued cleft palate phenotype in the Tgfbr2 
mutants (44%) (Iwata et al., 2014). 
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2.4 TGFβ signaling during palatal fusion 
Transforming growth factors and their receptors play a major role in embryonic palatal 
fusion. Tgfβ3 null mutant mice exhibit complete penetrance of secondary cleft palate, as the palatal 
shelves elevate, make contact but fail to fuse (Proetzel et al., 1995; Kaartinen et al., 1995). While 
numerous recent findings have allowed for a better understanding of cleft palate pathogenesis in 
Tgfβ3 null mice, gaps in our knowledge still remain. TGFβ3 in palatal epithelium induces p-
SMAD2 but not p-SMAD3. Indeed, in Tgfβ3 null mice, phosphorylation of SMAD2 fails to take 
place in the palatal epithelia, which renders the palatal epithelium more proliferative and devoid 
of apoptosis resulting in the persistence of MEE (Cui et al., 2003). TGFβ3 is required for the 
expression of matrix metalloproteinase Mmp-13 in MEE during palatal fusion and loss of Tgfβ3 
leads to reduced expression of Mmp13 in the MEE in Tgfβ3 null mice (Blavier et al., 2001). Our 
group recently reported that knockdown of Mmp-25 in palatal shelves impairs palatal fusion in in 
vitro organ culture system. Also, bio-neutralization of TGFβ3 using specific neutralizing antibody 
results in reduced expression of Mmp-25 (Brown and Nazarali, 2010). In chick embryos, the beak 
physically separates the palatal shelves from contact with each other, resulting in a physiological 
cleft palate. It is pertinent to note that unlike the rodent palatal MEE, the chick MEE is devoid of 
TGFβ3. Addition of TGFβ3, but not TGFβ1 or TGFβ2 proteins, aids in palatal fusion resulting in 
mesenchymal confluence in the chick embryos in palatal organ cultures (Sun et al., 1998). 
Moreover, transgenic mice carrying a knock-in of Tgfβ1 in the Tgfβ3 locus could only partially 
rescue the cleft palate phenotype of Tgfβ3 null mice due to the failure to rescue the reduced 
apoptosis and downregulated expression of Mmp13 (Yang and Kaartinen, 2007). Loss of Tgfβ3 in 
the mutant mice and absence of Tgfβ3 in avian palatal shelves results in failure of induction of 
chondroitin sulfate proteoglycan (Gato et al., 2002) and absence of filopodia (Taya et al., 1999) 
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leading to failure of palatal fusion. Epidermal growth factor (EGF) signaling through epidermal 
growth factor receptor (EGFR) mediated by phosphorylated extracellular signal-regulated kinases 
(p-ERK) is vital for cell proliferation and survival in the palatal epithelium and TGFβ3 is presumed 
to inhibit p-ERK to render the epithelial cells pro-apototic (Yamamoto et al., 2003). However, this 
mechanism has not been characterized yet.  
 TGFβ ligands signal through their receptors, TGFBR1, TGFBR2 and TGFBR3. Among 
these receptors, TGFBR3 (Nakajima et al., 2007) is expressed in palatal epithelium before the 
elevation of the palatal shelves and in the MES at E14.5, whereas TGFBR1 (Dudas et al., 2004) 
and TGFBR2 are expressed in both palatal epithelium and mesenchyme and also in the ossification 
centers of the palatine bone (Cui et al., 1998; Cui and Shuler, 2000). TGFBR3 is important for the 
phosphorylation of SMAD2 (P-SMAD2) and for the disintegration of palatal epithelium during 
palatal fusion in organ culture system in vitro (Nakajima et al., 2007). It is important to note that 
only P-SMAD2, but not P-SMAD3, is expressed in the palatal epithelium during fusion (Cui et 
al., 2003) and inhibition of Smad2 by siRNA in palatal organ culture is sufficient to inhibit palatal 
fusion preventing the MEE from degeneration (Shiomi et al., 2006). Moreover, Keratin 14 
promoter driven overexpression of Smad2 could partially rescue the cleft phenotype in Tgfβ3-/- 
mice (Cui et al., 2005). Activin receptor-like kinase-5 (Alk-5, synonymous to Tgfbr1) in the 
anterior MEE is necessary for p-SMAD2 expression and overexpression of constitutively active 
Alk-5 could rescue the palatal fusion in Tgfβ3-/- palatal shelves by 46% (Dudas et al., 2004).  
Ablation of Tgfbr2 in the palatal epithelial cells (K14-Cre; Tgfbr2fl/fl mice) results in soft 
palate cleft, submucous cleft and failure of the primary palate to fuse with the anterior secondary 
palate (Figure 2.4) (Xu et al., 2006). Loss of Tgfbr2 in the palatal epithelium resulted in loss of 
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expression of interferon regulatory factor 6, Mmp13, p-SMAD2 and failure in the induction of 
apoptosis at the MES.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Overview of signaling mechanisms governing embryonic palate development. 
FGF-BMP gradients/thresholds maintain proper palatal growth and elevation through 
proliferation. (A-B) Anterior FGF10 and BMPs control proliferation via Shh expression. This 
directs anterior palate to elevate and grow horizontally at E13.5-E14. After E13.5 to E14, the 
anterior palatal shelves first elevate to orient themselves horizontally above the tongue when the 
posterior palatal shelves are still lying in vertical position (A). Anterior FGF-BMP gradients along 
with posterior FGF8 regulate proliferation and growth via Barx1 in the posterior palate at E14-15. 
At E14, the posterior palatal shelves follow the anterior palatal shelves in orienting horizontally 
above the tongue, whereas the anterior palates begin to grow horizontally towards each other to 
make contact (B). At E15, TGFβ3 initiates fusion at the anterior palate through its receptor and the 
anterior palatal shelves have made contact and fused, whereas the posterior shelves grow 
horizontally (C). Then the fusion extends posteriorly through TGFβ-Meox2 and by E15.5, both the 
anterior and posterior palates have fused (D). Bmpr1a mediated Shox2 and TGFβ signaling through 
its receptors aid in the fusion between the primary and secondary palate at the future secondary 
choana, which marks the completion of palatal fusion at E16 (D, E). Palatal shelves are divided 
into anterior (pink) Msx1 and posterior (aqua) Barx1 expression domains (A-E) representing future 
hard and soft palate respectively.   
E13.5 E14 E15 
E15.5 E16 
Anterior 
Posterior 
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2.5 Osteogenesis 
In higher vertebrates, bones provide support and protection for various organs of the body. 
In addition to mechanical support, bones also aid in metabolic functions. Bone homeostasis is 
maintained as a balance between two processes namely, bone formation and bone resorption 
mediated by osteoblasts and osteoclasts, respectively (Zuo et al., 2012). Any impairment in the 
balance could result in deformed bones due to failure in the remodeling process.  
Bone and cartilage form the vertebrate skeleton. Bones are formed by either endochondral 
ossification or by intramembranous ossification. During endochondral ossification, initially the 
chondrocytes proliferate, undergo hypertrophy and die, which are then replaced by osteoblasts to 
form bone. In chondrocyte differentiation, the mesenchymal cells become immature chondrocytes, 
which express Collagen type II, alpha 1 (Col2a1) and proteoglycan, which then form hypertrophic 
chondrocytes characterized by Collagen type X, alpha 1 (Col10a1). These mature chondrocytes 
further differentiate into terminal hypertrophic chondrocytes, which express Secreted 
phosphoprotein 1 (Spp1) and Mmp13 (Komori et al., 2010). 
Intramembranous ossification is the process of laying down osteoblasts directly from the 
mesenchymal progenitor cells upon condensation (Komori et al., 2010). During intramembranous 
bone formation, the multipotent mesenchymal cells condense to differentiate into osteoblasts 
(Dobreva et al 2006) characterized by the expression of runt-related transcription factor 2 (Runx2) 
or core-binding factor alpha 1 (Cbfa1) and Sp7 transcription factor (Sp7) or Osterix (Osx). These 
osteoblasts then lay matrix and differentiate further into mineralized osteocytes, which express 
bone carboxy-glutamic acid containing protein (Bglap) or Osteocalcin (Ocn) (Komori et al., 2010; 
Javed et al., 2010).  
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Endochondral ossification is mainly seen in the long bones, whereas intramembranous 
ossification dominates in the craniofacial bones (Javed et al., 2010), although there are craniofacial 
bones derived from endochondral ossification. A majority of the craniofacial bones arise from the 
cranial neural crest cells and the rest arise from the paraxial mesoderm (Figure 2.5). The palatal 
bones are formed via intramembranous ossification include the anterior palatal process of the 
maxilla and the posterior palatal process of the palatine bone (Baek et al., 2011). The palatal 
process of the maxilla ossifies after the palatal fusion, as two mesenchymal condensations on either 
side of the degraded MES (Baek et al., 2011). The palatal process of the palatine bone ossifies 
early during palate development prior to elevation of palatal shelves at E13.5 (Wu et al., 2008).  
 
Figure 2.5 Craniofacial bones and their source of origin. Contribution of cranial neural crest 
cells and paraxial mesoderm to the development of craniofacial bones (Taken from Lee and Saint-
Jeannet, 2011, with permission). 
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2.6 Runt-related transcription factor 2 (Runx2) 
Runt related transcription factor 2 (Runx2), also previously known as core-binding factor 
alpha 1 (Cbfa1), has been extensively studied in osteoblast differentiation. The gene Runx2 
encodes for a full-length protein of about 57 kilo Dalton (kDa), with N-terminal runt homology 
DNA binding domain followed by nuclear localization signal and a C-terminal sub-nuclear 
targeting nuclear matrix targeting signal (Choi et al., 2001; Lou et al., 2009). Runx2-/- mice die 
immediately after birth due to breathing problems (Komori et al., 1997) and the majority of Runx2-
/- mice develop cleft palate (Aberg et al., 2004). These mice exhibit complete lack of ossification 
due to inhibited osteoblast differentiation and defective hypertrophic chondrocytes. Although the 
progenitors express alkaline phosphatase (Alpl) weakly in these mice, the expression of late 
markers such as Bglap and Spp1 are completely absent (Komori et al., 1997). Moreover, dosage 
of full length RUNX2 protein is critical, as 70% of full length protein leads to conditions like 
cleidocranial dysplasia (CCD) (Lou et al., 2009). The hypomorphic Runx2 allele generated by 
insertion of neomycin cassette into the intron before exon 8 leads to reduced level (55-70%) of 
wild type mRNA and protein, leading to no skeletal abnormalities, except in the clavicle and 
calvaria featuring the defects of CCD in humans (Lou et al., 2009). Also, in the deletion mutant 
mice, where the C-terminal nuclear matrix targeting signal domain of RUNX2 is deleted, a similar 
phenotype to the Runx2 null mice was observed. This C-terminal mutant of RUNX2 protein 
retained the DNA binding but exhibited decreased luciferase activity of Spp1, Bglap and Tgfbr1 
promoters. However, the intra-nuclear targeting is completely lost, which is essential for RUNX2 
function in osteoblasts (Choi et al., 2001). It has been shown that BMP2 induces Runx2 mediated 
by Dlx5 in C2C12 cells (Lee et al., 2003). FGF2 induces Runx2 mRNA expression in 
preosteoblastic MC3T3-E1 cell line, premyoblastic C2C12 cells and in rat osteosarcoma ROS 17 
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cells. FGF2 also induces Runx2 expression and its binding activity to the Bglap (Ocn) promoter 
(Kim et al., 2003). FGF2 induced ERK-MAPK signaling is important for RUNX2 phosphorylation 
at Serine 301 residue, which leads to acetylation of RUNX2 protein and its stabilization (Park et 
al., 2010). Indeed, site directed mutagenesis of two serine residues to alanine (S301A, S319A) 
reduced RUNX2 ability to induce osteoblast specific gene expression (Ge et al., 2009). Moreover, 
BMP2 also induces p-ERK signaling in the osteoblasts resulting in increased acetylation and 
stability of RUNX2 via increasing p300 protein levels and its histone acetyl transferase activity 
(Jun et al., 2010).  
2.7 Sp7 transcription factor (Sp7)/ Osterix (Osx) 
Sp7 zinc finger transcription factor, also referred as Osterix (Osx), is another important 
regulator of osteoblast differentiation. The mouse Sp7 gene codes a 428-amino acid polypeptide 
with a molecular mass of 46 kDa comprising of C-terminal C2H2 zinc finger domain and a N-
terminal proline rich region (Zhang, 2010). Sp7 null mice also lack both intramembranous and 
endochondral bone formation (Nakashima et al., 2002) and craniofacial bones are severely affected 
in the absence of Sp7 (Nakashima et al., 2002; Baek et al., 2013). In these mice, in addition to the 
absence of Spp1 and Bglap, ectopic expression of chondrogenic markers such as Sry-related HMG 
box genes, Sox9, Sox5, Col2a1 and Indian hedgehog protein in the intramembranous bones is 
observed, characterizing a failure in the induction of pre-osteoblasts to osteoblasts (Nakashima et 
al., 2002).  RUNX2 binds to the proximal promoter region of Sp7 at a consensus binding sequence 
AGTGGTT (-713 to -707 bp), which is conserved between human, mouse and rat (Nishio et al., 
2006). SP7 binds to the promoter of WNT antagonist Dkk1 (Zhang et al., 2008) and Sost (Yang et 
al., 2010) to activate their transcription to inhibit WNT signaling. It also disrupts the transcriptional 
activity of β-CATENIN/TCF and its target gene Ccnd1, thereby inhibiting proliferation (Zhang et 
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al., 2008).  Thus, Sp7 controls feedback mechanism of WNT signaling in the osteoblasts (Zhang 
et al., 2008; Zhang 2010; Tang et al., 2011). Mmp13 is another direct target of Sp7 in the 
osteoblasts and is important for degradation of extracellular matrix proteins particularly collagens 
type II, I and X (Zhang C et al., 2012). Recently, Sp7 acts upstream of special AT-Rich Sequence-
Binding Protein (Satb2), another transcription factor known to bind to AT rich regions in the 
nuclear matrix attachment regions. SP7 binds to the proximal promoter region (-130 bp) of Satb2 
to induce its expression in the osteoblasts (Tang et al., 2011). 
2.8 Special AT-Rich Sequence-Binding Protein (Satb2) 
Satb2 null mice have a shortened mandible and malformation of several intramembranous 
bones such as premaxilla, maxilla, nasal bones, frontal bones and the temporal process of the 
squamous bone (Dobreva et al., 2006). SATB2 binds to upstream promoter region (-290 to -181 
bp) of Spp1 to activate its transcription (Dobreva et al., 2006). Furthermore, SATB2 augments the 
DNA binding activity of RUNX2 and activating transcription factor 4 to the Osteoblast-specific 
elements (OSE) in the Bglap promoter for enhancing the transactivation of Bglap (Dobreva et al., 
2006).  However, SATB2 does not directly bind to OSE elements of the Bglap promoter (Dobreva 
et al., 2006). SATB2 also binds to the 3 enhancer region of Hoxa2 gene that has characteristics of 
nuclear matrix attachment region and represses its expression in osteoblasts (Dobreva et al., 2006).  
2.9 Osteogenic differentiation and cleft palate pathogenesis 
 Palatal bones comprise the palatal process of the maxilla in the anterior half of the palate 
and the palatal process of the palatine bone in the posterior half of the palate (Baek et al., 2011). 
The palatal process of the maxilla ossifies after the palatal fusion at E15.5, in the form of two 
mesenchymal condensations on either of the degraded MES (Baek et al., 2011). However, the 
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palatal process of the palatine bone ossifies independently at E13.5, prior to the elevation of the 
palatal shelves (Wu et al., 2008). Augmented expression of Pax3 (Pax3Cre/Cre, R26Pax3/Pax3) leads 
to cleft palate with decreased osteogenesis due to downregulation of Runx2 at E13.5 (Wu et al., 
2008). It is intriguing to note that the mutants of several osteoblast markers including Runx2-/- 
(Aberg et al., 2004), Dlx5-/- (Han et al., 2009), Satb2-/- (Dobreva et al., 2006) develop cleft palate. 
However, there are only a handful of reports on the role of osteogenic differentiation leading to 
cleft palate (Wu et al., 2008; Fu et al., 2017; Jia et al., 2017a, b). RNA-seq data from Osr2-/-  palatal 
shelves at E13.5 mainly revealed upregulation of genes involved in skeletogenesis and 
osteogenesis, including Runx2, Dlx5, Sp7 and several Bmp ligands such as Bmp3, Bmp5 and Bmp7 
(Fu et al., 2017). In addition to decreased cell proliferation (Lan et al., 2004), enhanced osteogenic 
differentiation could be causative for the cleft palate in the Osr2-/- mice (Fu et al., 2017). Pax9 is 
required for maintaining the expression of Osr2 in the palatal mesenchyme and Pax9-/- mice 
develop overt cleft palate due to reduced proliferation in the posterior palate. Restoration of Osr2 
in the Pax9-/- background using knock-in of Osr2 (Pax9Osr2KI/Osr2KI) rescues the palatal shelf 
elevation and cleft palate in 50% embryos, although the anterior secondary palate failed to fuse 
with the primary palate (Zhou et al., 2013). Pax9-/- palatal shelves exhibit decreased β-CATENIN 
mediated canonical WNT signaling in the posterior region of the palatal shelves at E13.5 and small 
molecule WNT agonist rescued palatal shelf elevation and cleft palate phenotype (Li et al., 2017) 
accompanied by restoration of defective cell proliferation and osteogenic differentiation (Jia et al., 
2017a). These works highlight the importance of controlled cell proliferation and osteogenic 
differentiation for elevation of palatal shelves during development.   
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2.10 Hoxa2 in cranial neural crest cell migration and skeletal development 
Cranial neural crest cells are a pluripotent migratory cell population specific to vertebrates 
which give rise to different cell lineages to give rise to bones, cartilage, nerves and connective 
tissue (Gammill and Bronner-Fraser, 2003; LeDouarin and Kalcheim, 1999; Morales et al., 2005; 
Steventon et al., 2005). During development of craniofacial skeleton, rostral (anterior) cranial 
neural crest cells largely give rise to the fronto-nasal skeleton and intramembranous bones of the 
skull, while the posterior cranial neural crest cells populate the pharyngeal arches to form the jaw, 
middle ear, hyoid and thyroid cartilages (Nodan, 1983). During early vertebrate development, the 
anterior region of the neural tube differentiates into forebrain (prosencephalon), midbrain 
(mesencephalon) and the hindbrain (rhombencephalon) (Lumsden and Keynes, 1989). Further 
during development, rhombencephalon segments into seven compartments called rhombomeres. 
In each rhombomere, an unique population of cells is maintained without exchange with other 
compartments. Cranial neural crest cells from posterior mesencephalon, rhombomere 1 and 
rhombomere 2, fill the first pharyngeal arch, whereas rhombomere 4 fills the second pharyngeal 
arch. Cranial neural crest cells from rhombomere 6 and rhombomere 7 mix to form the PA3 and 
PA4. Cranial neural crest cells from rhombomere 3 and rhombomere 5 undergo massive apoptosis, 
which makes minimal contribution to the arches (Graham et al., 1993; Minnoux and Rjili, 2010). 
Hox genes are necessary for maintenance of the A-P axis and for the patterning of PAs 
(Santagati and Rijli, 2003). Hoxa2 is the most anteriorly expressed Hox gene with its anterior limit 
at rhombomeres r1/r2 boundary (Krumlauf, 1993). However, Hoxa2 is not expressed in cranial 
neural crest cells which emigrate from rhombomeres boundary r1/r2 to populate the first 
pharyngeal arch (Prince and Lumsden, 1994), which makes the first pharyngeal arch devoid of 
Hox gene expression (Köntges and Lumsden, 1996). In the Hoxa2-/- mice, mirror duplication of 
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the proximal first pharyngeal arch elements such as malleus, incus, tympanic ring, gonial, 
squamosal and ptergoid bones in place of the second pharyngeal arch elements takes place 
(Gendron-Maguire et al 1993; Rijli et al., 1993). Hence, Hoxa2 is considered a selector gene of 
the second pharyngeal arch (Grammatopoulos et al., 2000; Pasqualetti et al., 2000; Hunter and 
Prince, 2002; Santagati et al., 2005). 
Hoxa2 expression is excluded from the chondrogenic condensations in the second 
pharyngeal arch, which express Sox9 and in the Hoxa2-/- mice, Sox9 expression domain is shifted 
into the Hoxa2 expression domain (Kanzler et al., 1998). Overexpression of Hoxa2 in the Col2a1 
chondrogenic lineage leads to stunted growth in the long bones due to the inhibition of WNT/β-
CATENIN signaling (Deprez et al., 2012). HOXA2 binds to the promoters of several WNT 
signaling genes and activates their expression in early development of the second pharyngeal arch 
at E10.5 (Donaldson et al., 2012). Also, Runx2 is upregulated in the second pharyngeal arch of 
Hoxa2 null mutants (Kanzler et al., 1998). Moreover, Runx2 is downregulated in ST2 cells 
(stromal cell line) when overexpressed with Hoxa2 expression plasmid and during osteoblast 
differentiation Runx2 induces micro-RNA 3960 to inhibit translation of Hoxa2 (Hu et al., 2011). 
Also, Hoxa2-/- embryos exhibit increased bone mineralization in the calvaria and the double 
mutants of Hoxa2 and Satb2 (Satb2-/- Hoxa2-/-) were able to rescue the reduced mineralization 
defects in the frontal and interparietal bones of the Satb2 mutants (Dobreva et al., 2006). 
2.11 Hoxa2 in palate development 
In addition to the complete penetrance of middle ear abnormalities (Rijli et al., 1993; 
Gendron-Maguire et al., 1993), Hoxa2-/- mice develop cleft palate with a penetrance of 81% 
(Barrow and Capecchi 1999). The cleft palate in the Hoxa2-/- mice was initially believed to be due 
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to the tongue musculature in these mice, as Hoxa2 is not expressed in the cranial neural crest cells, 
which populate the first pharyngeal arch, that gives rise to the palate (Barrow and Capecchi 1999). 
However, we have found that Hoxa2 is expressed in the palatal shelves (Nazarali et al., 2000) and 
plays a direct role in secondary palate development by regulating cell proliferation (Smith et al., 
2009). Hence, expression in the migrating cranial neural crest cells from rhombomere 1 and 
rhombomere 2 does not appear to be a pre-requisite of the genes that are important in regulating 
palatogenesis. When Hoxa2-/- mouse embryonic heads devoid of their tongue were cultured in 
chemically defined media in rolling bottle cultures, the palatal shelves failed to fuse. Also, 
knocking down of Hoxa2 expression with antisense retroviral infections in the wild type cultures 
resulted in decreased palatal fusion rate (Smith et al., 2009). Hence, tongue musculature may not 
be the main reason for the cleft palate phenotype in the Hoxa2-/- mice (Smith et al., 2009). In the 
palatal shelves of the Hoxa2-/- mice, there was increase in the expression of Msx1, Bmp4, Ptx1 and 
Barx1. It is pertinent to note that Msx1 along with Bmp4 in the anterior palate and Barx1 in the 
posterior palate are necessary for cell proliferation. However, the role of Hoxa2 in the osteogenic 
differentiation of the embryonic palatal mesenchyme have not been investigated and whether 
abnormal osteogenic differentiation in the Hoxa2-/- palatal mesenchyme could be a reason for the 
cleft palate pathogenesis in the Hoxa2-/- mutants remains to be studied.  
2.12 High temperature requirement factor A (Htra) family of proteins 
Serine proteases HTRA family members are known to regulate TGFβ ligands (Oka et al., 
2004). TGFβ family members play vital roles in palatal shelf growth (Cui et al., 2003) and fusion 
(Kaartinen et al., 1995). In addition, Hoxa2 binds to intronic region of Htra3 to repress its 
expression in the spinal cord during development (Yan., 2008). The role of Htra family members 
during palatogenesis has not been investigated yet.   
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Htra are a family of serine proteases which are conserved from bacteria to humans (Chien 
et al., 2009). In bacteria, HTRA proteins are involved in quality control and signal transduction in 
periplasmic space. HTRA proteins are vital in bacteria for survival at high temperature and hence 
their name High temperature requirement factor A.  In vertebrates, there are four Htra family 
members, namely HTRA1 to HTRA4. Among them, HTRA2 has unique mitochondrial 
localization signal with the N-terminal region found to be present in the mitochondrial 
transmembrane domain and the protease domain is believed to protrude into the intermembrane 
space. Htra2 is known to play role in apoptosis in caspase dependent and independent manners. 
Htra2 null mice exhibit a Parkinsonian phenotype due to the loss of neurons in the striatum 
(Martins et al., 2004).  
 Htra-1, 3 and 4 have a mac-25 domain at the N-terminal end, which includes an insulin-
like growth factor binding domain and a Kazal-type protease inhibitor domain. The mac-25 
domain has homology with follistatin, which is a known inhibitor of activin. Mac-25 domain is 
followed by a serine protease domain that is indispensable for its activity and a PDZ [abbreviated 
from Post synaptic density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1) and 
Zonula occludens-1 protein (zo-1)] domain for interaction with the target substrates (Figure 2.6).  
HTRA1 was initially identified as the serine protease that was downregulated in SV40 
transformed fibroblasts. It was believed to modulate the availability of insulin growth factors 
(IGFs) by cleaving the IGF binding proteins (Zumbrunn and Trueb, 1996). Since then Htra1 has 
been extensively studied as a candidate gene in various forms of cancers, osteoarthritis, cerebral 
autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy, Alzheimer's 
disease, age related macular degeneration, and during development. 
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Figure 2.6 Schematic diagram of HTRA1 and HTRA3 protein domains. SS, signal sequence; 
IGFBP, Insulin Growth Factor Binding Protein; KI, Kazal protease inhibitor; PDZ, (abbreviated 
from Post synaptic density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1) and 
Zonula occludens-1 protein (zo-1).    
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2.12.1 HTRA and TGFβ 
HTRA1 binds to and inhibits TGFβ/BMP family members such as TGFβ1, TGFβ2, BMP4 
and growth differentiation factor 5 (GDF5) in vitro (Oka et al., 2004). The affinity of HTRA1 for 
mature TGFβ proteins decreases as follows: BMP4>TGFβ2>TGFβ1>ACTIVIN>GDF5 (Oka et 
al., 2004). The serine protease domain along with the linker region (aa 155-202) that precedes it 
was essential and sufficient for the binding of HTRA1 to the TGFβ family members (Oka et al., 
2004). It is interesting to note that HTRA1 was not bound to FGF2 and EGF. The authors also 
ruled out the possibility of HTRA1 inhibiting the intracellular signaling of BMPR, as Htra1 failed 
to inhibit the signal that originated from constitutively active BMPRIB (Oka et al., 2004). Like 
HTRA1, HTRA3 has been shown to bind to and inhibit TGFβ/BMP family members such as 
TGFβ1, 2, GDF5 and BMP4 in vitro (Tocharus et al., 2004). In contrast, HTRA1 has been shown 
to co-localize and cleave the pro-domain of pro-TGFβ1 in the endoplasmic reticulum to block 
signaling of pSMAD2. However, HTRA1 failed to bind to mature TGFβ1 (Shiga et al., 2011). 
Similarly, several other findings did not identify a negative correlation in expression between 
TGFβ1 and HTRA1 (Wang et al., 2012). Recently, HTRA1 is demonstrated to positively regulate 
TGFβ1 mediated pSMAD2/3 signaling by binding, to process latent TGFβ binding protein 1 to 
mature TGFβ1 (Beaufort et al., 2014). Further evidence is needed to address the discrepancies and 
to validate the role of Htra1 in TGFβ signaling.  
2.12.2 HTRA1 and FGF signaling 
In Xenopus embryos, Htra1 was found to share similar expression domains with FGFs. 
FGF4 and FGF8-soaked beads induced Htra1 expression and similarly microinjection of Htra1 
mRNA into the embryos induced FGF proteins and p-ERK signaling by cleavage of proteoglycans 
such as biglycan, syndecan-4 and glypican-4 (Hou et al., 2007). In contrast, knockdown of Htra1 
36 
 
in zebrafish induces FGF8 expression and p-ERK activation, whereas overexpression of Htra1 
inhibits FGF8 and p-ERK expression (Kim et al., 2012). The discrepancy with the earlier report 
was suggested to be due to the difference in the Htra1 expression across the stages in the different 
model organisms. Xenopus Htra1 is not detected from the maternal to the blastula periods but 
detected at low levels in the early gastrula, whereas at these stages Htra1 is highly expressed in 
zebrafish leading to difference in FGF signaling regulation (Kim et al., 2012). Another report 
identified FGF8 as an inducible factor of Htra1 in chick facial mesenchyme at Hamilton and 
Hamburger (HH) 19 stage (Ferrer-Vaquer et al., 2008). Fgf8 is expressed at high levels in the 
ectoderm between the two olfactory placodes and in the forebrain and Htra1 transcripts are 
detected in the underlying mesenchyme. Chick facial mesenchyme explants cultured without the 
overlying ectoderm show no Htra1 expression; however, when mesenchyme is cultured together 
with FGF8-soaked heparin acrylic beads, strong Htra1 expression is detected around the bead. In 
addition, Htra1 transcripts were downregulated in explants cultured with FGFR1 inhibitor SU5402 
(Ferrer-Vaquer et al., 2008). Although Htra1 is induced by FGF8 in facial mesenchyme (HH19) 
and in forelimb bud (HH17), Htra1 is not downregulated by SU5402 in younger embryo explants 
(HH11). The overall expression pattern of Htra1 is found to be different from that of FGF signaling 
and it can be argued that Htra1 is not a member of the FGF syn-expression group (Ferrer-Vaquer 
et al., 2008). Together these data suggest that FGF signaling regulates Htra1 in a tissue and stage 
dependent manner. Recently, a Flp-In system (Invitrogen) was used to overexpress and silence 
Htra1 in MCF10A mammary epithelial cells to study the role of Htra1 in epithelial-mesenchymal 
transition and its downstream targets. Silencing of Htra1 leads to increase in FGFR3, FGFR4 and 
Fibroblast growth factor binding protein 1 (FGFBP1) expression and overexpression of Htra1 
induces downregulation of the FGF family members (Wang et al., 2012). Hence the interaction 
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between Htra1 and FGF signaling cannot be neglected and the two may have a reciprocal feedback 
signaling.  
2.12.3 HTRA1 intracellular localization and cell signaling 
  Htra1 has been extensively studied in cancer development and progression, as a tumor 
suppressor gene (Chien et al., 2004; Narkiewicz et al., 2009; He, X., et al., 2010; Mullany et al., 
2011; Wang et al., 2012; Xia et al., 2012). HTRA1 was initially believed to be a secreted protease 
but recently HTRA1 was also reported to be expressed in the cytoplasm (Chien et al., 2009) and 
in the nucleus (Clawson et al., 2008; He, X., et al., 2010; Wang et al., 2012). HTRA1 is associated 
with the microtubules in nocadazole dependent manner and co-precipitated with α-, β- and γ-
tubulins. The PDZ domain is important for this association and bound HTRA1 inhibits cell motility 
(Chien et al., 2009). Moreover, a 29 kilodalton (kDa) isoform that lacks the PDZ domain is found 
localized in the nucleus (Wang et al., 2012), and retains its proteolytic activity (Clawson et al., 
2008). However, a majority of the HTRA1 protein is localized in the cytoplasm with some in the 
nucleus and only a limited amount is secreted (Wang et al., 2012). HTRA1 binds to EGFR both in 
the cell membrane and in the nucleus and inhibits EGFR phosphorylation. The downregulation of 
EGFR by Htra1 has been shown to be important for anoikis in suspension SKOV3 ovarian 
carcinoma cell line (He et al., 2010). HTRA1 binds to and degrades tuberous sclerosis protein 2 
but not tuberous sclerosis protein 1 in cytoplasm both in vivo and in vitro to activate the 
downstream targets such as eukaryotic translation initiation factor 4E binding protein and S6 
kinase (Campioni et al., 2010). HTRA1 also degrades X-linked inhibitor of apoptosis protein in 
presence of cisplatin drug to render SKOV3 cancer cells responsive to chemotherapy (He et al., 
2012). HTRA1 protein when incubated with fibronectin protein produces fibronectin fragments, 
which is important for the transcriptional expression of Mmp-1 and Mmp-3 in human synovial 
38 
 
fibroblasts (Grau et al., 2006). Similar mechanisms are also noted in IVD cell cultures and the 
induction of Mmps by Htra1 was blocked by mitogen activated protein kinase kinase (MEK) 
inhibitor PD98059, showing that the mechanism is MEK dependent (Tiaden et al., 2012b). 
2.12.4 Htra1 and osteoblast differentiation 
 Htra1 is expressed in bone matrix during development (Oka et al., 2004; Tsuchiya et al., 
2005). However, its role in bone matrix mineralization is not clear as it has been shown to regulate 
matrix mineralization both positively (Tiaden et al., 2012a) as well as negatively (Hadfield et al., 
2008). HTRA1 is found to colocalize with integrin-binding sialoprotein (IBSP) during bone 
regeneration (Tiaden et al., 2012a). Htra1 is involved in the lineage commitment of mesenchymal 
stem cells to form osteoblasts, inhibiting adipogenic differentiation (Tiaden et al., 2016). Htra1 
induces the expression of MMPs during osteogenesis in a MAPK dependent manner (Tiaden et 
al., 2016). However, Htra1 has also shown to be involved in RANKL-induced osteoclastogenesis 
in KusaO cells and to inhibit osteogenic differentiation via downregulation of BMP2 induced 
pSMAD 1/5/8, p-ERK and p38 MAPK signaling (Wu et al., 2014b). Therefore, the role of Htra1 
in osteogenic differentiation remains to be determined and the molecular targets upstream and 
downstream of Htra1 are yet to be delineated.  
2.12.5 Htra3  
High temperature requirement factor A 3 (HTRA3) has similar structural domains to that 
of HTRA1(Figure 2.6) suggesting that both these serine proteases may have similar functions but 
with differential expression patterns (Zumbrunn and Trube, 1996; Nie et al., 2003). Indeed, 
HTRA3 also binds to TGFβ/BMP family members such as TGFβ1 and BMP4 to inhibit their 
downstream Smad luciferase reporters (Tocharus et al., 2004). In contrast to Htra1, Htra3 produces 
two variants namely long and short forms due to alternative splicing (Figure 2.6) (Nie et al., 2003). 
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Although Htra3 expression is limited in the cartilaginous condensations, it is upregulated when 
the ossifications are initiated (Tocharus et al., 2004). Htra3 is essential during placental 
development and inhibition of Htra3 in HTR-8 cells (derived from the first trimester placenta) 
results in an increase in invasion. While exogenous addition of TGFβ1 would be expected to result 
in a similar effect to the inhibition of Htra3 in invasion; however, excess of TGFβ1 results in a 
decrease in placental cell invasion (Singh et al., 2010; Singh et al., 2011). Thus, this finding did 
not demonstrate the inhibitory effect of HTRA3 on TGFβ1 (Singh et al., 2010). Htra3 is 
downregulated in lung cancer with smoking leading to methylation induced gene silencing of 
Htra3 (Beleford et al., 2010a). Overexpression of Htra3 promotes etopside- and cisplatin-induced 
apoptosis in lung cancer cells. Interestingly, mac-25 domain deletion variant of HTRA3 attenuated 
cell survival and caused greater induction of apoptosis than the full length HTRA3 (Beleford et 
al., 2010b). Htra3 expression is significantly downregulated during osteogenic differentiation in 
vitro (Filliat et al., 2017). However, the role of Htra3 in osteogenic differentiation is yet to 
elucidated.   
Previous thesis work from our lab has identified Htra3 as a downstream target of Hoxa2 
during spinal cord development. HOXA2 binds to the fifth intron of Htra3 gene and inhibits Htra3 
gene expression (Yan., 2008). It remains to be characterized whether Htra3 or any of the Htra 
family members are direct downstream targets of Hoxa2 in other regions during development, 
including the secondary palate.  
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Preamble to Chapter 3: Hoxa2 inhibits osteogenic differentiation of the palatal mesenchyme 
via BMP signaling 
Rationale 
A previous work from our group showed that Hoxa2 is expressed intrinsically in palatal 
shelves during development and it regulates cell proliferation in the palatal mesenchyme. 
Furthermore, during craniofacial development, Hoxa2 inhibits osteogenesis in the second 
pharyngeal arch and in the calvaria. Given that Hoxa2 is expressed in the palatal shelves during 
development, I hypothesized that Hoxa2 regulates the timing of osteogenic differentiation. I also 
tested to see if there is any abnormal osteogenic differentiation in the Hoxa2-/- palatal shelves prior 
to elevation at E13.5, which could be causative for cleft palate pathogenesis. Also, I explored the 
underlying signaling pathway that could be responsible for the aberrant osteogenic differentiation 
in the palatal mesenchymal cells due to the loss of Hoxa2.  
Publication 
Iyyanar, P. P. R*., and Nazarali, A. J. (2017). Hoxa2 Inhibits Bone Morphogenetic Protein 
Signaling during Osteogenic Differentiation of the Palatal Mesenchyme. Front. Physiol. 8, 929.  
*Corresponding author 
Contribution statement 
Paul P. R. Iyyanar designed the study, performed experiments, analyzed data and wrote the 
manuscript. Adil J. Nazarali was the senior author who conceived, coordinated the study and after 
his passing away, Paul P. R. Iyyanar corresponded the manuscript for publication.   
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3. HOXA2 INHIBITS OSTEOGENIC DIFFERENTIATION OF THE PALATAL 
MESENCHYME VIA BMP SIGNALING 
 
3.1 Summary 
Hoxa2 plays a direct role in secondary palate development and Hoxa2 null (Hoxa2-/-) mice 
exhibit cleft palate due to failure in the elevation of palatal shelves after E13.5. However, the 
molecular mechanism governing the cleft palate phenotype in Hoxa2-/- mice is largely unknown. 
In this study I report that Hoxa2 inhibits spatial and temporal osteogenic differentiation in the 
developing palate by modulating the expression of osteoblast markers. Loss of Hoxa2 increased 
the expression of osteoblast markers including Runx2, Alpl and Sp7 in the palatal shelves at E13.5 
and E15.5. Consistent with this, mouse embryonic palatal mesenchymal (MEPM) cells from 
Hoxa2-/- embryos exhibit increased ossified matrix deposition and mineralization in vitro. 
Moreover, loss of Hoxa2 results in increased osteoprogenitor commitment and osteoprogenitor 
proliferation prior to the elevation of palatal shelves at E13.5. Consistent with the upregulation of 
osteoblast markers, Hoxa2-/- palate exhibited higher expression of canonical BMP signaling in 
Hoxa2-/- palatal shelves. Blocking BMP signaling using dorsomorphin restores the increase in cell 
proliferation and osteogenic differentiation in Hoxa2-/- primary palatal mesenchymal cells. 
Collectively, the data show for the first time that Hoxa2 regulates palate development by inhibiting 
osteogenic differentiation of palatal mesenchyme via modulation of BMP signaling in the 
developing palate. 
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3.2 Introduction 
Cleft palate is one of the most common congenital birth defects in humans with an 
incidence of 1 in 700 to 1 in 1000 live births and is influenced by genetic and environmental factors 
(Dixon et al., 2011). In mice, secondary palate development begins at E11.5 and the palatal fusion 
is complete by E15.5 ( Ferguson, 1988). Impairment in any of the aforementioned events during 
palatogenesis results in cleft palate. The maxillary region comprises of six primordia namely pairs 
of premaxilla, maxilla and palatine bones, which are all derived from the cranial neural crest cells 
through intramembranous ossification (Iwata et al., 2010). The palatal bones comprise of the 
palatal process of the maxilla and the palatal process of the palatine bone constituting the anterior 
and posterior part of the hard palate, respectively (Baek et al., 2011). While the structural changes 
during palate development are well defined, there is a scarcity of knowledge on the molecular 
mechanisms governing the patterning of the palate. 
Hoxa2 is the most anteriorly expressed Hox gene with its anterior limit at rhombomeres 
r1/r2 boundary ( Krumlauf, 1993). Mutation in the Hoxa2 gene in humans is associated with cleft 
palate (Alasti et al., 2008). In the Hoxa2-/- mice, cleft palate phenotype had been attributed to the 
physical obstruction of the tongue preventing elevation and fusion of the palatal shelves above the 
tongue (Barrow and Capecchi, 1997). Our group previously reported that Hoxa2 is expressed in 
the palatal shelves after emerging from the maxillary prominence (Nazarali et al., 2000) and plays 
a direct role in secondary palate development by regulating cell proliferation (Smith et al., 2008). 
The palatal shelves from Hoxa2-/- mouse embryonic heads devoid of tongue grown in rolling bottle 
cultures failed to fuse. In addition, knock-down of Hoxa2 with antisense retroviral infections in 
the wild type organ cultures resulted in reduced palatal fusion (Smith et al., 2008). Hence, tongue 
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musculature may not be the reason for the cleft palate phenotype in Hoxa2-/- mice (Smith et al., 
2008).  
Bone morphogenetic protein (BMP) signaling plays a critical role in palate development 
regulating cell proliferation (Zhang et al., 2002). Bmp4 is upstream of Bmp2 to induce proliferation 
in the palatal mesenchyme and is able to reverse the reduced cell proliferation and cleft palate 
phenotype in the Msx1-/- mice (Zhang et al., 2002). Defective cell proliferation observed in Pax9-/- 
embryos is consistent with the reduced Bmp4 expression in the palatal mesenchyme at E13.5 (Zhou 
et al., 2013). Similarly, reduced expression of Bmp2 is associated with reduced cell proliferation 
in the palatal shelves of Hand2 hypomorphic mice (Hand2LoxP/−) (Xiong et al., 2009). In addition, 
growing evidence highlight the importance of osteogenic differentiation in the elevation of palatal 
shelves and abnormal osteogenic differentiation could lead to cleft palate manifestations (Fu et al., 
2017; Jia et al., 2017a, 2017b; Wu et al., 2008). BMP signaling is critical for osteogenic 
differentiation in the palatal mesenchyme (Baek et al., 2011; Hill et al., 2014; Wu et al., 2008), 
where it is required for the expression of osteoblast markers such as Runx2, Sp7 and Alpl (Baek et 
al., 2011). During craniofacial development, Hoxa2 restricts the bone mineralization in the calvaria 
(Dobreva et al., 2006). Moreover, Hoxa2-/- mice exhibit ectopic Runx2-positive osteogenic center 
in the second pharyngeal arch that results in duplication of tympanic ring (Kanzler et al., 1998). 
During palatogenesis, Hoxa2 appears to be a key regulator, yet the molecular signaling pathways 
downstream of Hoxa2 remain largely unknown.  
In this study, I used a combination of in vivo and in vitro approaches to investigate the role 
of Hoxa2 in osteoblast differentiation of the palatal mesenchyme. My findings reveal that Hoxa2 
plays a vital role in regulating the spatial and temporal expression of osteoblast markers during 
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palate development via modulating bone morphogenetic protein (BMP) signaling pathway in the 
developing palate.   
3.3 Materials and Methods 
3.3.1 Animals  
  Wild type and Hoxa2-/- embryos were obtained from timed pregnant Hoxa2+/- 
(heterozygous) mice. Genotype was confirmed using PCR as previously described (Gendron-
Maguire et al., 1993). This research was approved by the University of Saskatchewan’s Animal 
Research Ethics Board and adhered to the Canadian Council on Animal Care guidelines for 
humane animal use.  
3.3.2 Primary MEPM cell culture and osteogenic induction  
 Primary MEPM cells were isolated by microdissection of palatal shelves from wild type or 
Hoxa2-/- mouse embryos at E13.5. The palatal shelves were treated with 0.25% trypsin- 
ethylenediaminetetraacetic acid (EDTA) for 15 min, passed through a 70 µm cell strainer and 
cultured as monolayer cells (Iwata et al., 2012) in Dulbecco’s Modified Eagle’s Medium (DMEM): 
Ham’s F12 (DMEM/F12) (1:1) media containing 10% fetal bovine serum (FBS), 1% antibiotic-
antimycotic solution (Sigma). Osteogenic differentiation was carried out as described previously 
(Kwong et al., 2008) with minor modifications. Briefly, MEPM cells were seeded on 0.1% PDL-
coated plates at a cell density of 5  104 cells per well in 24 well plates and cultured until they 
reached confluence. Osteogenic differentiation was induced with osteogenic differentiation media 
(DMEM, 10% FBS, 2 mM L-glutamine and 1% antibiotic-antimycotic solution) supplemented 
with osteogenic inducing agents, including 50 µg/ml L-ascorbic acid 2-phosphate 
sesquimagnesium salt (Sigma), 10 mM β-glycerophosphate (Sigma) and 100 nM dexamethasone 
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(Sigma). Cells were differentiated for up to 21 days (d). In case of dorsormorphin treatment, 
MEPM cells were treated with 5 µM final concentrations of dorsomorphin or dimethyl sulfoxide 
(DMSO) and the cells were harvested for RNA isolation or fixed for alkaline phosphatase (ALPL) 
staining at d8.  
3.3.3 ALPL staining  
ALPL staining in the palatal shelves in vivo was carried out as previously described (Baek 
et al., 2011). Embryonic mouse heads were fixed overnight in freshly prepared 4% 
paraformaldehyde at 4°C. Frozen coronal sections (10 μm) were prepared on slides coated with 
0.5% gelatin. The sections were air dried for at least 2 hours (h) and then rehydrated with TBS 
with 0.08% tween-20 twice for 10 min each. Subsequently, the sections were treated with ALPL 
buffer (100 mM NaCl, 100 mM Tris–HCl pH 9.5, 50 mM MgCl2, 0.1% Tween-20) for 20 min 
and stained with 4.5 μl/ml of 5-Bromo-4-chloro-3-indolyl phosphate (Roche) and 3.5 μl/ml of nitro 
blue tetrazolium (Roche) in alkaline phosphatase buffer for 10 min. The reaction was stopped with 
phosphate buffer saline (PBS) containing 20 mM (EDTA) buffer and counter stained with nuclear 
fast red stain. The stained sections were dehydrated in a series of PBS/ethanol, ethanol/xylene and 
finally mounted in DPX mounting media (Sigma). In primary MEPM cells, ALPL staining was 
carried out after fixing the cells with 4% paraformaldehyde for 15 min.  
3.3.4 Alizarin red (ARS) staining and quantification  
The ARS staining and quantification was carried out according to the method of Gregory 
et al., 2004, with minor modifications. Briefly, monolayer MEPM cells were fixed in 4% 
paraformaldehyde for 15 min and stained with 250 µl of 40 mM ARS (Sigma) solution (pH 4.1) 
at room temperature (RT) for 20 min with gentle shaking. Excess dye was aspirated and washed 
46 
 
with deionized water before imaging. ARS quantification was carried using an acid  extraction 
method (Gregory et al., 2004). Standard plot of ARS concentration was constructed by serially 
diluting the 40 mM ARS in the buffer containing 10% (v/v) acetic acid and 10% (v/v) ammonium 
hydroxide. The absorbance values of the standard concentrations were used to interpolate the 
concentrations of the test samples. 
3.3.5 Quantitative real-time polymerase chain reaction (qPCR)  
Total RNA from the micro-dissected palatal shelves was isolated using RNA mini spin 
column (Bio-Rad) as per the manufacturer’s protocol. First strand complementary DNA (cDNA) 
synthesis (reverse transcription) was performed in 20 µl reactions with 500 ng of total RNA using 
High-Capacity complementary DNA Reverse Transcription Kit (Invitrogen). qPCR was carried 
out by according to Thangaraj et al., (2017) using SYBR green (Applied Biosystems)  in 7300-
real time PCR system (Applied Biosystems) with primers listed in Table 3.1. 
3.3.6 Western Blotting  
Western blot analyses were carried out as previously described (Brown and Nazarali, 2010). 
Briefly, palatal tissues were homogenized in radioimmunoprecipitation assay buffer (RIPA) 
buffer. Total protein content was quantified using the Bradford assay and proteins were separated 
in 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel. Primary antibodies used were: RUNX2 
(1:500; Abcam), SP7 (1:1500; Abcam), pSMAD 1/5/8 (1:500; Cell signaling), SMAD 1/5/8 
(1:500; Santa Cruz Biotechnology) and β-ACTIN (1:2000; Developmental Studies Hybridoma). 
Densitometric analyses were carried out using AlphaView software. 
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3.3.7 Immunohistochemistry  
Embryonic mouse heads were fixed overnight in freshly-prepared 4% paraformaldehyde 
and rehydrated in 30% sucrose at 4°C. Frozen coronal sections (10 μm) were rehydrated with PBS 
for 45 min, pre-permeabilized with 0.1% Triton-x-100 and blocked with 3% skim milk containing 
0.1% Triton-x-100 in 1x PBS for 1 h at RT. Sections were then incubated overnight with RUNX2 
(1:200; Abcam) or SP7 (1:800; Abcam) in 1X PBS with 0.1% triton-x-100 at 4° C. Double labeling 
was carried out by co-incubating: Ki67 (1:100) and RUNX2 (1:200; Abcam) overnight at 4°C. 
Sections were then washed three times five min each and treated with secondary antibodies 
conjugated with Alexa Fluor® 488 (1:200) or Alexa Fluor® 594 (1:400) in 1X PBS with 0.1% 
Triton-x-100 RT for 1.5 h. Cell counting analyses were carried out manually using ImageJ 
software platform (NIH). 
3.3.8 Cell proliferation assay  
Cell proliferation assay was carried out in MEPM cells using cell-counting kit-8 (Dojindo) 
as previously described (Iwata et al., 2010). CCK-8 reagent was added 1 h prior to reading and the 
absorbance measured at 450 nm was plotted to calculate the relative cell proliferation rate.   
3.3.9 Statistical analyses  
  Statistical analyses were carried out by Prism5 software (Graphpad). Unpaired t-test was 
used in the case of two groups, one-way ANOVA or two-way ANOVA with Bonferroni multiple 
comparison test was used where applicable. Data were analyzed and represented as mean ± S.E.M 
relative to wild type.  A p-value of <0.05 was considered significant. 
  
48 
 
Table 3.1 Primer sequences used for the relative quantification of the transcripts by qPCR using 
SYBR green assay.  
Transcript Primer sequences 
Length 
(bases) 
Amplicon 
size (bp) 
Alkaline phosphatase 
(Alpl) 
CCTTGACTGTGGTTACTGCT 
CCTGGTAGTTGTTGTGAGCG 
20 
20 
216 
Bone morphogenic protein 
2 (Bmp2) 
CAGTAGTTTCCAGCACCGAA 
CACTTCCACCACAAACCCAT 
20 
20 
199 
Bone morphogenic protein 
4 (Bmp4) 
AGGAAGGAGTAGATGTGAGAG 
AGGGACGGAGACCAGATAC 
21 
19 
158 
Bone carboxy-glutamic 
acid containing protein 
(Bglap) 
GCAGGAGGGCAATAAGGTAG 
ATGCGTTTGTAGGCGGTC 
20 
18 
159 
CyclinD1 (Ccnd1) 
ACCCTGACACCAATCTCCTC 
AAGCGGTCCAGGTAGTTCAT 
20 
20 
214 
Sp7 transcription factor 
(Sp7)  
CACAAAGAAGCCATACGCTG 
CCAGGAAATGAGTGAGGGAAG 
20 
21 
165 
Runt-related transcription 
factor 2 (Runx2)  
TGCCTCCGCTGTTATGAAAA 
CTGTCTGTGCCTTCTTGGTT 
20 
20 
187 
Beta- actin (β-actin) 
ATTGTAACCAACTGGGACG 
TTGCCGATAGTGATGACCT 
19 
19 
180 
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3.4 Results 
3.4.1 Hoxa2-/- palate exhibits increased expression of osteogenic markers in vivo  
To understand the cellular and molecular mechanisms underlying the role of Hoxa2 in palate 
development, I first examined if the loss of Hoxa2 leads to changes in the osteogenic differentiation of the 
palatal mesenchyme using alkaline phosphatase (ALPL; a marker of osteoblast differentiation) staining in 
E16.5 embryonic palate, a stage when both the prospective palatal processes of the maxilla and the palatine 
bone evidently ossify (Baek et al., 2010). Results indicate an expansion in the ALPL expression domain 
in the Hoxa2-/- palatal mesenchyme compared to wild type (Figure 3.1A-H). In wild type, at the anterior 
region of the hard palate, ALPL staining is restricted to the nasal half of the palate in the two condensations 
of the prospective palatal process of the maxilla on either side of the degraded midline epithelial seam 
(Figure 3.1A and E). In contrast, the domain of ALPL positive preosteoblast area in the Hoxa2-/- palate is 
increased and expanded towards the oral side covering the nasal-oral axis of the palate (Figure 3.1B and 
F). In the posterior half of the hard palate, ALPL staining is present in the ossifying centers of the palatal 
process of the palatine bone in the wild type palate (Figure 3.1C and G), whereas in the Hoxa2-/- palate, 
there is an expansion in the expression domain of ALPL positive preosteoblasts (Figure 3.1D and H).  
 Runx2 (Komori et al., 1997) and SP7 (Osterix) (Nakashima et al., 2002) are well-known regulators 
of osteogenic differentiation and are critical for the patterning of the palatal bones (Baek et al., 2010). 
Hence, I next investigated if the spatial expression domains of these two osteoblast-specific transcription 
factors are altered in the Hoxa2-/- palate. Immunohistochemical analyses revealed that RUNX2 (Figure 
3.1I) and SP7 (Figure 3.1M) are expressed in the condensations of the palatal process of the maxilla at the 
anterior hard palate in E16.5 wild type embryos, whereas in the Hoxa2-/- palate, RUNX2 (Figure 3.1J) and 
SP7 (Figure 3.1N) expression is increased leading to an expansion in the developing palatal process of the 
maxilla. In the posterior side along the developing palatal process of the palatine bone, the expression of 
RUNX2 (Figure 3.1L) is increased; whereas the expression of SP7 (Figure 3.1P), a downstream target of 
Runx2 and a marker of mature osteoblasts, was not evidently increased in the Hoxa2-/- palate. This suggests 
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that cells at the oral sides of the Hoxa2 null palate could be at an immature preosteoblast stage and may 
not have developed bone matrix yet. Nevertheless, loss of Hoxa2 resulted in an increase in mRNA 
expression of osteoblast markers such as Runx2, Alpl, Sp7 and Bglap or Osteocalcin (Ocn) in the Hoxa2-
/- palate at E13.5 (Figure 3.2A-D) and E15.5 (Figure 3.2E-H). At E13.5, compared to the wild type, Runx2, 
Alpl and Sp7 mRNA expression was increased to ~6.36, ~9.65 and ~2.62-fold, respectively, in Hoxa2-/- 
palate; in contrast, mRNA expression of Bglap was not significantly altered. At E15.5, loss of Hoxa2 
upregulated the mRNA expression of Runx2 ~1.86-fold; Alpl ~2.29-fold; Sp7 ~1.42-fold and Bglap ~3.27-
fold. Consistent with this, protein expression of RUNX2 was upregulated ~1.4-fold at E13.5 and E15.5 
(Figure 3.2I and J), whereas SP7, both long (Figure 3.2I and K) and short isoforms (Figure 3.2I and L) 
were upregulated ~1.4-fold at E15.5. These data indicate that Hoxa2 could be a potential inhibitor of 
osteoblast differentiation in the palatal mesenchyme by spatially restricting the expression of osteoblast 
markers in the palate during development in vivo. 
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Figure 3.1 Loss of Hoxa2 leads to increased osteogenic differentiation of the palatal mesenchyme at 
E16.5. Position matched coronal sections of wild type and Hoxa2-/- embryos at E16.5 were stained for 
ALPL (A-H), RUNX2 (I-L) and SP7 (M-P). Sections in the anterior region (A, B, E, F, I, J, M and N) 
were through the middle of the first molar tooth bud to detect osteogenic condensation of the palatal 
process of the maxilla. Sections in the posterior region (C, D, G, H, K, L, O and P) were through the 
osteogenic centers of the developing palatal process of the palatine bone. A-D, ALPL staining (blue) 
counterstained with nuclear fast red. Scale bar, 100 µm. Boxed regions in A-D are enlarged (E-H). Scale 
bar, 50 µm. E and F, in the anterior hard palate, ALPL staining in the two condensations of the palatal 
process of the maxilla is marked in black dotted lines in wild type (E) and is evidently increased in the 
Hoxa2-/- embryos (F). G and H, in the posterior hard palate, ALPL stained developing palatal process of 
the palatine bone (marked in black dotted lines) in the Hoxa2-/- embryos (H) is increased compared to the 
wild type (G). I-P, Immunohistochemical analyses of RUNX2 (green; I-L) and SP7 (red; M-P) in wild 
type and Hoxa2-/- palate at E16.5. RUNX2 is increased in both anterior (J) and posterior regions (L) of the 
Hoxa2-/- palate. SP7 was upregulated only in the anterior hard palate (N). Scale bar, 50 µm.  
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Figure 3.2 Loss of Hoxa2 leads to increase in quantitative expression of osteogenic markers in the 
developing palate at E13.5 and E15.5. Quantitative real-time PCR (qPCR) analyses indicate that the 
gene expression of osteogenic markers such as Runx2 (A and E), Alpl (B and F), Sp7 (C and G) and Bglap 
(D and H) were upregulated in the developing Hoxa2-/- palate at E13.5 (A-D) and E15.5 (E-H). qPCR data 
(n=5 biological replicates) were normalized to β-actin (mean ± S.E.M; unpaired t-test, *, p<0.05; **, 
p<0.01; ***, p<0.001). Western blot analyses of RUNX2 (I and J) and SP7 (I, K and L) were carried out 
from the microdissected palatal shelves from wild type and Hoxa2-/- mice at E13.5 and E15.5. RUNX2 
protein expression was upregulated in the Hoxa2-/- palate at E13.5 and E15.5 (I and J), whereas SP7 
isoforms are upregulated at E15.5 (I, K and L). Densitometric analyses (n=4 biological replicates) were 
normalized to β-ACTIN and represented relative to wild type (mean ± S.E.M; unpaired t-test, **, p<0.01).  
 
 
3.4.2 Hoxa2 inhibits osteogenic differentiation of mouse embryonic palatal mesenchymal (MEPM) 
cells in vitro  
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Osteogenesis involves sequential stages of proliferation, osteogenic commitment followed by matrix 
deposition and mineralization (Gordon et al., 2010). To identify the temporal role of Hoxa2 in osteogenic 
differentiation of the palatal mesenchyme, the primary mesenchyme cells from the wild type and Hoxa2-
/- palatal shelves were subjected to osteogenic differentiation in vitro for up to d21. The differentiated cells 
were then stained for ALPL at d8 and ARS staining at d15 and d21. ALPL staining revealed an increase 
in osteoblast differentiation at d8 in Hoxa2-/- MEPM cells compared to the wild type cells (Figure 3.3A 
and B). In addition, ARS staining and quantification of ARS extracted matrix revealed that Hoxa2-/- 
MEPM cells exhibit increased matrix deposition ~2-fold at d15 (Figure 3.3C, D and G) and mineralization 
~1.5-fold at d21 (Figure 3.3E, F and H) compared to the wild type MEPM cells. Next, I examined the gene 
expression of osteogenic markers in wild type and Hoxa2-/- MEPM cells during osteogenic differentiation 
in vitro. The mRNA expression of Runx2 was increased ~1.9-fold in Hoxa2-/- MEPM compared to wild 
type during osteoblast commitment stage at d8 (Figure 3.3I). Expression of Alpl and Sp7 mRNA in Hoxa2-
/- MEPM cells were increased ~2.85-fold and ~3.37-fold, respectively, during matrix deposition and 
maturation stage at d15 (Figure 3.3J and K). Expression of Bglap mRNA was increased ~6.37-fold during 
matrix deposition at d15 and ~8.09-fold during matrix mineralization stage at d21 in Hoxa2-/- MEPM cells 
(Figure 3.3L).  Thus, loss of Hoxa2 results in upregulation of osteogenic marker expression in a stage-
specific manner as early as d8 (osteogenic commitment stage) in MEPM cells. These data indicate that 
Hoxa2 might play a role in early osteoblast differentiation by inhibiting the expression of osteoblast 
markers temporally. 
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Figure 3.3 Hoxa2 inhibits osteoblast differentiation of MEPM cells in vitro. Wild type and Hoxa2-/- 
MEPM cells were allowed to differentiate into osteoblasts for up to 21 days (d). The differentiated cells 
were stained for ALPL at d8 (A and B), ARS at d15 (C and D) and d21 (E and F). Scale bar, 200 µm. ARS 
stained osteocyte matrices from wild type and Hoxa2-/- MEPM cells were extracted and quantified at d15 
(G) and d21 (H) (n=3 biological replicates; mean ± S.E.M; unpaired t-test, *, p<0.05; ***, p<0.001). 
Hoxa2-/- MEPM cells displayed increased matrix deposition and mineralization at d15 (G) and d21 (H), 
respectively. I-L, qPCR analyses revealed that gene expression of osteogenic markers such as Runx2 (I), 
Alpl (J), Sp7 (K) and Bglap (L) were upregulated in the Hoxa2-/- MEPM cells in a stage-specific manner 
during osteoblast differentiation. Data was normalized to β-actin (n=3 biological replicates; mean ± 
S.E.M; two-way ANOVA with Bonferroni post-hoc test, *, p<0.05; **, p<0.01; ***, p<0.001) and 
represented relative to wild type at d0. 
3.4.3 Increased osteoprogenitor commitment and cell proliferation in the palatal mesenchyme 
during early palate development  
Hoxa2-/- mice exhibit cleft palate due to failure in the palatal shelves to elevate and reorient 
horizontally above the tongue (Barrow and Capecchi, 1999). Abnormal osteogenic differentiation could 
affect palatal shelf elevation and result in cleft palate phenotype (Wu et al., 2008; Fu et al., 2017; Jia et 
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al., 2017a and b). Hoxa2 expression peaks in the developing palate at E13.5 (Smith et al., 2009), a stage 
when the mesenchymal cells simultaneously proliferate and commit to form preosteoblasts of the 
prospective palatal process of the palatine bone. To gain further insight into the role of Hoxa2 during 
palate development, the commitment of mesenchymal cells to osteoprogenitor cells and the mesenchymal 
cell proliferation rate in E13.5 wild type and Hoxa2-/- palatal shelves was examined. ALPL staining (Figure 
3.4A and B) and RUNX2 immunohistochemistry (Figure 3.4C and D) was carried out to evaluate 
osteoprogenitor commitment in wild type and Hoxa2-/- palatal shelves. Our results indicate an increase in 
the expression domain of ALPL (Figure 3.4B) and RUNX2 (Figure 3.4D) in the Hoxa2-/- mutants similar 
to E16.5, whereas in the wild type, ALPL (Figure 3.4A) and RUNX2 (Figure 3.4C) expression were 
restricted to the bend region in the nasal side of the palate. In addition, the number of RUNX2+ve 
osteoprogenitor cells in the nasal side of the palatal shelves were significantly higher in the Hoxa2-/- 
mutants (~64%) compared to wild type (~33%) (Figure 3.4J). Next, I assessed the rate of cell proliferation 
using Ki67 immunostaining in the wild type and Hoxa2-/- palatal mesenchyme. The percentage of Ki67+ve 
cells was significantly increased in the Hoxa2-/- palatal mesenchyme (~50%) compared to wild type 
(~26%) (Figure 3.4E, F and K). In the nasal side of the palatal shelves, the percentage of Ki67+ve cells was 
~53%, which was higher in Hoxa2-/- mice compared to ~26% in the wild type (Figure 3.4K).  Interestingly, 
in Hoxa2-/- palatal shelves, the nasal side mesenchyme displayed higher proliferation rates of ~53% 
compared to the oral side at ~23% (Figure 3.4K). In addition, the percentage of proliferating 
osteoprogenitor cells (RUNX2+ve/Ki67+ve) in the nasal side of the Hoxa2 null palatal shelves was higher 
(~20%) compared to ~11% in wild type (Figure 3.4G, H and L). Furthermore, the mRNA expression of 
cyclin D1 (Ccnd1), a critical G1 phase cell cycle regulator was also upregulated in the Hoxa2-/- palatal 
shelves from E12.5 to E14.5 (Figure 3.4I), indicating the role of Hoxa2 as an inhibitor of cell proliferation 
in the developing palatal shelves.  These results indicate that Hoxa2 plays a critical role by inhibiting 
osteoprogenitor commitment and mesenchymal cell proliferation during early palate development.      
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Figure 3.4 Hoxa2-/- palatal shelves exhibit increased osteoprogenitor cell commitment and 
mesenchyme cell proliferation at E13.5. Osteoprogenitor cells in the developing palatal shelves of wild 
type and Hoxa2-/- embryos were stained using ALPL (A and B) and RUNX2 (C and D). Proliferation rate 
was assessed using Ki67 (E and F) at E13.5. Scale bar, 50 µm; N, nasal; O, oral. Double-positive cells 
(RUNX2+ve/Ki67+ve) (G and H) amongst a total number of mesenchymal cells (DAPI+ve) from wild type 
and Hoxa2-/- palatal shelves were counted in the nasal side (L). Hoxa2-/- embryos exhibit increased 
RUNX2+ve (J), Ki67+ve (K) and RUNX2+ve/Ki67+ve (L) in the nasal side of the palate (n=5 biological 
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replicates; mean ± S.E.M; unpaired t-test, *, p<0.05; **, p<0.01; ***, p<0.001). Expression of cell cycle 
regulator Cyclin D1 (Ccnd1) mRNA was upregulated in the Hoxa2-/- palatal shelves (I) from E12.5 to 
E14.5. qPCR data was normalized to β-actin (n=6 biological replicates; mean ± S.E.M; unpaired t-test, *, 
p<0.05; ***, p<0.001) and represented relative to wild type at respective embryonic stages. 
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3.4.4 Increased canonical BMP signaling pathway in the Hoxa2-/- palatal shelves  
The molecular mechanisms by which Hoxa2 regulates cell proliferation and osteogenic 
differentiation remain elusive. Canonical BMP signaling is critical for proliferation (Zhang et al., 2002; 
Han et al., 2009; Baek et al., 2011) and osteogenic differentiation (Baek et al., 2011; Wu et al., 2008; Hill 
et al., 2014) in the developing palate. To investigate if canonical BMP signaling is altered in the developing 
Hoxa2-/- palate, the mRNA expression of bmp ligands that are critical for osteoblast differentiation namely, 
Bmp2 and Bmp4, in the developing palatal shelves were examined. Indeed, the mRNA expression of Bmp2 
(Figure 3.5A) and Bmp4 (Figure 3.5B) are upregulated by ~3.5-fold and ~4.3-fold, respectively, in the 
Hoxa2 null palatal shelves at E13.5. In addition, immunoblotting analyses revealed that canonical BMP 
signaling mediated by phosphorylated SMAD 1/5/8 (pSMAD 1/5/8) was also upregulated to ~1.5-fold in 
the Hoxa2-/- palate at E15.5 (Figure 3.5C and D). These results indicate that canonical BMP signaling 
pathway is upregulated and could be responsible for the increased osteoblast differentiation in the Hoxa2-
/- palate. 
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Figure 3.5 Hoxa2 regulates canonical BMP signaling in the developing palate. Gene expression of 
Bmp ligands, Bmp2 (A) and Bmp4 (B), were upregulated in Hoxa2-/- palatal shelves at E13.5. qPCR data 
(n=4 biological replicates) were normalized to β-actin (mean ± S.E.M; unpaired t-test, *, p<0.05). 
Immunoblotting analyses (C and D) of pSMAD 1/5/8 protein from the developing palate of wild type and 
Hoxa2-/- embryos at E15.5. D, Densitometric analysis represents the relative expression of pSMAD 1/5/8 
normalized to SMAD 1/5/8 and represented relative to wild type (n=4 biological replicates; mean ± S.E.M; 
unpaired t-test, *, p<0.05).  
 
3.4.5 Blocking canonical BMP signaling rescues aberrant cell proliferation and osteogenic 
differentiation in Hoxa2-/- MEPM cells  
To determine if upregulated canonical BMP signaling is functionally responsible for the increased 
mesenchymal cell proliferation and osteogenic differentiation observed in the Hoxa2-/- palate, 
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dorsomorphin was used to inhibit BMP signaling during osteogenic differentiation of MEPM cells in vitro. 
Upon dorsomorphin treatment, the mRNA expression of Bmp2 (Figure 3.6A), Bmp4 (Figure 3.6B) and 
Runx2 (Figure 3.6C) upregulated in the Hoxa2-/- MEPM cells were restored to the wild type levels. 
Moreover, increased protein expression of RUNX2 and pSMAD 1/5/8 (Figure 3.6D) in the Hoxa2-/- 
MEPM cells were brought close to wild type levels after dorsomorphin treatment. Furthermore, the 
increased cell proliferation (Figure 3.6E) and osteogenic differentiation (Figure 3.6F) in the Hoxa2-/- 
MEPM cells were also reduced after dorsomorphin treatment. These results reveal that upregulated 
canonical BMP signaling is functionally responsible for the increased cell proliferation and osteogenic 
differentiation in the Hoxa2-/- palate.  
Together, the data here reveal that Hoxa2 inhibits cell proliferation and commitment of mesenchymal 
cells to osteoprogenitor cells in the developing palatal shelves. Hoxa2 controls the spatial and temporal 
expression of osteoblast markers by inhibiting BMP signaling for proper patterning of the palatal bones. 
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Figure 3.6 Blocking canonical BMP signaling with dorsomorphin rescues the aberrant cell 
proliferation and osteogenic differentiation in the Hoxa2-/- MEPM cells. Dorsomorphin treatment 
restored gene expression of Bmp2 (A), Bmp4 (B) and Runx2 (C) in Hoxa2-/- MEPM cells during osteogenic 
differentiation in vitro at d8. Data represented relative to wild type MEPM cells treated with DMSO (n=4 
biological replicates; mean ± S.E.M; one-way ANOVA followed by Bonferroni post-hoc test, *, p<0.05; 
***, p<0.001; ns, not significant). D, Representative immunoblot showing restoration of RUNX2 and 
pSMAD 1/5/8 in Hoxa2-/- MEPM cells treated with dorsomorphin during osteogenic differentiation in 
vitro at d8 (n=3 biological replicates). E, Cell proliferation analysis in the wild type and Hoxa2-/- MEPM 
cells treated with DMSO or dorsomorphin during osteogenic differentiation at d3 (n=5 biological 
replicates; mean ± S.E.M; one-way ANOVA followed by Bonferroni post-hoc test, ***, p<0.001; ns, not 
significant). F, ALPL staining revealed that treatment with dorsomorphin nullified the aberrant osteogenic 
differentiation in Hoxa2-/- MEPM cells in vitro at d8. Scale bar, 200 µm. 
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Figure 3.7 Schematic diagram depicting the role of Hoxa2 in proliferation and osteogenic 
differentiation of the palatal mesenchyme. A, Hoxa2 inhibits canonical BMP signaling in the 
developing palate, which in turn restricts the expression domain of osteogenic markers such as Runx2, 
Alpl and Sp7. B, in wild type, Hoxa2 expression peaks during early palatogenesis to control cell 
proliferation and to maintain mesenchymal cells in an undifferentiated stage by regulating BMP 
signaling pathway. C, Loss of Hoxa2 leads to upregulation of BMP signaling resulting in increased 
cell proliferation and osteogenic differentiation. 
 
 
 
 
 
 
 
 
3.5 Discussion 
 Mice lacking Hoxa2 exhibit cleft palate (Barrow and Capecchi, 1999; Gendron-Maguire et al., 
1993; Rijli et al., 1993) and microtia (Minoux et al., 2013), which are consistent with Hoxa2 mutations in 
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humans (Alasti et al., 2008). Our group has previously shown that Hoxa2 is expressed in the palatal shelves 
during development (Nazarali et al., 2000) reaching a maximal expression at E13.5 and regulates cell 
proliferation in the developing palate (Smith et al., 2009). There are several lines of evidence that Hoxa2 
regulates palate development intrinsically (Smith et al., 2009), yet the mechanism is largely unknown. In 
this study, I have found that Hoxa2 inhibits BMP signaling dependent osteogenic differentiation spatially 
and temporally to regulate palate formation. The present study deepens the current understanding of the 
role of Hoxa2 in palate formation and the mechanisms underlying the cleft palate phenotype in Hoxa2-/- 
mice linking Hoxa2, BMP signaling and osteogenesis.  
The findings here reveal that Hoxa2 controls the temporal and spatial expression pattern of 
osteoblast markers in the developing palatal mesenchyme. Ossifying domains characterized by RUNX2 
and ALPL were increased in the palatal process of the maxilla and in the palatal process of the palatine 
bone in Hoxa2-/- mice. In contrast, SP7 a marker of mature osteoblasts was expanded only in the palatal 
process of the maxilla and not in the palatal process of the palatine bone at E16.5. This suggests that cells 
towards the oral side of the palatal process of the palatine bone are at an immature osteoblast stage and 
may not have developed bone matrix by E16.5. Patterning of the palatal process of the palatine bone and 
of the maxilla are through independent skeletogenic processes (Baek et al., 2011). The palatal process of 
the palatine bone ossifies at E13.5, whereas the ossification of the palatal process of the maxilla begins 
only at E15.5. Consistent with this, qPCR and immunoblot analyses revealed a corresponding upregulation 
of osteogenic markers in the Hoxa2-/- palate at these two critical stages E13.5 and E15.5. In addition, 
primary Hoxa2-/- MEPM cells displayed an increase in osteogenic differentiation and a stage-specific 
increase in the expressions of the osteoblast-specific transcripts indicating that Hoxa2 regulates temporal 
differentiation of mesenchyme cells to osteoblasts in the palate. Together, my results reveal that Hoxa2 
functions as an inhibitor of osteogenic differentiation in the palatal mesenchyme during development. The 
findings from this study are in agreement with previous studies showing the role of Hoxa2 as an inhibitor 
of bone formation in other craniofacial regions (Kanzler et al., 1998; Dobreva et al., 2006).  
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Very little is known about the signaling network downstream of Hoxa2 during palatogenesis. Here, 
I have demonstrated that Hoxa2-/- palatal shelves exhibit upregulated canonical BMP signaling mediated 
by pSMAD 1/5/8. In addition, the expression of BMP ligands such as Bmp2 and Bmp4 are upregulated in 
Hoxa2-/- palatal shelves in vivo and in Hoxa2-/- MEPM cells in vitro. BMP signaling plays a critical role in 
proliferation (Zhang et al., 2002; Baek et al., 2011) and osteogenic differentiation of the palatal 
mesenchyme (Baek et al., 2011; Han et al., 2009; Wu et al., 2008). Importantly, abnormal BMP signaling 
in the palatal mesenchyme leads to cleft palate manifestation (Zhang et al., 2002; He et al., 2008). 
Inactivation of Bmpr1a in the palatal mesenchyme (Osr2-IresCre; Bmpr1af/f) results in submucous cleft 
palate, absence in the patterning of the palatal process of the maxilla and defective palatal process of the 
palatine bone (Baek et al., 2011). ChIP-seq analysis revealed that Bmp2, Bmp4 and Bmpr1a are possible 
targets of Hoxa2 (Donaldson et al., 2012) and HOXA2 protein binds to the intronic region of Bmp4 
(Minoux et al., 2013) in the developing pharyngeal arch2. In this study, dorsomorphin was used to inhibit 
BMP signaling in the wild-type and Hoxa2-/- primary palatal mesenchymal cells during osteogenic 
differentiation. In this study, dorsomorphin treatment not only rescued the upregulated gene expression of 
osteogenic factors such as Bmp2, Bmp4 and Runx2, but also the aberrant cell proliferation and osteogenic 
differentiation in the Hoxa2-/- MEPM cells. These experiments highlight the involvement of BMP 
signaling in the abnormal osteoprogenitor cell proliferation and osteogenic differentiation in the Hoxa2-/-  
palate, which could attribute to the cleft palate phenotype in these mutants.  
To my knowledge, there is no report available on the characterization of osteoprogenitor cell 
proliferation and commitment in the palatal mesenchyme during development. In this study, we have 
unraveled the role of Hoxa2 in maintaining the palatal mesenchymal cells in an undifferentiated stage by 
inhibiting osteoprogenitor proliferation and commitment preventing abnormal ossification in the 
developing palate. Palatal mesenchymal cells derived from cranial neural crest undergo osteogenic 
proliferation and commit to form osteoblasts (Iwata et al., 2010). Double immunolabeling analyses of 
RUNX2 and Ki67 at E13.5 revealed that among the total population of mesenchyme cells, there was a 
significantly higher number of (i) proliferating cells (Ki67-positive cells), (ii) osteoprogenitor cells 
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(RUNX2-positive cells) and (iii) proliferating osteoprogenitor cells (RUNX2-positive /Ki67-positive cells) 
in the nasal side of the Hoxa2-/- palatal shelves compared to the wild-type. In the palatal mesenchyme, 
increased or decreased cell proliferation could result in failure of the palatal shelves to elevate and reorient 
above the tongue leading to cleft palate (Bush and Jiang, 2012; Smith et al., 2013). Recent studies show 
evidence for abnormal osteogenic signaling prior to the elevation of palatal shelves in several well-studied 
cleft palate mutant mice models including Pax9-/- mice (Jia et al., 2017a and b) and Osr2-/- mice (Fu et al., 
2017). Consistent with our findings here in the Hoxa2-/- mice, Osr2-/- exhibit increased osteogenic centers 
of the palatal process of the palatine bone prior to the elevation of the palatal shelves at E13.5 and in 
addition to defective cell proliferation, enhanced osteogenesis could contribute to cleft palate phenotype 
in Osr2-/- mice (Fu et al., 2017). In addition, RNA-Seq data from Osr2-/- palatal shelves revealed 
upregulation of several positive regulators of osteogenesis including Runx2, Runx3, Sp7 and Bmp ligands- 
Bmp3, Bmp5 and Bmp7. Furthermore, Pax9-/-  mice exhibit reduced cell proliferation and osteogenesis in 
the developing palate (Jia et al., 2017a). Restoration of reduced cell proliferation and osteogenesis by Wnt 
agonists (Dkk inhibitors) rescued the cleft palate phenotype in Pax9-/- mice (Jia et al., 2017a). The increase 
in cell proliferation in the nasal side of the Hoxa2-/-  palate indicates a strong role for Hoxa2 in the spatial 
maintenance of mesenchymal cells in an undifferentiated state for temporal coordination of osteoblast 
differentiation (Figure 3.7). The findings here exemplify the regional heterogeneity in proliferation and 
osteogenic differentiation by Hoxa2 along the oral-nasal axis in the palatal mesenchyme prior to the 
elevation of palatal shelves. The data argue that improper BMP signaling leading to the increased 
osteoprogenitor cell proliferation and commitment could be a reason for the cleft palate pathogenesis in 
the Hoxa2-/- mice. Further studies are needed to address if the cleft palate phenotype in the Hoxa2-/- mice 
could be rescued using other mutant mice with impaired osteogenesis.  
The data demonstrate that Hoxa2 inhibits osteoprogenitor cell proliferation and osteogenic 
commitment via modulating BMP signaling in the mouse embryonic palatal mesenchyme. Hoxa2 
regulates spatial and temporal programs of osteogenesis by maintaining mesenchymal cells in an 
undifferentiated stage until osteogenic clues arrive. In conclusion, the findings from this study provide 
69 
 
new insights into the signaling mechanism underlying the role of Hoxa2 during embryonic palate 
development. 
 
 
Preamble to Chapter 4: Expressions of Htra1 and Htra3 increase during mouse palatogenesis and 
Htra3 expression in the palatal epithelium may be indicative of its role in palatal fusion 
Rationale 
In the previous chapter, I demonstrated the role of Hoxa2 in osteogenic differentiation of the palatal 
mesenchyme. In pursuit of identifying targets of Hoxa2 during palatogenesis, this chapter explores the 
temporal and spatial expression pattern of a serine protease Htra3, which was identified as a direct target 
of Hoxa2 in spinal cord during development. HTRA family members, Htra1 and Htra3, are known to 
influence TGFβ signaling. In this transitioning chapter, I examined the mRNA and protein expression 
profile of Htra1 and Htra3 in comparison with TGFβ1 and TGFβ3 across the palate development stages 
E12 to E15. This chapter provides a novel expression pattern of Htra3 in the developing palate and gives 
directions on the speculative role of Htra3 during palatogenesis.  
Contribution statement 
Paul P. R. Iyyanar designed the study, performed experiments, analyzed data in this chapter. Adil J. 
Nazarali conceived, coordinated the study. These data have not yet been submitted for any publication.  
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4.0 EXPRESSIONS OF HTRA1 AND HTRA3 INCREASE DURING MOUSE 
PALATOGENESIS AND HTRA3 EXPRESSION IN THE PALATAL EPITHELIUM MAY 
BE INDICATIVE OF ITS ROLE IN PALATAL FUSION 
 
4.1 Summary 
HTRA are a conserved family of serine proteases involved in several cellular processes. Among 
HTRA proteases, HTRA1 and HTRA3 are reported to bind and inhibit transforming Growth Factor β 
(TGFβ) signaling. TGFβ signaling plays a vital role in palatal development and perturbing TGFβ signaling 
leads to cleft palate in mice. I examined the expression of Htra3 in developing mouse secondary palate 
using quantitative PCR, western blot and immunohistochemistry. Htra3 mRNA and protein increase from 
E12 to E15 and are highest at E15 during which the palatal shelves fuse. Immunohistochemistry showed 
that HTRA3 is exclusively expressed in the palatal epithelia at E13.5 and at the midline epithelial seam 
during fusion at E14.5. Interestingly, from E13.5 to E15.5, HTRA3 has similar overlapping expression 
patterns with TGFβ3. Hence, it is plausible that HTRA3 might mediate TGFβ signaling rather than 
inhibiting it. To answer this question, I used lentiviral siRNA to silence Htra3 during palatal fusion in ex-
vivo organ culture. Despite the efficiency of the siRNA to knockdown Htra3 in primary palatal epithelial 
cells in vitro, I failed to demonstrate a significant knockdown of Htra3 mRNA ex-vivo, which hindered 
the identification of a possible role of Htra3 in palatal fusion. Here, I report the novel expression of 
HTRA3 in mouse embryonic secondary palate development. The expression of HTRA3 in the epithelium 
and in osteogenic domains may be indicative of its role in palatal fusion and osteogenic differentiation, 
respectively. 
 
4.2 Introduction 
Several gene networks and signaling pathways have been implicated in governing palate 
development (Smith et al., 2012). Secondary palate development begins at E11.5 in mice and is complete 
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by E15.5 (Ferguson 1988). During these stages, the vertical palatal shelves grow, elevate above the tongue, 
contact with each other resulting in subsequent formation and disintegration of midline epithelial seam. 
Cleft palate can occur due to failure in any of these events. Proliferation, apoptosis and epithelial-
mesenchymal transition mediated by signaling molecules are important for proper palate growth and 
fusion (Bush and Jiang, 2012).  
TGFβ signaling plays a critical role in palate development. TGFβ3 in the palatal epithelia and 
signaling through the serine threonine kinase receptors namely, TGFβRI and TGFβRIII, are indispensable 
for phosphorylation of SMAD-2 (Nakajima et al., 2007), activation of matrix metalloproteinases (MMP), 
Mmp13 (Blavier et al., 2001) and Mmp25 transcripts (Brown and Nazarali, 2010), expression of 
chondroitin sulfate proteoglycan (Gato et al., 2002) and subsequent degeneration of medial edge epithelia 
(MEE). TGFβ3 is also vital for the inhibition of palatal epithelial proliferation, induction of apoptosis (Cui 
et al., 2003) and epithelial-mesenchymal transition (Kaartinen et al., 1995).  
High temperature requirement factor A, HTRA1 and HTRA3, belong to the conserved family of 
serine proteases that mediate proliferation, apoptosis and epithelial-mesenchymal transition in cancer as 
tumor suppressor genes (Chien et al., 2004; Wang et al., 2012; Xia et al., 2013). Both HTRA1 and HTRA3 
bind to transforming growth factor beta/bone morphogentic protein (TGFβ/BMP) family members and 
inhibit signaling of Smad responsive luciferase reporters (Oka et al 2004; Tochorus et al., 2004). 
Moreover, expression and function of HTRA family of serine proteases has not been determined in the 
palate. Hence, I sought to delineate the expression patterns and functional role of Htra3 in developing 
mouse secondary palate. 
4.3 Materials and methods 
4.3.1 RNA isolation and qPCR 
Total RNA from the micro-dissected palatal shelves was isolated using RNA miniprep kits as per 
the manufacturer’s protocol. First strand cDNA synthesis (Reverse transcription) was performed in 20 µl 
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reactions with 500 ng of total RNA using QuantiTect Reverse Transcription Kit (QIAGEN) with universal 
primers.  
qPCR was carried out using the E12 to E15 palatal shelves cDNA and SYBR green assay with the 
7300 Real Time PCR System (Applied Biosystems) using primers listed in Table 4.1. Relative quantitation 
values for the secondary palate were obtained in comparison to an E12 sample with values normalized to 
beta actin (β-actin). All data are presented as mean ± standard error of mean (SEM). Data was analyzed 
by one-way ANOVA followed by Bonferroni’s multiple comparison test for comparison between the 
stages (GraphPad Prism) to determine statistically significant difference. A p value < 0.05 was considered 
significant. 
 
 
 
 
 
 
Table 4.1 Primer sequences used for the relative quantification of the transcripts in palatal shelves by 
qPCR using SYBR green assay.  
Transcript Primer sequences Length 
(bases) 
Amplicon size 
(bp) 
High temperature 
requirement 
factor A1 (Htra1) 
AGTTCTTGACAGAGTCCCACGA    
TATGCCCCAGAGAGCACATCC 
22 
21 
154 
High temperature 
requirement 
factor A3 (Htra3 
short form) 
TCTCACCAGCACTGCACT 
TCTGCCTGCTCCTGTCATCTT 
18 
21 
178 
High temperature 
requirement 
CAAGAGGTGGTTCCCAAT 18 181 
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factor A3 (Htra3 
long form) 
GGATGATGCTGAAGAGGAGA 20 
Glyceraldehyde 
3-phosphate 
dehydrogenase 
(Gapdh) 
ACCACAGTCCATGCCATCAC 
TCCACCACCCTGTTGCTGTA 
20 
20 
452 
Beta-actin (β-
actin) 
ATTGTAACCAACTGGGACG 
TTGCCGATAGTGATGACCT 
19 
19 
180 
 
4.3.2 Western blot analysis 
Western blot analysis was carried out as previously described (Brown and Nazarali, 2010). Briefly, 
palatal tissues were homogenized in RIPA buffer (5 mM ethylenediaminetetraacetic acid, 10 mM Tris pH 
8.0, 0.1% sodium deoxycholate, 0.01% sodium dodecyl sulfate (SDS), 1% Triton X-100, 150 mM sodium 
chloride, 1 μg/mL aprotinin, 1 μg/mL pepstatin). Homogenized samples were centrifuged at 11,000 rpm 
at 4°C for 15 minutes (min). Supernatant total protein content was quantified using Bradford assay (Bio-
Rad; Mississauga, ON, Canada) and separated using SDS poly-acrylamide gel electrophoresis with a 
10.0% separating gel. Proteins were transferred to a polyvinylidene fluoride membrane. After separation, 
the proteins were transferred to a polyvinylidene difluoride (PVDF) membrane, which was blocked 
overnight in 4% skim milk in PBS at 4°C. The membranes were then probed for protein expression with 
specific primary antibodies: HTRA1 (R&D systems, Minneapolis, MN; 1:3000), HTRA3 (goat 
polyclonal; Santa-Cruz Biotechnologies, CA; 1:1000) and β-ACTIN (mouse monoclonal; Developmental 
Studies Hybridoma, IA; 1:2000). This was followed by three consecutive washes of 10 min each in PBST 
(PBS with 0.08% Tween-20). Horseradish peroxidase (HRP) conjugated species specific secondary 
antibodies were probed and after four washes of 20 min with PBST, the membranes were then exposed to 
chemiluminescence reagent for 1-3 min and images were captured in CCD camera. Densitometric analyses 
were carried out using Alpha View Imaging software. One-way ANOVA followed by Bonferroni’s 
multiple comparison tests for comparison between the stages (GraphPad Prism) to determine statistically 
significant difference and a p value < 0.05 was considered significant. 
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4.3.3 Immunohistochemistry 
Immunohistochemical analysis was done as previously described (Brown and Nazarali, 2010) with 
minor modifications. Embryonic mouse heads were preserved in freshly-prepared 4% paraformaldehyde 
and dehydrated in 30% sucrose at 4°C. Frozen coronal sections (10 μm) were prepared on slides coated 
with 0.5% gelatin. The sections were air dried for at least 2 h and then rehydrated with PBS twice, each 
10 min. Then the sections were blocked with 4% skim milk with 0.1% Triton-X-100 in PBS at RT for 1 
h. Primary antibodies were incubated overnight at 4°C with the following dilutions: HTRA3 (Tochorus et 
al., 2004; 1:500), and TGFβ3 (chicken monoclonal; Developmental Studies Hybridoma, IA; 1:40). The 
sections were washed with PBS twice for 7 min each time, followed by probing with secondary antibodies 
labeled with Alexa Fluor® 488 or Alexa Fluor® 594 at RT for 1.5 h, followed by washes with PBS twice 
for 7 min each time. The sections were then exposed to 30 µl of Hoechst for 15 min followed by followed 
by washes with PBS twice for 7 min each time. Coverslips were mounted over the sections using 
ProLong® Gold antifade reagent (Invitrogen). The slides were then imaged using fluorescent microscope 
(Olympus America Inc., Center Valley, PA).  
4.3.4 In vitro palatal organ culture 
Palatal shelves were cultured based on a modified Trowell type organ culture method as described 
previously (Shiomi et al 2006; Nakajima et al 2007; Brown and Nazarali, 2010) with minor modifications. 
Briefly, timed-pregnant C57BL/6J mice were sacrificed at E13.5. Palatal shelves were dissected from the 
fetal murine head under sterile conditions and placed in pairs on 0.4 µm Millipore filters inserts with 
correct anterior–posterior orientation and with their medial edges in contact. The palatal shelves were 
cultured in BGJB medium for 60 h (Gibco) at 37°C with 5% CO2.  
4.3.5 Generation of lentiviral particles 
Lentiviral particles expressing green fluorescent protein (GFP) were generated using iLenti-siRNA-
GFP vectors as per the manufacturer’s protocol (Applied Biological Materials Inc). Briefly, iLenti-siRNA-
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GFP vectors carrying Htra3 siRNA sequences and scramble control siRNA sequence were transformed 
individually into DH5α cells and selected on Luria Bertani plates containing 50 µg/ml kanamycin. Single 
colonies were picked and grown overnight in Luria Bertani broth. Plasmid DNA was isolated from the 
respective cultures using endotoxin free plasmid DNA maxiprep kit (Qiagen). Restriction digestion of the 
plasmid DNA using BamHI was carried out for plasmid containing siRNA sequences and NheI and XhoI 
for the mock vector plasmid for the confirmation of the siRNA sequences.   
293T cells were co-transfected with plasmid DNA and lentiviral packaging vectors pMD2.G and ps-
PAX2 using polyethyleneimine (Addgene) and checked for the expression of GFP in the cells. Lentiviral 
particles collected after 48 h and 72 h were then concentrated by ultracentrifugation at 25,000 rpm for 2 h 
at 4°C in SW-25 rotor (Beckman). Lentiviral particles were then titrated using qPCR by a comparative Ct 
method (Applied Biological Materials Inc). Lentiviral particles were transduced in the palatal shelves in 
in vitro organ culture systems at various infection units (IU) and checked for the expression of GFP in the 
palatal shelves.  
4.3.6 Isolation and primary culture of palatal epithelial cells  
Palatal shelves from E13.5 C57BL/6J mice embryos were excised in Hank’s balanced salt solution. 
Palatal shelves were treated using Dispase II (Stemcell technologies, BC) for 1 h at 37°C. Epithelial sheets 
were removed from the underlying mesenchyme using a fine needle. The epithelial sheets were then 
pipetted thoroughly and passed through 70 µm cell strainer (BD Falcon) and plated on poly-D-lysine 
(PDL) coated plates and grown on F12 media containing 10% FBS and 1% penicillin/streptomycin 
solution. Palatal epithelial cells were used for transduction of lentiviral particles containing Htra3 siRNA 
sequences to test the efficiency in knockdown of Htra3 mRNA.   
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4.4 Results 
4.4.1 Htra1 and Htra3 are expressed in developing palatal shelves  
HTRA1 and HTRA3 bind to TGFβ/BMP ligands such as TGFβ1, 2, Growth differentiation factor 5 
(GDF5) and BMP4 and inhibit downstream signaling in vitro (Oka et al., 2004; Tochorus et al., 2004). 
Given the significant roles of TGFβ/BMP family members in palatal development, I investigated the 
expression of Htra1 and Htra3 in the developing palate. Due to alternative splicing, Htra3 produces two 
forms of mRNAs, the long form which is the full-length form and the short form which lacks the c-terminal 
PDZ domain.  Indeed, qPCR reveals that Htra1 and Htra3 mRNAs are endogenously expressed in palatal 
shelves throughout E12 to E15. mRNA expression of Htra1, Htra3 long form and Htra3 short form 
increases from E12 to E15 and are highest at E15 (Figure 4.1A-C) during which the palatal shelves fuse. 
Tgfβ1 mRNA also increases from E12 to E15, whereas Tgfβ3 mRNA increases from E12 to E14 and then 
slightly decreases at E15(data not significant) (Figure 4.2A, B).  
Western blot analyses reveal that the expression of HTRA1 (Figure 4.3A, B) protein increases as 
palatogenesis proceeds from E12 to E15, analogous to the expression of Htra1 mRNA. Interestingly, two 
bands of HTRA3 are observed in the immunoblots with a full-length isoform at ~55 kDa and a cleaved 
isoform at ~27 kDa. Both bands at ~55 kDa and ~27 kDa are upregulated from E12 to E15 in the 
developing palate (Figure 4.4A-C).  
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Figure 4.1 Htra1 and Htra3 mRNAs increase in developing palatal shelves from E12 to E15. Relative 
Htra1 (A), Htra3 short (B) and Htra3 long form (C) mRNA expression levels in developing mouse palate 
were determined by qPCR using SYBR green assay normalized to β-actin. Graphs represent mean ± SEM, 
n=3. One-way ANOVA to calculate statistical significance and Bonferroni’s multiple comparison test for 
comparison between the stages (* P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 4.2 Tgfβ1 mRNA increases from E12 to E15, whereas Tgfβ3 mRNA increases from E12 to 
E14 and then decreases at E15. Relative Tgfβ1 (A) and Tgfβ3 (B) mRNA expression levels in developing 
mouse palate were determined by qPCR using Taqman FAM probes, normalized to labelled actin. Graphs 
represent mean ± SEM, n=3. One-way ANOVA to calculate statistical significance and Bonferroni’s 
multiple comparison test for comparison between the stages (* P < 0.05, **P < 0.01, ***P < 0.001).  
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Figure 4.3 HTRA1 protein increases during palatal development from E12 to E15. Western blot 
analysis of proteins extracted from palatal shelves of E12 to E15 mouse embryos. Proteins (20 µg) were 
separated on 10% polyacrylamide-SDS gel and transferred to a PVDF membrane and probed with HTRA1 
and β-ACTIN antibodies. Densitometry analysis was carried out using AlphaView software and one-way 
ANOVA to calculate statistical significance and Bonferroni’s multiple comparison test for comparison 
between the stages (* P < 0.05, **P < 0.01).   
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Figure 4.4 HTRA3 protein increases during palatal development from E12 to E15. Western blot 
analysis of proteins extracted from palatal shelves of E12 to E15 mouse embryos. Proteins (20 µg) were 
separated on 10% polyacrylamide-SDS gel and transferred to a PVDF membrane and probed with HTRA3 
and β-ACTIN antibodies. Densitometry analyses were carried out using AlphaView software and one-way 
ANOVA to calculate statistical significance and Bonferroni’s multiple comparison test for comparison 
between the stages (* P < 0.05, **P < 0.01).   
 
 
 
4.4.2 HTRA3 and TGFβ3 are co-expressed mainly in the palatal epithelia 
Immunohistochemistry shows that HTRA3 is expressed in the epithelia of the palatal shelves at 
E13.5 (Figure 4.5) and in the midline epithelial seam at E14.5 (Figure 4.6) along the anterior-posterior 
axis. HTRA3 colocalizes with the epithelial marker E-CADHERIN in the palatal epithelium at E13.5 and 
E14.5 and at the MES at E14.5 (Figure 4.5 and 4.6).  This expression pattern is characteristic of TGFβ3 
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in the epithelia at E13.5 and in the MES at E14.5 (Figure 4.7). These results show that HTRA3 is expressed 
in the epithelia in the developing palate and its expression in the MES might be indicative of its role in 
palatal fusion. In addition, there is a strong staining for HTRA3 in the developing palatal process of the 
palatine bone at E14.5 (Figure 4.6), which indicates that HTRA3 could also play a role in the ossification 
of the palatal bones. 
4.4.3 Htra3 siRNA knockdown efficiency in palatal epithelial cells and transduction of lentiviral-
GFP particles in palatal shelves organ culture ex-vivo 
Four sets of lentiviral Htra3 siRNA sequences in iLenti-siRNA-GFP vectors were purchased and 
lentiviral particles were produced in house by co-transfecting HEK 293T cells with individual lentiviral 
siRNA plasmids along with packing vectors pMD2.G and ps-PAX2 (Addgene). Four different siRNA 
sequences were evaluated for their efficiency to knockdown Htra3 in palatal epithelial cells. Among the 
tested siRNAs, siRNA-A showed highest efficiency, with a knockdown of 90% of Htra3 mRNA in palatal 
epithelial cells (Figure 4.8A).  
Prior to evaluating the efficiency of lentiviral particles to knockdown Htra3 in palatal shelves in 
organ culture in vitro, 107 infection units (IU) lentiviral particles expressing GFP (mock particles) were 
used to transduce the palatal shelves in organ culture system. After 48 h, the palatal shelves showed intense 
fluorescence of GFP expressing lentiviral particles (Figure 4.8B). However, repeated attempts of lentiviral 
siRNA transduction in the palatal fusion culture failed to efficiently silence Htra3 mRNA in the organ 
culture. Therefore, the functional role of Htra3 in the palatal epithelia remains to be characterized.  
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Figure 4.5 HTRA3 is expressed epithelia of the palatal shelves at E13.5. Immunohistochemistry 
staining of HTRA3 and E-CADHERIN in coronal sections of wild type embryonic heads at E13.5. Top 
row panels are in anterior region of the palate, bottom row panels are in the posterior region of the palate 
and middle rows are in the middle region of the palate. Scale bar, 50 µm.  
 
 
 
 
 
 
 
 
 
Figure 4.6 HTRA3 is expressed in MES during palatal fusion at E14.5. Immunohistochemistry 
staining of HTRA3 and E-CADHERIN in coronal sections of wild type embryonic heads at E14.5. Top 
row panels are in anterior region of the palate, bottom row panels are in the posterior region of the palate 
and middle rows are in the middle region of the palate. Scale bar, 50 µm.  
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Figure 4.7 HTRA3 and TGFβ3 are co-expressed in the palatal epithelia and MES. 
Immunohistochemistry staining of HTRA3 and in coronal sections of wild type embryonic heads at E14.5. 
Top row panels are at the respective immunostaining at E13.5, bottom row panels are at E14.5. HTRA3-
positive or TGFβ3-positive cells are stained in red and DAPI-positive nuclei are stained in blue.  
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Figure 4.8 Efficiency of Lentiviral siRNA particles in palatal epithelial cells in vitro and in palatal 
shelves in ex-vivo organ culture. Palatal epithelial cells were transduced with scramble control siRNA or 
Htra3 siRNA A, B, C or D. Relative Htra3 mRNA expression levels in palatal epithelial cells were 
determined by qPCR using SYBR green assay normalized to β-actin 48 h after transfection. Graphs 
represent mean ± SEM. One-way ANOVA to calculate statistical significance and Bonferroni’s multiple 
comparison test for comparison between the stages **P < 0.01, ***P < 0.001). E13.5 palatal shelves were 
transduced with around 107 lentiviral IU and grown on organ culture dish for 48 h and then evaluated for 
the GFP fluorescence. Palatal shelves not transduced with any lentiviral particles served as the control.  
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4.5 Discussion  
 The data in this chapter reveal a novel expression pattern of Htra3 in the developing palate giving 
insight into the possible role of Htra3 during palatogenesis. Htra3 is expressed during the growth, 
elevation and fusion stages of palate development, with its expression highest during the fusion stages at 
E15. IHC analysis revealed that HTRA3 protein is expressed principally in the nasal side palatal epithelia, 
oral side palatal epithelia and in the MEE at E13.5. At E14.5, HTRA3 is expressed in the MES, which 
starts to degrade due to apoptosis (Cui et al., 2003). Htra3 is known to induce apoptosis in lung cancer 
cells (Beleford et al., 2010). It would be interesting to double label activated-CASPASE3 and HTRA3 in 
the palatal sections at E14.5 to determine whether most of the HTRA3-positive cells are apoptotic in nature 
in the MES during palatal fusion at E14.5. HTRA3 is also expressed in the developing palatine bone. At 
E15.5, the palatal process of maxilla starts to ossify and Htra3 is at its peak during this stage. It is plausible 
that Htra3 could be involved in the osteogenic differentiation of the palatal mesenchyme.  
 The data here indicate that Htra family members- Htra1 and Htra3 share similar temporal 
expression patterns with TGFβ family members. TGFβ3 in the MEE in indispensable for the formation 
and degradation of MES (Cui et al., 2003). An existing hypothesis suggests that HTRA family members 
could facilitate TGFβ signaling by cleaving the latent TGFβ binding protein ligands (Beaufort et al., 2014). 
Therefore, it is possible that Htra3 could be acting upstream of TGFβ3 to activate downstream signaling 
for the induction of apoptosis and palatal fusion. In the physiological cleft palate of the chick embryos, 
the developing palate is devoid of TGFβ3 (Sun et al., 1998). Addition of TGFβ3 to palatal explant cultures 
ex-vivo results in palatal fusion. It would be interesting to check if HTRA3 is expressed in the developing 
palatal shelves of the avian embryos and whether addition of HTRA3 protein could induce palatal fusion 
ex-vivo, which could be easier to do than lentiviral transduction to silence Htra3 mRNA ex-vivo. The 
siRNA sequences were validated to silence Htra3 mRNA in vitro in both MEPM (data not shown) and in 
palatal epithelial cells. Despite multiple attempts to transfect using duplex siRNA and to transduce using 
lentiviral particles, I failed to demonstrate a consistent knockdown of Htra3 mRNA ex-vivo. This could 
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be due to the robust elevation in the expression of Htra3 after E13.5, when the palatal explants are cultured 
ex-vivo. In addition, the expression of Htra3 from the developing palatal bones could be a hindrance in 
knocking down Htra3 expression in the palatal shelves. Furthermore, it is also possible that the 
multilayered tissue structure might have been a barrier in the diffusion of lentiviral particles along the 
epithelial layers.  
TGFβ signaling inhibits osteogenic differentiation of the palatal mesenchyme (Iwata et al., 2010). 
The expression of Htra3 in the osteogenic fronts could be indicative of its role in the osteogenic 
differentiation of the palatal mesenchyme. It is important to note that Htra3-/- mice do not show any bone 
related abnormalities (Filliat et al., 2017). Expression patterns of Htra1 and Htra3 show overlaps 
temporally across different stages of palate development. Hence, it is possible that Htra1 and Htra3 could 
be redundant in regulating osteogenic differentiation. However, it is also important to note that among the 
TGFβ ligands, knockin of Tgfβ1 in the Tgfβ3 locus could only partially rescue the cleft palate along the 
anterior-posterior axis in Tgfβ3-/- mice (Yang and Kaartinen, 2007). Therefore, it would be intriguing to 
identify if there is any functional redundancy between Htra1 and Htra3 in osteogenic differentiation of 
the palatal mesenchyme. In addition, the role of Htra3 in palatal fusion and osteogenic differentiation 
remains to be characterized.  
 
Preamble to Chapter 5: Htra1 positively regulates osteogenic differentiation of the palatal 
mesenchyme and is a direct transcriptional target of Runx2 during osteogenic differentiation 
Rationale 
 Data emerged from the literature during the progress of this thesis indicating that Htra1 may not 
be a direct downstream target of Hoxa2 during craniofacial development. In addition, a recent report of 
genome-wide RUNX2 bound regions indicated that Htra1 may be regulated by RUNX2 during osteogenic 
differentiation. In the previous chapter, I examined the quantitative mRNA and protein expression profile 
of Htra1 and Htra3, which increase from E12 to E15. In this chapter, I examine the localization of HTRA1 
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protein in the developing palate and the role of Htra1 in osteogenic differentiation. Using pull-down and 
luciferase assays, I demonstrate the molecular interaction of Htra1 and RUNX2.  
Manuscript 
Iyyanar, P. P. R*., Thangaraj, M. P., Eames, B. F., and Nazarali, A. J. Htra1 is a novel direct downstream 
target of Runx2 during osteogenic differentiation. Manuscript to be submitted to Osteoarthritis and 
Cartilage.   
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5. HTRA1 POSITIVELY REGULATES OSTEOGENIC DIFFERENTIATION OF THE 
PALATAL MESENCHYME AND IS A DIRECT TRANSCRIPTIONAL TARGET OF 
Runx2 DURING OSTEOGENIC DIFFERENTIATION 
5.1 Summary 
Craniofacial bones are mainly formed via intramembranous ossification. Transcription factor RUNX2 
is a master regulator of osteoblast differentiation. The downstream targets of Runx2 during 
osteoblastogenesis remain largely unknown. HTRA1 is a serine protease involved in cell survival, 
proliferation, and apoptosis. However, the role of Htra1 during osteoblast differentiation remains elusive. 
In this chapter, I show that Htra1 is expressed mainly in the ossifying matrix of the craniofacial region 
during development. Hence, I investigated the role of Htra1 in osteogenic differentiation of MEPM cells 
and the regulation of Htra1 by Runx2. The data here show that overexpression of Htra1 increased the 
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matrix deposition and mineralization of MEPM cells at d15 and d21, respectively. In addition, 
overexpression of Htra1 caused increased mRNA expression of osteoblast markers, Alpl and Sp7 or Osx 
at d8 and d15. Overexpression of Runx2 resulted in the upregulation of Htra1 mRNA. Streptavidin agarose 
pulldown assay (SAPA) using biotin probes (-1000 bp and -400 bp upstream promoter of Htra1) showed 
that RUNX2 interacts with the Htra1 promoter. Chromatin immunoprecipitation (ChIP) assay further 
confirmed that RUNX2 protein binds to the proximal -400 bp region of the Htra1 promoter during 
osteoblast differentiation. Dual luciferase assay data revealed that Runx2 significantly increased the 
luciferase reporter activity of the proximal Htra1 promoter constructs. Mutation of the putative RUNX2 
consensus binding sites revealed that RUNX2 interacts with the Htra1 promoter at -252 bp and -84 bp to 
regulate the promoter activity of Htra1. These findings suggest that Htra1 is a positive regulator of 
intramembranous osteoblast differentiation and is a direct downstream target of Runx2 during osteoblast 
differentiation. 
5.2 Introduction 
Craniofacial bones are mainly formed via intramembranous ossification of cranial neural crest cells, 
which does not involve formation of an intermediate cartilaginous template (Jiang et al., 2002). The 
maxillary region comprises of six primordia, which includes pairs of premaxilla, maxilla, and palatine 
bones (Iwata et al., 2012). Transcription factor RUNX2 is a critical regulator of osteogenic differentiation 
and Runx2 null mutants exhibit complete lack of ossification (Komori et al., 1997). RUNX2 binds to the 
consensus RUNT binding site RCCRC(A/T) (Kamachi et al., 1990) to bind to the promoter region of 
several osteoblast regulators for their transcriptional regulation (Roca et al., 2005; Lamour et al., 2007; Li 
et al., 2011). Several transcriptional targets of RUNX2 during osteogenic differentiation are not yet known 
and remain to be characterized (Wu et al., 2014a).  
  HTRA1 is one of the four members of the HTRA family of serine proteases. HTRA1 is more 
known for its role in age-related macular degeneration (Yang et al., 2006) and cerebral autosomal recessive 
arteriopathy with subcortical infarcts and leukoencephalopathy (Hara et al., 2009; Mendioroz et al., 2010). 
HTRA1 is expressed in hypertrophic cartilage and osteoblasts in physiological conditions (Tocharus et al., 
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2004) and in disease phenotypes like osteoarthritis bone regions (Tsuchiya et al., 2005) and fracture callus 
(Tiaden et al., 2012). Silencing of Htra1 using siRNA inhibits all-trans retinoic acid (ATRA) induced 
osteogenic differentiation of adipose derived stromal cells (Glanz et al., 2016). Preliminary findings 
indicate that Htra1 is a positive regulator of osteogenic differentiation, where it is involved in the lineage 
commitment of mesenchymal stem cells to form osteoblasts (Tiaden et al., 2012) at the expense of 
adipogenesis (Tiaden et al., 2016). In contrast, other studies have found Htra1 as a negative regulator of 
osteogenesis (Hadfield et al., 2008; Wu et al., 2014). Therefore, the role of Htra1 in osteogenesis remains 
unclear and there is limited evidence on the gene networks and signaling pathways both upstream and 
downstream of Htra1 in osteogenic differentiation.  
Here I investigated the role of Htra1 in osteogenic differentiation of primary mesenchymal cells 
in vitro. I show that for the first time that RUNX2 binds to two putative consensus bindings sites on the 
proximal Htra1 promoter to regulate its expression. In addition, the data show that Htra1 as a positive 
regulator of osteogenic differentiation in vitro.  
5.3 Materials and Methods 
5.3.1 Primary cultured cells derived from mouse embryonic palatal mesenchyme (MEPM) 
Primary MEPM cells were isolated from palatal shelves of wild type C57BL/6J mice embryos at 
E13.5. Briefly, palatal shelves were micro-dissected from the maxilla of E13.5 embryos and incubated 
with 0.25% trypsin (Sigma) for 15 min at 37°C (Iwata et al., 2012). Cells were gently pipetted up and 
down, passed through 70 µm cell strainer (BD Falcon) and plated on PDL coated T25 flasks.  Cells were 
cultured in (DMEM): Ham’s F12 (DMEM/F12) (1:1) media containing 10% FBS, 1% antibiotic-
antimycotic solution (Sigma) and passaged three times or less. Osteogenic differentiation was carried out 
as described previously (Kwong et al., 2008) with minor modifications. Briefly, MEPM cells were seeded 
on PDL coated 24-well plates at a cell density of 5  104 cells per well in triplicate and cultured until they 
reached confluence. Osteogenic differentiation was induced with osteogenic differentiation media 
comprising of DMEM with 4,500 mg/L glucose, 10% FBS, 2 mM L-glutamine and 1% antibiotic-
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antimycotic solution. Media was also supplemented with osteogenic inducing agents, including 50 µg/ml 
L-ascorbic acid 2-phosphate sesquimagnesium salt (Sigma), 10 mM β-glycerophosphate (Sigma) and 100 
nM dexamethasone (Sigma). Media was changed every third day for up to 8, 14 or 21 days. In the case of 
all-trans retinoic acid (ATRA) treatment, MEPM cells were treated with 1 µM or 5 µM final concentration 
of ATRA or vehicle in osteogenic differentiation media with 0.5% FBS. Cells were harvested for RNA 
isolation or fixed for ALPL staining at day 8.  
5.3.2 ALPL staining 
MEPM cells were washed once with PBS, pH 7.4, followed by fixation in 4% paraformaldehyde for 
15 min and then washed two times with PBS. Cells were subsequently washed with deionized water to 
remove excess PBS. Cells were then treated with ALPL buffer (100 mM NaCl, 100 mM Tris–HCl pH 9.5, 
50 mM MgCl2, 0.1% Tween-20) for 10 min prior to staining with 4.5 μl/ml of 5-Bromo-4-chloro-3-indolyl 
phosphate (Roche) and 3.5 μl/ml of nitro blue tetrazolium (Roche) in alkaline phosphatase buffer for 10 
min. The reaction was stopped with PBS containing 20 mM EDTA buffer.   
5.3.3 ARS staining and quantification 
ARS staining and quantification was carried out as described in Gregory et al., 2004 with minor 
modifications. Briefly, monolayer MEPM cells were washed once with PBS, pH 7.4, followed by fixation 
in 4% paraformaldehyde for 15 min and then washed two times with PBS. Cells were subsequently washed 
with deionized water to remove excess PBS, prior to the addition of 250 µl of 40 mM ARS (Sigma) 
solution (pH 4.1). Cells were incubated at room temperature for 20 min with gentle shaking. Excess dye 
was aspirated and cells were washed with deionized water and imaged. For quantification of ARS, 400 µl 
of 10% acetic acid (Fisher Scientific) was added to each well and incubation proceeded for 30 min with 
shaking. The loosely attached monolayer cells were then dislodged using a cell scraper (Fisher Scientific) 
and transferred to a micro-centrifuge tube containing 10% acetic acid. After vortexing for 30 s, samples 
were heated at 85°C for 10 min and cooled on ice for another 5 min. The slurry was centrifuged at 15,000 
g for 15 min and 300 µl of the supernatant transferred to a new micro-centrifuge tube followed by the 
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addition of 150 µl of 10% solution of ammonium hydroxide (Sigma). After vortexing, 150 µl was 
transferred from this mixture to an opaque walled 96-well plate for measurement of absorbance at 405 nm. 
Standard plot of ARS concentration was constructed by serially diluting 40 mM ARS in a buffer containing 
10% (v/v) acetic acid and 10% (v/v) ammonium hydroxide. Absorbance values of standard concentrations 
were used to interpolate concentrations of the test sample. 
5.3.4 Quantitative real-time polymerase chain reaction (qPCR) 
Total RNA from the micro-dissected palatal shelves was isolated using RNA mini spin column as 
per the manufacturer’s protocol (BioRad). First strand cDNA synthesis (Reverse transcription) was 
performed in 20 µl reactions with 500 ng of total RNA using High-Capacity cDNA Reverse Transcription 
Kit (Invitrogen). qPCR was carried out using SYBR green with the 7300-real time PCR system (Applied 
Biosystems) and the primers used for the qPCR assay are listed in Table 5.1.  
 
 
 
 
 
 
Table 5.1 Primer sequences used for the relative quantification of the transcripts in palatal shelves by 
qPCR using SYBR green.  
Transcript Primer sequences Length 
(bases) 
Amplicon 
size (bp) 
Alkaline 
phosphatase 
(Alpl) 
CCTTGACTGTGGTTACTGCT 
CCTGGTAGTTGTTGTGAGCG 
20 
20 
216 
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High temperature 
requirement 
factor A1 (Htra1) 
AGTTCTTGACAGAGTCCCACGA 
TATGCCCCAGAGAGCACATCC 
22 
21 
154 
Runt-related 
transcription 
factor 2 (Runx2) 
TGCCTCCGCTGTTATGAAAA 
CTGTCTGTGCCTTCTTGGTT 
20 
20 
187 
Sp7 transcription 
factor (Sp7) 
CACAAAGAAGCCATACGCTG 
CCAGGAAATGAGTGAGGGAAG 
20 
21 
165 
18s ribosomal 
RNA (18s rRNA) 
CGCGGTTCTATTTTGTTGGT 
AGTCGGCATCGTTTATGGTC 
20 
20 
219 
 
5.3.5 Htra1 overexpression transfections 
Htra1-myc-ddk vector (Origene) was digested using SalI and XhoI restriction enzymes to separate 
the Htra1 cDNA, and the negative control vector was synthesized by self-ligation of SalI and XhoI 
compatible sticky ends. Site directed mutagenesis of Htra1 on serine residue at 328 to alanine was carried 
out by PCR using QuikChange Lightning kit (Agilent Technologies) with the following primers: 
5′CATCAATTATGGAAATGCCGGAGGCCCGTTAG 3ʹ and 
5′GTAGTTAATACCTTTACGGCCTCCGGGCAATC 3ʹ. MEPM cells were transfected with 
polyethylenimine (PEI) [Linear Mol. Wt 25,000, Polysciences, Inc.] at a ratio of 2.5:1 to the DNA 
concentration. For each well of a 24-well plate, 700 ng of Htra1-myc-ddk vector or the negative control 
vector was transfected with 1,750 ng of PEI every fourth day in the presence of serum and without 
antibiotics.  After transfection, the media was changed after overnight incubation and fresh osteogenic 
media was added. Cells were either fixed for ALPL or ARS staining or lysed for RNA isolation. Similarly, 
Runx2-myc-ddk vector (Origene) was used for the overexpression of Runx2 in MEPM cells.  
5.3.6 Biotinylated probes  
Biotinylated probes were synthesized by PCR amplification from mouse genomic DNA using 5' 
biotin labelled primers (Invitrogen). For synthesizing 1 kb Htra1 promoter probe (-994 to +72 bp) the 
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primers used were forward primer 5'-biotin-TCCTCCTTGAGTCAGGGTCA-3' and reverse primer 5'-
biotin-GCAGCAGTAGCAAAGACAGG-3'. The primers for the -400 bp probe were forward primer 5'-
biotin-AAGTTCACAGCCACAGTCCC-3' and reverse primer 5'-biotin-
TAGCAAAGACAGGAGCGTGG-3'. The annealing temperature for the primers was 60°C. All PCR 
amplified biotinylated probes were electrophoresed on an agarose gel and purified using gel extraction kit 
(Thermo Fisher).  
 5.3.7 Streptavidin agarose pull-down assay 
The streptavidin agarose pull-down assay (SAPA) was carried out as previously described (Deng et 
al., 2006; Ji et al., 2011) with minor modifications. At d8 of osteogenic differentiation, MEPM cells were 
detached from the T75 flasks using 0.25% trypsin and centrifuged at 2,000 g for 5 min. To the cell pellet, 
200 µl of RIPA buffer containing 50 mM Tris–HCl, pH 7.4, 1% NP-40, 0.25% Na deoxycholate,150 mM 
NaCl, 1 mM NaF, 1 mM Na3VO4, 1 mM EDTA, and 1% protease inhibitor cocktail (Sigma) was added to 
lyse the cells, vortexed and passed through 28-gauge needle and incubated on ice for a minimum of 30 
min. The lysates were then centrifuged and the supernatant was collected. Protein concentration measured 
using the Bradford assay. 5 µg biotinylated DNA probe added to the cell lysates (250 µg) and incubated 
at 4°C overnight with rotational mixing. Streptavidin-agarose beads (20 µl) were added to each sample at 
4°C for 4 h with rotational mixing. The beads were then washed and centrifuged four times in 1 ml RIPA 
buffer at 4°C. Beads were then suspended in 30 µl of 2X SDS loading buffer, boiled for 15 min at 95°C, 
centrifuged and collected supernatant used for Western blot analysis. 
5.3.8 Chromatin immunoprecipitation assay  
Chromatin immunoprecipitation (ChIP) assay was carried (Ji et al., 2011) out using a rabbit 
monoclonal antibody against RUNX2 (Cell Signaling). Briefly, MEPM cells were fixed with 0.75% 
formaldehyde in 1X PBS for 10 min and then blocked with 0.125 M glycine for 5 min at room temperature. 
After washing twice with ice cold PBS, cells were scraped in cold PBS and to the cell pellet 200 µl of cell 
lysis buffer containing 50 mM HEPES-KOH (pH 7.5), 140 mM NaCl, 1 mM EDTA (pH 8), 1% Triton X-
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100, 0.1% sodium deoxycholate, 0.1% SDS, 1% protease inhibitors was added. Samples were then 
sonicated to shear the DNA with four rounds of 12 sec pulses each at 50% power output and 90% duty 
cycle using a Branson Sonicator 200. DNA samples were electrophoresed on a 1% agarose gel to ensure 
DNA shearing was between 400 bp to 1000 bp. Following sonication, 50 µl of the supernatant was stored 
as input and to measure DNA concentration of the sonicated samples. Protein A/G beads were washed and 
precleared with 50 µg of sonicated DNA in ChIP dilution buffer containing 1% Triton X-100, 2 mM 
EDTA (pH 8), 20 mM Tris-HCL (pH 8), 150 mM NaCl, 1% protease inhibitors for each 
immunoprecipitation for 1 h at 4°C and spun at 2,000 g for two min. The precleared supernatant was then 
mixed either the RUNX2 monoclonal antibody or the normal rabbit IgG and rotated at 4°C overnight. This 
was followed by addition of 40 µl of fresh protein A/G beads to the immunoprecipitated complex and 
further mixing by rotation at 4°C for 4 h. Beads were then washed four times with low salt wash buffer 
containing 0.1% SDS, 1% Triton X-100, 2 mM EDTA (pH 8), 20 mM Tris-HCL (pH 8), 150 mM NaCl 
and two times with high salt buffer containing 0.1% SDS, 1% Triton X-100, 2 mM EDTA (pH 8), 20mM 
Tris-HCL (pH 8), 500 mM NaCl at 4°C for 2 min each wash. The chromatin immunoprecipitant complex 
was eluted from the beads using 150 µl of elution buffer containing 1% SDS, 100 mM sodium bicarbonate 
at 30°C for 15 min with rotational mixing. The eluted DNA samples were treated with proteinase K and 
RNase A and incubated at 65°C for 2 h. Following incubation, DNA concentration was measured and 
PCR carried out using the primer set to amplify -295 to +72 bp region of Htra1 promoter.  
5.3.9 Cloning of 5’ flanking region of Htra1 
Five different regions of Htra1 promoter were amplified by PCR using Phusion High-Fidelity DNA 
polymerase (NEB) using primers listed in Table 5.2. Annealing temperature used for all primers was 63°C. 
Using dATP, an A-overhang was introduced to the 3' end of the PCR amplicons by non-proof reading Taq 
DNA polymerase (Lucigen). The PCR products were then purified by gel extraction and cloned into 
pGEM-T easy vector (Promega). From the positive clones of the pGEM-T easy vector cloning, the 
respective Htra1 promoter fragments were digested with KpnI and XhoI for cloning into the destination 
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pGL3 promoter luciferase vector (Promega). All clones were verified by Sanger sequencing at National 
Research Council (NRC) sequencing facility (Saskatoon, SK) and found to match perfectly with the 
promoter region of Htra1 (M. musculus|chr7|138078749-138079949). 
 
Table 5.2 Primer sequences used for the cloning of Htra1 promoter fragments into pGL3 promoter 
luciferase vector. The underlined are the sequences for restriction enzymes KpnI and XhoI, which were 
used to clone the fragments into the destination vector. Sequences in red are the mutated putative RUNX2 
binding sites.  
Htra1 promoter 
region 
Primer sequences 
-994 to +72 bp 
TAGGTACCTCCTCCTTGAGTCAGGGTCA 
TACTCGAGTAGCAAAGACAGGAGCGTGG 
-399 to +72 bp 
TAGGTACCAAGTTCACAGCCACAGTCC 
TACTCGAGTAGCAAAGACAGGAGCGTGG 
-811 to -439 bp 
TAGGTACCGGTGACAGTTGCTCTTCCTGA 
ATCTCGAGAAACCCAGTGCCCAGACCTA 
-295 to +72 bp 
AAGGTACCTTTCCAGGCGATTGCGCAGT 
TACTCGAGTAGCAAAGACAGGAGCGTGG 
-199 to +72 bp 
CCGGTACCGGTCTTCAATCTCTGAGGAAA 
TACTCGAGTAGCAAAGACAGGAGCGTGG 
Site M1 
GATTGAAGACCTTAAGACCAAAATAATACGTAACAGAGGGAAACCTGCCT
AGCACTGCGC 
GCGCAGTGCTAGGCAGGTTTCCCTCTGTTACGTATTATTTTGGTCTTAAGGT
CTTCAATC 
Site M2 
GGTTAAGCCCATTGGCCTAACAACAATGACGAAGCGCCAGGGGGA 
TCCCCCTGGCGCTTCGTCATTGTTGTTAGGCCAATGGGCTTAACC 
Site M3 
CGGCCACGGGCTGGATTATAGATGAAAAACCGCGCTCGGGA 
TCCCGAGCGCGGTTTTTCATCTATAATCCAGCCCGTGGCCG 
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5.3.10 Luciferase assay 
Dual luciferase reporter assay (Promega) was carried out as previously described (Thangaraj et al., 
2017). Briefly, 104 MEPM cells were seeded into white opaque 96-well plate. Next day, the cells were 
transfected using polyethylenimine (PEI) [Linear Mol. Wt 25,000, Polysciences, Inc.] with 100 ng of 
pGL3 firefly luciferase vector constructs, 100 ng of either the negative control or the Runx2 expression 
vector and 40 ng of pRL-CMV renilla luciferase vector as the transfection control. After 48 h, cells were 
lysed with the passive lysis buffer and then firefly luciferase assay reagent II was added to measure the 
firefly luciferase activity. This was followed by the addition of Stop & Glo reagent and the renilla 
luciferase activity measured. The relative luciferase activity was calculated by normalizing the firefly 
luciferase activity values to the respective renilla luciferase values.  
5.3.11 Statistical analyses 
Statistical analyses were carried out by Prism5 software (Graphpad). Unpaired t-test was used in 
the case of two groups, one-way ANOVA or two-way ANOVA with Bonferroni multiple comparison test 
was used where applicable. Data were analyzed and represented as mean ± S.E.M relative to wild type.  A 
p-value of <0.05 was considered significant. 
5.4 Results 
5.4.1 All-trans retinoic acid (ATRA) inhibits osteogenic differentiation of primary MEPM cells 
ATRA is known to have a pleiotropic role in osteogenic differentiation and Htra1 is shown to 
modulate osteogenic differentiation downstream of ATRA (Glanz et al., 2016). However, whether ATRA 
regulates Htra1 expression during osteogenic differentiation is unknown. To answer this, MEPM cells 
were treated with 1 µM or 5 µM of ATRA during osteogenic differentiation. ALPL staining shows reduced 
osteogenic differentiation of MEPM after treatment with ATRA in vitro at d8 (Figure 5.1A-C). In addition, 
ATRA treatment decreased matrix mineralization stained by ARS at d21 (Figure 5.1D-F). Consistently, 
98 
 
ATRA treatment resulted in a complete downregulation of Runx2, a master regulator of osteogenic 
differentiation at d8 (Figure 5.1G). In contrast, Hoxa2, a negative regulator of osteogenic differentiation 
was upregulated ~1.67 and ~1.5-fold after treatment with ATRA 1 µM and 5 µM, respectively (Figure 
5.1H). Interestingly, similar to the levels of Runx2, Htra1 is significantly downregulated after treatment 
with ATRA during osteogenic differentiation at d8 (Figure 5.1I). These data indicate that ATRA inhibits 
osteogenic differentiation of primary mesenchymal cells from the palate potentially via downregulation 
of Runx2 and Htra1.  
5.4.2 Htra1 expression is characteristic of osteogenic markers  
Next, expression of HTRA1 was evaluated in the craniofacial region during development using IHC 
staining. HTRA1 is mainly expressed in ossifying matrix regions of the maxilla (Figure 5.2A), mandible 
(Figure 5.2B) and palatal bone (Figure 5.2C) regions in wild type embryos at E16.5. In the Hoxa2-/- palate, 
which exhibited increased osteoblast differentiation, HTRA1 is upregulated in the palatal process of 
maxilla at E16.5 (Figure 5.2D). In addition, Htra1 mRNA is upregulated at stages E13.5 and E15.5 during 
palatogenesis, times when the palatal process of the palatine bone and the palatal process of maxilla are 
ossifying, respectively (Figure 5.2E). Intriguingly, Htra1 follows a temporal pattern of expression 
comparable to Runx2, Alpl and Sp7 (Osx) during osteogenic differentiation of the palatal mesenchyme in 
vitro (Figure 5.2F). These results show that Htra1 is expressed osteogenic differentiation and might play 
role in osteogenic differentiation of MEPM cells.      
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Figure 5.1 All-trans retinoic acid (ATRA) inhibits osteogenic differentiation of primary MEPM cells. 
(A-C) Alkaline phosphatase (Alpl) staining at d8 revealing osteogenic differentiation of MEPM cells 
treated with DMSO (A), ATRA 1 µM (B) and ATRA 5 µM (C) for 8 days. (D-F) Alizarin red (ARS) 
staining in MEPM cells after treatment with DMSO (D), ATRA 1 µM (E) and ATRA 5 µM (F) for 21 
days during osteogenic differentiation. Gene expressions of Runx2 (G), Hoxa2 (H) and Htra1 (H) at d8 of 
osteogenic differentiation with ATRA treatment. Data was normalized to 18s rRNA (n=4 biological 
replicates; mean ± S.E.M; one-way ANOVA with Bonferroni post-hoc test, *, p<0.05; **, p<0.01; ***, 
p<0.001) and represented relative to DMSO control. 
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Figure 5.2 Htra1 expression is characteristic of osteogenic markers.  Immunohistochemical staining 
for HTRA1 in maxilla (A) and mandible (B) in wild type embryos at E16.5. HTRA1 protein expression 
in the palatal process of maxilla in wild type (C) and Hoxa2-/-  embryos (D). Relative gene expression of 
Htra1 in the developing palate from E12.5 to E15.5 in wild type and Hoxa2-/-  embryos (E). Data was 
normalized to 18s rRNA (n=4 biological replicates; mean ± S.E.M; unpaired t-test and represented relative 
to wild type controls at each stage. Relative gene expression of Runx2, Alpl, Sp7 and Htra1 during 
osteogenic differentiation of MEPM cells (F). Data was normalized to 18s rRNA (n=4 biological 
replicates; mean ± S.E.M; one-way ANOVA with Bonferroni post-hoc test and represented relative to 
gene expression to d0. 
5.4.3 Htra1 positively regulates osteogenic differentiation in vitro 
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The role of Htra1 in osteogenic differentiation is controversial, with reports indicating a role of 
Htra1 as an inducer (Tiaden et al., 2012; Li and Zhang, 2015; Glanz et al., 2016) as well as an inhibitor 
(Hadfield et al., 2008; Graham et al., 2014; Wu et al., 2014b) of osteogenic differentiation. Hence, to 
investigate the role of Htra1 in osteogenic differentiation in MEPM cells, Htra1 was overexpressed using 
the pCMV-Htra1-myc-ddk vector and an inactive protease mutant of Htra1 (Htra1 S328A) generated by 
site directed mutagenesis was used as a control against the serine protease activity of active Htra1. At day 
8, the ALPL staining revealed little difference between the Htra1 overexpressed MEPM cells and that of 
the negative control (Figure 5.3A-C). However, overexpression of Htra1 resulted in a clear increase in 
osteogenic differentiation of MEPM cells stained by ALPL at day 15 (Figure 5.3D-F). In addition, ARS 
staining exhibited increased mineralized matrix in MEPM cells overexpressed with Htra1 compared to 
the negative control and the protease inactive Htra1 mutant at day 15 (Figure 5.3G-I and M) and day 21 
(Figure 5.3J-L and N). Furthermore, overexpression of Htra1 increased the expression of osteoblast 
markers such as and Alpl to ~2.1-folds at d7 and d15 (Figure 5.4A) and Sp7 (Osx) to ~1.7-fold at d7 and 
~1.37-fold at d15 (Figure 5.4B). These results demonstrate that Htra1 could be an inducer of osteogenic 
differentiation in primary mesenchymal progenitor cells.   
 To address the signaling mechanism downstream of Htra1 during osteogenic differentiation, 
ossification and bone remodelling real-time PCR array (Bio-Rad) was utilized to identify differentially 
expressed genes upon overexpression of Htra1. In addition to Alpl, several other osteogenic related genes 
such as Fgf9, Fgfr3, Ibsp, Vegfa, Mmp9 and Esr2 were upregulated to ~1.98, 1.95, 2.97, 1.5, 2.33, 4.04 
and 2-folds respectively, after overexpression of Htra1 in differentiating mesenchymal progenitor cells at 
d7 (Figure 5.4C). In contrast, inhibitors of osteogenesis such as Sost, Calca and Esr1 were downregulated 
to ~0.23, 0.6 and 0.51-fold, respectively, upon Htra1 upregulation (Figure 5.4C). These data indicate that 
Htra1 could regulate several osteogenesis related genes to positively modulate osteogenic differentiation.  
RUNX2 is a key transcription factor that regulates several osteoblast specific gene expression 
(Roca et al., 2005; Lamour et al., 2007; Li et al., 2011). Given the similarity in the expression profile of 
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Htra1 and Runx2 in vivo and in vitro, next I investigated whether Runx2 induces Htra1 during osteoblast 
differentiation of MEPM cells. Indeed, Htra1 was upregulated (Figure 5.5B) after the overexpression of 
Runx2 (Figure 5.5A), similar to the levels of Sp7 (Osx) (Figure 5.5C), a known transcriptional target of 
Runx2, at d8 during osteogenic differentiation. These results reveal that Htra1 is a positive regulator of 
osteogenic differentiation of primary mesenchymal cells from the palate and is regulated by RUNX2 
during osteogenic differentiation.  
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Figure 5.3 Htra1 promotes osteogenic differentiation of MEPM cells in vitro. (A-F) ALPL staining in 
MEPM cells transfected with negative control-CMV-myc-ddk vector (A and D), Htra1 S328A inactive 
mutant (B and E) and Htra1-CMV-myc-ddk vector (C and F) after day 8 (A-C) and day 15 (D-F) of 
osteoblast differentiation. (G-L) ARS staining in MEPM cells after Htra1 overexpression at day 15 (G-I) 
and day 21 (J-L). Quantification of ARS stained osteoblast matrix after overexpression of Htra1 at day 15 
(M) and day 21 (N).  
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Figure 5.4 Htra1 regulates the expression of osteogenesis related genes during differentiation of 
primary mesenchymal progenitor cells. Relative mRNA expression of osteoblast markers Sp7 (Osx) (A) 
and Alpl (B) at d7 and d15 in primary mesenchymal progenitor cells after overexpression of Htra1. Data 
was normalized to 18s rRNA (n=4 biological replicates; mean ± S.E.M; one-way ANOVA with Bonferroni 
post-hoc test, *, p<0.05; **, p<0.01; ***, p<0.001) and represented relative to cells transfected with 
negative control vector. Osteogenesis gene expression array was carried at d8 in primary mesenchymal 
progenitor cells transfected with negative control and Htra1 overexpression vector during osteogenic 
differentiation. Differentially expressed genes between the negative control and Htra1 overexpressing 
osteoblasts are plotted in the bar graph (C) (n=3 biological replicates) and the data were normalized to 
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) Ct values of the respective samples and analyzed 
using unpaired T-test, *, p<0.05; **, p<0.01. 
5.4.4 RUNX2 interacts with the 5’ flanking region of Htra1 to induce Htra1 expression during 
osteoblast differentiation  
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Runx2 is one of the master regulators of osteoblast differentiation. The targets of Runx2 during 
osteoblast differentiation are still largely being explored (Wu et al., 2014). Analysis of the proximal 5’ 
flanking region of Htra1 (1 kb) revealed several putative binding sites of RUNX2 (Figure 5.5D). To test 
whether RUNX2 interacts with the 5’ flanking region of Htra1, primers labelled with 5' biotin were used 
to amplify the 5’ flanking region of region of Htra1. This 1 kb biotin probe was then used to pull-down 
proteins from the lysates of MEPM cells (d8 of osteogenic differentiation) using streptavidin agarose pull-
down assay (SAPA). Results indicate that RUNX2 protein interacts with the 5’ flanking region of of Htra1 
(Figure 5.5E). Similarly, the pull-down assay using a biotin probe of -400 bp from the transcription start 
site of Htra1 (-399 bp to +72 bp) also showed an interaction of RUNX2 with the Htra1 5’ flanking region 
(Figure 5.5E). In addition, ChIP analysis further confirmed that RUNX2 interacts within the proximal -
400 bp of the Htra1 5’ flanking region during osteoblast differentiation (Figure 5.5F). These results reveal 
that RUNX2 binds to the Htra1 promoter during osteogenic differentiation.  
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Figure 5.5 RUNX2 promotes the expression of Htra1 and interacts with the Htra1 proximal 
promoter in primary mesenchymal progenitor cells. (A-C) Relative mRNA expression of Runx2 (A), 
Htra1 (B) and Sp7 (C) at d8 during osteogenic differentiation of primary mesenchymal progenitor cells 
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after over expression of Runx2. Data was normalized to 18s rRNA (n=4 biological replicates; mean ± 
S.E.M; unpaired T-test, **, p<0.01; ***, p<0.001) and represented relative to cells transfected with 
negative control vector.  Schematic diagram showing the 5’ flanking region region of Htra1 (-994 bp to 
+200 bp) with putative RUNX2 binding sites (D). RCCRC is the known RUNX2 consensus binding site 
and TGTGGT is the reverse complement of ACCACA (RCCRC). Western blot analyses (E) showing the 
interaction of RUNX2 with biotinylated Htra1 promoter probes of length 1 kb (-994 to +72) (upper panel 
in E) and proximal (-399 to +72 bp) (lower panel in E) by streptavidin-agarose pull down assay (SAPA). 
(F) ChIP assay was performed in differentiating primary mesenchymal progenitor during osteoblast 
differentiation at d5. Cells were cross-linked with formaldehyde, lysed and the sonicated chromatin were 
immunoprecipitated with RUNX2 rabbit monoclonal antibody or normal rabbit IgG antibody. PCR was 
performed using the primers targeting the proximal -399 to +72 region of Htra1 promoter (upper panel in 
F) and an unrelated control 18s rRNA as a control. TSS, transcription start site; WCL, whole cell lysate; 
NC, negative control (rabbit IgG) antibody.  
 
 
 
 
 
 
 
 
 
5.4.5 RUNX2 regulates the promoter activity of Htra1 
Next, to determine whether the binding of RUNX2 to the Htra1 promoter regulates its activity and 
to discover the RUNX2 binding region on the Htra1 promoter, five different PCR amplified regions of 
Htra1 promoter were cloned into the pGL3 promoter luciferase vector. The regions cloned into the pGL3 
promoter luciferase vector were as follows: (i) -994 to +72 bp (ii) -399 to +72 bp (iii) -811 to -439 bp (iv) 
-295 to +72 bp (v) -199 to +72 (Figure 5.6A). All cloned constructs were sequenced using specific forward 
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and reverse primers for respective PCR fragments. Constructs were transfected individually along with 
either the negative control vector or the Runx2 expression vector (Runx2-myc-ddk vector) into MEPM 
cells. The dual luciferase reporter assay was carried out after 48 h as per the manufacturer’s protocol 
(Promega). The data showed that RUNX2 promotes luciferase reporter activity of the Htra1 promoter. 
Amongst the different constructs of the Htra1 promoter tested, Runx2 overexpression increased the 
reporter activity of all the proximal promoter constructs as well as the full length 1 kb promoter construct, 
whereas it did not increase the reporter activity of the distal promoter construct (-811 to -439 bp) (Figure 
5.6B).  These results indicate that Runx2 could induce the expression of Htra1 during osteoblast 
differentiation of MEPM cells by interacting with the Htra1 promoter and the putative binding site(s) for 
interaction could be between -399 to +72 bp.  
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Figure 5.6 RUNX2 association increases the reporter activity of Htra1 promoter. Five different 
lengths of Htra1 promoter fragments were cloned into pGL3 promoter luciferase vector (A). Relative 
luciferase activity of the Htra1 promoter fragments 48 h after transfection with Runx2 overexpression 
vector. RUNX2 induces the luciferase activity of all the Htra1 promoter fragments except the distal 373 
bp (-811 to -439 bp) in MEPM cells.  
 
5.4.6 RUNX2 interaction at the RUNX2 consensus binding sites at -252 bp and -84 bp in the proximal 
5’ flanking region of Htra1 regulates Htra1 promoter activity 
The Htra1 proximal 5’ flanking region (-400 bp) contains four putative RUNX2 consensus binding 
sites. To investigate which one of the RUNX2 consensus binding sites is critical for Htra1 promoter 
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activity, site directed mutagenesis was used to mutate these binding sites at -252 bp, -84 bp and +11 bp 
alone or in combination (Figure 5.7A) in the pGL3 promoter vector and carried out a luciferase assay after 
overexpression of Runx2. Mutations at site 1 (-252 bp) or site 2 (-84 bp) alone or in combination failed to 
increase the promoter activity of Htra1 by RUNX2. In contrast, mutation at site 3 (+11 bp) increased the 
Htra1 promoter activity after Runx2 overexpression (Figure 5.7B). These results indicate that sites at -252 
bp and -84 bp are critical for the inducing Htra1 promoter activity for its expression by RUNX2.  
In conclusion, the data show that Htra1 is an inducer of osteogenic differentiation of primary 
mesenchymal cells and is a direct downstream target of Runx2. Runx2 regulates Htra1 expression through 
its interaction with the Htra1 promoter at -252 bp and -84 bp.    
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Figure 5.7 RUNX2 interaction at the RUNX2 consensus binding sites at -252 bp and -84 bp in the 
Htra1 proximal promoter regulates Htra1 promoter activity. Schematic diagram showing the three 
putative RUNX2 consensus binding sites on the Htra1 promoter and site directed mutagenesis of binding 
sites alone or in combination in pGL3 promoter luciferase vector. Relative luciferase activity of the Htra1 
promoter fragment (-399 to +72 bp) with respective mutations after overexpression of Runx2 for 48 h.   
 
 
 
 
 
 
 
5.5 Discussion 
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In this chapter, I have demonstrated the role of serine protease HTRA1 as an inducer of osteogenic 
differentiation of primary mesenchymal progenitor cells. In addition, I have examined the specific 
molecular interaction between RUNX2 and Htra1 during osteogenic differentiation delineating that 
RUNX2 binds to the Htra1 proximal promoter to transactivate Htra1 expression. Despite the 
advancements in the knowledge of the signaling mechanisms governing osteogenic differentiation, several 
interacting partners and their role in osteogenesis remain obscure. The data here significantly improve the 
understanding of the role of Htra1 in osteogenic differentiation and unravel a novel interaction between 
Htra1 and Runx2.  
Htra1 expression follows the expression pattern of osteogenic markers such as Runx2 in osteogenic 
fronts in vivo and during osteogenic differentiation in vitro. Using IHC, I have demonstrated that HTRA1 
protein is expressed in the developing maxilla, mandible and in the palatal process of the maxilla. The 
expression pattern of HTRA1 in the developing jaw regions were similar to the previously reported 
expression profile of osteoblast markers such as Runx2, Sp7 and Alpl (Baek et al., 2011). Similarly, there 
was a coordinated expression of Htra1 along with other osteogenic markers including Runx2 during 
osteogenic differentiation of primary mesenchymal progenitor cells. The pilot study indicated that ATRA 
inhibits osteogenic differentiation of primary mesenchymal progenitor cells. This is in agreement with 
previous reports on ATRA in osteogenesis of craniofacial mesenchyme (Chen et al., 2010; Morkmued et 
al., 2017). Interestingly, ATRA inhibited the expression of Runx2 and Htra1, whereas it upregulated the 
expression of Hoxa2. Hoxa2-/- mice exhibit increased osteogenic differentiation of the palatal mesenchyme 
with increased expression of osteoblast markers including Runx2 (Chapter 3). Htra1 was upregulated in 
the palatal bones of the Hoxa2-/- mice during development. These findings lead to the hypothesis that 
Htra1 may regulate osteogenic differentiation of the primary mesenchymal progenitor cells and it could 
be regulated by Runx2 during osteogenesis.  
Gain of function of Htra1 in primary mouse mesenchymal progenitor cells results in enhanced 
osteogenesis and osteogenic marker expression. These findings are in line with the role of Htra1 in 
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osteogenesis reported in human bone marrow-derived stem cells (Tiaden et al., 2012a), mouse adipose-
derived stromal cells (Glanz et al., 2016) and periodontal ligament cells (Li and Zhang, 2015). Conversely, 
contradicting evidence suggest Htra1 as an inhibitor of matrix mineralization in murine 2T3 and KusaO 
cell lines (Hadfield et al., 2008; Wu et al., 2014b). However, the expression of Htra1 is significantly 
reduced in immortalized cell lines transformed with SV40 (Zumbrunn and Trueb, 1996) and the impeded 
osteogenesis by Htra1 is considered to be due to the confounding effects of the transformed cell lines than 
the actual effect by Htra1  (Filliat et al., 2017; Tiaden et al., 2012a). Therefore, the role of Htra1 in 
osteogenesis is selectively dependent on the nature of the cells as primary or transformed. In addition, it 
is pertinent to note that these studies investigated the role of Htra1 after stimulation with BMP2 in 
osteoblast cells (Hadfield et al., 2008; Wu et al., 2014b). Moreover, exogenous addition of recombinant 
BMP2 in C2C12 preosteoblasts results in upregulation of Htra1 (Bustos-valenzuela et al., 2011). Hence, 
it is plausible that the role of Htra1 could be surpassed by BMP2, a dominant inducer of osteogenesis and 
there might be a feedback mechanism preventing augmented osteogenesis in response to simultaneous 
stimulation with Bmp2 and Htra1. Htra1 deficient mice exhibit no obvious alteration in bone phenotype in 
vivo (Filliat et al., 2017). It is intriguing to note that HTRA3, which shares the highest homology with 
HTRA1, is also expressed in adjacent regions of bone formation (Filliat et al., 2017; Tocharus et al., 2004). 
The role of Htra3 in osteogenic differentiation is unknown and it is possible that Htra1 and Htra3 could 
be functionally redundant in mediating osteogenesis of mesenchymal stem cells. Further work is needed 
to decipher the role and mechanism involving these two-family members in an osteoblast-specific 
compound mutant mice model.  
The data here address the specific role of Htra1 in osteogenesis of the mesenchymal progenitor 
cells during differentiation with insights into the molecular mechanisms both upstream and downstream 
of Htra1. Osteogenic gene expression array analysis revealed the upregulation of several ECM related 
genes namely, Fgf9, Fgfr3, Ibsp, Vegfa, Col2a1 and Mmp9. In Xenopus embryo, the proteolytic cleavage 
of ECM proteins such as biglycan, syndecan-4 and glypican-4 by HTRA1 promotes FGF/ERK signaling. 
In turn, FGF signaling is necessary and sufficient for Htra1 expression in chick facial and forelimb 
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mesenchyme (Ferrer-Vaquer et al., 2008). Consistent with our findings, previous studies have reported 
increased expression of Ibsp after overexpression of Htra1 in human bone marrow-derived mesenchymal 
stem cells (Tiaden et al., 2012a). HTRA1 and IBSP co-localize during bone regeneration, in osteo-induced 
spheroid cultures, where HTRA1 is hypothesized to fragment IBSP for proper matrix mineralization 
(Tiaden et al., 2012a). Htra1 induces osteogenesis over the expense of adipogenesis via MAP kinase-
dependant MMP production in human mesenchymal stem cells (Tiaden et al., 2016). Proteolytic cleavage 
of ECM proteins such as fibronectin by HTRA1 induces the expression of MMPs during osteogenesis 
(Tiaden et al., 2016) and in other pathological conditions such as intervertebral disc degeneration (Tiaden 
et al., 2012b) and in age-related macular degeneration (Vierkotten et al., 2011). In this study, Col2a1 is 
another gene that was upregulated in Htra1 overexpressing primary mesenchymal progenitor cells. Yeast 
two-hybrid screening revealed the interaction of HTRA1 with procollagens including COL2A1 
(Murwantoko et al., 2004). Htra1 overexpression leads to downregulation of genes such as Sost, Calca 
and Esr1. Negative regulation of Sost by Htra1 was reported in human bone marrow-derived mesenchymal 
stem cells (Tiaden et al., 2012a). The osteogenic array data also revealed some unreported putative 
downstream genes such as Calca, Esr1, Esr2 and Fgfr3. 
The findings here show that RUNX2 is recruited to the proximal Htra1 promoter to transactivate 
Htra1 gene expression during osteoblastogenesis. Runx2 is a master regulator of osteogenic differentiation 
and plays a critical role in chondrocyte maturation and bone formation (Komori et al., 1997). RUNX2 
binds to RUNT binding site RCCRC(A/T) (Kamachi et al., 1990) in the promoter region to drive 
osteoblast-specific gene expression (Lamour et al., 2007; Roca et al., 2005b). Several targets of RUNX2 
during osteoblastogenesis are not yet functionally characterized (Wu et al., 2014a). The data from SAPA 
and ChIP assays revealed that RUNX2 interacts with the proximal -399 to +72 bp region of the Htra1 
promoter during osteogenic differentiation. Luciferase reporter assay using different regions of Htra1 
promoter also revealed the interaction of RUNX2 between -399 to +72 bp. Mutation analysis revealed two 
critical RUNX2 binding sites at -252 bp and -84 bp for the transactivation of Htra1 osteoblastogenic 
expression. This region of interaction, close to the transcription start site, is comparable to the promoter 
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interaction of RUNX2 with other target genes such as Col10a1 (Li et al., 2011), Ibsp (Roca et al., 2005a) 
and Mmp9 (Pratap et al., 2005). To my knowledge, the nucleotide sequences, GCCACT (-252 bp) and 
GCCGCT, are the two novel RUNX2 binding sites that were not reported previously with any other target 
genes. The data here uncovers a previously unknown functional interaction between RUNX2 and Htra1. 
Htra1 has been recently reported to promote osteoclastogenesis in bone marrow macrophages (Wu et al., 
2014b). Runx2 null mice exhibit complete lack of osteoclast cells in the calvarial region. Therefore, Htra1 
could act downstream of RUNX2 during osteoclastogenesis in addition to osteogenesis. Runx2 is a 
negative regulator of cell proliferation and suppression of Runx2 expression is linked to tumorigenesis 
(Kilbey et al., 2007; Zaidi et al., 2007). Moreover, forced expression of Runx2 inhibits osteosarcoma cell 
proliferation (Lucero et al., 2013). Htra1 is also a tumor suppressor gene, which inhibits cancer cell 
proliferation (Baldi et al., 2002; Chien et al., 2004a). Transactivation of Mmp9 by Runx2 has been 
observed in osteoblast lineage cells and in cancer cells (Pratap et al., 2007). Therefore, considering the 
role of Htra1 as a tumor suppressor along with its potential in modulating the expression of MMPs, the 
regulation of Htra1 by Runx2 identified here in osteoblast cells might have physiological and pathological 
relevance in other cell lineages. Further studies are needed to address the interaction of RUNX2 
and Htra1 in other systems including tumor where these two molecules have significant roles.  
In conclusion, my data here show that Htra1 is a direct downstream target of Runx2 and is an 
inducer of osteogenic differentiation of primary mesenchymal progenitor cells. Runx2 regulates Htra1 
expression through its interaction with the Htra1 promoter at -252 bp and -84 bp. 
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6. GENERAL DISCUSSION 
 In this thesis, I have demonstrated the role of Hoxa2 as an inhibitor of osteogenic differentiation 
by restricting the BMP signaling dependent osteogenic markers spatially and temporally. This study 
deepens the current understanding on the role of Hoxa2 in palatogenesis shedding light on the signaling 
mechanisms downstream of Hoxa2.  
 Hoxa2 was previously identified to be expressed in the developing palate (Nazarali et al., 2000), 
regulating palate development intrinsically (Smith et al., 2009); however, the mechanisms remained 
largely unknown. My findings here reveal that Hoxa2 controls the expression domain of preosteoblast 
markers by inhibiting osteoprogenitor commitment and osteoprogenitor proliferation on the nasal side of 
the palate and the loss of Hoxa2 leads to accelerated osteogenic signaling in the developing palate. The 
greater cell proliferation rate and osteogenic differentiation on the nasal side of the palate highlights the 
regional heterogeneity on the role played by Hoxa2 in this region. The greater cell proliferation in the 
nasal side of the Hoxa2-/- palatal shelves is reaffirmed by a parallel study carried out in our group (Okello 
et al., 2017). Until recently, improper palatal osteogenesis as a causative agent in the pathogenesis of cleft 
palate received little attention (Wu et al., 2008; Fu et al., 2017; Jia et al., 2017 a, b), despite mutants of 
several osteoblast markers known to develop cleft palate (Aberg et al., 2004; Dobreva et al., 2006; Han et 
al., 2009). IHC analyses in vivo evidently revealed augmented bone differentiation and proliferation 
(Smith et al., 2017; Okello et al., 2017) in the Hoxa2-/- palatal shelves at stage E13.5 prior to the elevation, 
which could be responsible for the cleft palate pathogenesis. However, further investigations using gene 
ablations of osteoblast-specific specific mutants such as Runx2-/- or Satb2-/- to test if these mutants could 
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rescue the cleft palate phenotype in the Hoxa2-/- mice are necessary. Such an approach may also directly 
answer the role of osteogenic differentiation in cleft palate pathogenesis in the Hoxa2-/- mice.  
 The role of Htra1 in osteogenic differentiation remained controversial and the study here is the 
first one to exemplify molecular regulation of Htra1 in osteogenic differentiation. Evidence demonstrated 
in this study may possibly have placed Htra1 as an osteoblast marker and a key target of the master 
regulator, Runx2.  
 In this thesis, I have demonstrated that Htra1 promotes osteogenic differentiation of palatal 
mesenchymal cells in vitro, and that it is regulated transcriptionally by Runx2. Luciferase experiments 
revealed that RUNX2 binds to Htra1 proximal promoter at -252 bp and -84 bp to transactivate Htra1 
expression. In addition, Htra1 induces MMPs possibly via degradation of ECM proteins like biglycan and 
syndecan to activate FGF signaling (Hou et al., 2007). Although the evidence provided here makes a strong 
case for Htra1 as an osteogenic inducer, Htra1-/- mice reported elsewhere display very few abnormalities 
in bone formation (Filliat et al., 2017). This could be due to the functional redundancy of other members 
of the HTRA family. IHC analyses here revealed that Htra3 is expressed in similar regions in the palate 
and in other craniofacial regions. Indeed, Htra3 shares the highest homology with Htra1 and a functional 
redundancy may not be surprising. It remains to be identified whether Htra3 also promotes osteogenic 
differentiation and whether Runx2 regulates Htra3 expression during osteogenic differentiation.   
 Htra family members are putative targets of Hoxa2 in embryonic spinal cord and my initial 
hypothesis was to test if Htra1 is a direct downstream target of Hoxa2 during palate development. IHC 
and qPCR analyses revealed upregulation of Htra1 in the Hoxa2-/- palatal shelves. In addition, the 
upregulated Htra1 expression corroborates with the enhanced osteogenesis in the Hoxa2-/- palatal 
mesenchyme. During the progress of this work, a report on HOXA2 bound regions on the genome in the 
developing second pharyngeal arch revealed several previously known as well as novel targets of HOXA2 
(Donaldson et al., 2012). The report did not show any of the promoters of the Htra family members bound 
by HOXA2. Although the possibility of Htra1 as a direct transcriptional target of Hoxa2 cannot be ignored, 
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it is highly unlikely considering several other known targets have been demonstrated to be bound by 
HOXA2. It remains to be tested whether Htra1 is a direct downstream target of Hoxa2 in osteoblast lineage 
determination.  
 In summary, the data here unravels a deeper understanding on the signaling mechanisms 
downstream of Hoxa2 in palate development. The regulation of BMP signaling-dependent osteogenic 
differentiation by Hoxa2 is a novel finding in understanding the cleft palate pathogenesis of Hoxa2-/- mice 
(Figure 6.1). The direct transcriptional regulation of Htra1 by Runx2 is a novel finding in bone 
development research and it is the first study to reveal any specific molecular regulation of Htra1 during 
osteogenesis (Figure 6.1).  
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Figure 6.1 Novel insights from the thesis on the molecular mechanism governing palatogenesis and 
osteogenesis. Schematic diagram showing key findings from this thesis work deciphering gene networks 
and signaling mechanisms in palatogenesis and osteogenesis. This thesis work explored the role of Hoxa2 
and its putative downstream target Htra1 in osteogenic differentiation of the palatal mesenchyme. The 
findings on Hoxa2 inhibiting BMP signaling and Runx2-dependent transcriptional program to control 
osteogenic domain in the palatal mesenchyme is a new finding on the signaling mechanism in 
palatogenesis. In addition, the data on the involvement of Htra1 in as part of the Runx2 governed 
transcriptional program of osteogenesis is a new finding in bone development research, which for the first 
time puts Htra1 into context in molecular mechanism of osteogenesis.  
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7. FUTURE DIRECTIONS 
7.1 Hoxa2 in palatogenesis 
 Although several lines of evidence indicate that Hoxa2 plays an intrinsic role during palatogenesis, 
the use of a palatal mesenchyme specific deletion of Hoxa2 using Osr2cre will aid in deciphering the 
comprehensive cell autonomous requirement of Hoxa2 in palate development. Furthermore, increased 
osteogenesis during early palate development could be responsible for the cleft palate pathogenesis. 
However, further evidence is needed using a compound mutant of Hoxa2 and Runx2 or Stab2, which 
would give insight into the specific role of osteogenic differentiation in cleft palate pathogenesis and 
whether the cleft palate in the Hoxa2-/- due to accelerated osteogenic differentiation can be rescued by the 
genetic ablation of the critical osteoblast markers, which also develop cleft palate. In addition, if the cleft 
palate phenotype is recued in the compound mutant mouse, it could lead to future therapy work for cleft 
palate. This thesis work provided some insights into the signaling mechanisms downstream of Hoxa2, yet 
major targets of Hoxa2 in palate development remain unknown. RNA-seq and ChIP-seq analyses using 
some elegant genetic tools like Osr2RFP/+ knockin mice, which could be used to isolate RNA from RFP+ 
Hoxa2 deleted cells would give insights into the downstream targets of Hoxa2 in palatogenesis. From the 
list of differentially regulated targets from the RNA-seq data and genes that are known to cause cleft palate 
in mouse and humans (Funato et al., 2015), some possible downstream targets of Hoxa2 that could have a 
role in palate development, could be chosen for further exploration using genetic tools to address 
functional targets of Hoxa2 to better fill the gaps in the existing knowledge. During this thesis work, I was 
also involved in using X-ray fluorescence imaging at the Canadian Light Source, Saskatoon, Canada, to 
identify the metal distributions across different stages of palate development. Although we identified some 
interesting patterns of metal distribution across palatogenesis, we have not identified the metal distribution 
in the palatal shelves of Hoxa2 mutants that develop cleft palate, which has elevated cell proliferation and 
osteogenic differentiation. Metal distribution during palatogenesis is unknown and comparative metal 
distribution between wild type and Hoxa2-/- would give insights into the influence of key chemical 
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elements in cell proliferation and osteogenic differentiation during palatal shelf elevation and fusion. 
Understanding the metal distribution using XRF imaging could give information on the abundance of 
critical elements that could influence palatogenesis, which could open new avenues of an unexplored 
interactions between metal elements and genetic elements during palatogenesis.    
7.2 Htra1 and Htra3  
 The role of Htra3 in osteogenic differentiation remains unknown. A preliminary investigation 
using Htra3 siRNA in primary mesenchymal cells to identify the role of Htra3 in osteogenic differentiation 
is warranted. As Htra3 null mice do not show any abnormal bone phenotype, a compound mutant of Htra1 
and Htra3 could be useful in understanding the redundant role during development. In particular, a 
compound preosteoblast-specific deletion of Htra1 and Htra3 using Runx2-cre would reveal the role and 
redundancy of these serine proteases in osteogenic differentiation. In order to decipher the role in palatal 
fusion, chick embryonic palatal explants in culture which do not fuse naturally could be exploited to 
exogenously add HTRA3 protein along with pro-TGFβ3 to check if Htra3 aids in palatal fusion via aiding 
the activation of mature TGFβ3 by cleaving the inactive form. This could be more successful than the 
usage of lentiviral particles. In addition, an epithelial specific K14-Cre compound deletion of Htra1 and 
Htra3 could reveal the role and redundancy of these two serine proteases in palatal fusion during 
development. Although it is plausible that the regulation of Htra1 by Hoxa2 is indirectly through Runx2, 
the hypothesis of a direct regulation of Htra3 and/or Htra1 by Hoxa2 cannot be neglected. Therefore, an 
in-silico analysis of Htra1 and Htra3 promoter could indicate whether there are any putative binding sites 
of Hoxa2 in the promoter regions of Htra1 and Htra3. In addition, ChIP analysis or ChIP-seq analysis 
using wild type and Hoxa2-/- palatal mesenchymal cells will shed further light into any possible interaction 
between Hoxa2 and these two serine protease genes Htra1 and Htra3.  
8. CONCLUSIONS 
The data presented in this thesis is the first to show that Hoxa2 inhibits BMP signaling to regulate 
osteoprogenitor commitment and proliferation unraveling a possible mechanism for the cleft pathogenesis 
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in the Hoxa2-/- mice. This study is also one of the very few studies to show that controlled osteogenic 
differentiation in the palatal mesenchyme could be critical for the palatal shelf elevation. Htra1 acts 
downstream of Runx2 to promote bone matrix mineralization. This study also identified Htra1 as a novel 
direct downstream target of Runx2 during osteogenic differentiation.  
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Cleft palate is one of the most common congenital birth defects worldwide. The homeobox 
(Hox) family of genes are key regulators of embryogenesis, with Hoxa2 having a direct role 
in secondary palate development. Hoxa2
−/−
 mice exhibit cleft palate; however, the cellular 
and molecular mechanisms leading to cleft palate in Hoxa2
−/−
 mice is largely unknown. 
Addressing this issue, we found that Hoxa2 regulates spatial and temporal programs of 
osteogenic differentiation in the developing palate by inhibiting bone morphogenetic protein 
(BMP) signaling dependent osteoblast markers. Expression of osteoblast markers, including 
Runx2, Sp7, and AlpI were increased in Hoxa2
−/−
 palatal shelves at embryonic day (E) 13.5 
and E15.5. Hoxa2
−/−
 mouse embryonic palatal mesenchyme (MEPM) cells exhibited 
increased bone matrix deposition and mineralization in vitro. Moreover, loss of Hoxa2 
resulted in increased osteoprogenitor cell proliferation and osteogenic commitment during 
early stages of palate development at E13.5. Consistent with upregulation of osteoblast 
markers, Hoxa2
−/−
 palatal shelves displayed higher expression of canonical BMP signaling 
in vivo. Blocking BMP signaling in Hoxa2
−/−
 primary MEPM cells using dorsomorphin 
restored cell proliferation and osteogenic differentiation to wild-type levels. Collectively, 
these data demonstrate for the first time that Hoxa2 may regulate palate development by 
inhibiting osteogenic differentiation of palatal mesenchyme via modulating BMP signaling. 
 
 
Keywords: Hoxa2, cleft palate, bone morphogenetic protein (BMP), osteoblast, osteoprogenitor, proliferation, RUNX2 
 
 
INTRODUCTION 
 
Cleft palate is one of the most common structural birth defects in humans with an incidence of 1 in 700–1,000 live 
births (Dixon et al., 2011). Studies using mouse model which has a high similarity to human palate development 
helped to identify several key stages and cellular processes during palate formation (Yu et al., 2017). In mice, 
secondary palate development begins at embryonic day (E)11.5 and is completed with palatal fusion by E15.5 
(Ferguson, 1988). During palate development, the 
 
 
Abbreviations: AlpI, alkaline phosphatase I; ARS, Alizarin red S; BMP, bone morphogenetic protein; CNCC, cranial neural crest 
cells; d, day; E, embryonic day; MEPM, mouse embryonic palatal mesenchyme; pSMAD 1/5/8, phosphorylated SMAD 1/5/8; qRT-
PCR, quantitative real-time PCR; Runx2, runt-related transcription factor 2.  
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vertical palatal shelves grow downward along the sides of the tongue 
until E13.5 and then elevate above the tongue at E14. The palatal shelves 
on either side contact each other forming midline epithelial seam at 
E14.5, which eventually disintegrates leading to palatal fusion by E15.5 
(Kaufman, 1992). Impairment in any of these distinct stages during 
palatogenesis may result in cleft palate. The palate is comprised of the 
palatal process of the maxilla and the palatal process of the palatine bone 
derived from the cranial neural crest cells (CNCC) (Iwata et al., 2010), 
constituting the anterior and posterior part of the hard palate, respectively 
(Baek et al., 2011). While the structural changes during palate 
development are well defined, there is a scarcity of knowledge on the 
molecular mechanisms governing the patterning of the palate. 
 
In murine models, deletion of about 280 genes are known to cause cleft palate 
(Funato et al., 2015). Among these genes, mutations of 55 genes are 
associated with cleft palate in humans (Funato et al., 2015). Mutation in the 
Hoxa2 gene is associated with cleft palate in humans (Alasti et al., 2008) and 
mouse models (Gendron-Maguire et al., 1993; Rijli et al., 1993). In Hoxa2
−/−
 
mice, the cleft palate phenotype was initially attributed to the physical 
obstruction of the tongue preventing the palatal shelves to elevate and fuse 
(Barrow and Capecchi, 1999). However, our group has previously 
demonstrated that Hoxa2 is expressed in the palatal shelves (Nazarali et al., 
2000) and plays an intrinsic role in palatogenesis (Smith et al., 2009). The 
palatal shelves from Hoxa2
−/−
 mouse embryonic maxilla devoid of tongue 
grown in rolling bottle cultures failed to fuse (Smith et al., 2009). Hence, 
tongue musculature may not be the principal reason for the cleft palate 
phenotype in Hoxa2
−/−
 mice. Hoxa2 appears to be a key regulator of 
palatogenesis, yet the molecular signaling pathways downstream of Hoxa2 
remain largely unknown. 
 
Bone morphogenetic protein (BMP) signaling plays a critical role in palate 
development regulating cell proliferation (Zhang et al., 2002). Bmp4 is 
upstream of Bmp2 to induce proliferation in the palatal mesenchyme and is 
able to reverse the reduced cell proliferation and cleft palate phenotype in the 
Msx1
−/−
 mice (Zhang et al., 2002). Defective cell proliferation observed in 
Pax9
−/−
 embryos is consistent with the reduced Bmp4 expression in the 
palatal mesenchyme at E13.5 (Zhou et al., 2013). Similarly, reduced 
expression of Bmp2 is associated with reduced 
 
cell proliferation in the palatal shelves of Hand2 hypomorphic mice 
(Hand2
LoxP/−
) (Xiong et al., 2009). In addition, growing  
evidence highlight the importance of osteogenic differentiation in the 
elevation of palatal shelves and abnormal osteogenic differentiation could 
lead to cleft palate manifestations (Wu et al., 2008; Fu et al., 2017; Jia et al., 
2017a,b). BMP signaling is critical for osteogenic differentiation in the 
palatal mesenchyme (Wu et al., 2008; Baek et al., 2011; Hill et al., 2014), 
where it is required for the expression of osteoblast markers such as Runx2, 
Sp7, and AlpI (Baek et al., 2011). During craniofacial development, Hoxa2 
restricts the bone mineralization in the calvaria (Dobreva et al., 2006). 
Moreover, Hoxa2
−/−
 mice exhibit ectopic Runx2-positive osteogenic center 
in the second pharyngeal arch that results in duplication of tympanic ring 
(Kanzler et al., 1998). 
 
In this study, we tested the hypothesis that Hoxa2 inhibits osteogenic 
differentiation of the palatal mesenchyme in vivo  
 
 
 
and in vitro using Hoxa2
−/−
 mice. Our findings reveal that Hoxa2 
plays a critical role in the spatial and temporal regulation of 
osteogenic differentiation via modulating BMP signaling 
pathway in the developing palate. 
 
MATERIALS AND 
METHODS Animals 
Wild-type and Hoxa2
−/−
 embryos were obtained from timed 
pregnant Hoxa2
+/−
 (heterozygous) mice. Genotype was confirmed 
using PCR as previously described (Gendron-Maguire et al., 1993). 
This research was approved by the University of Saskatchewan’s 
Animal Research Ethics Board and adhered to the Canadian Council 
on Animal Care guidelines for humane animal use. 
 
Primary Mouse Embryonic Palatal 
Mesenchyme (MEPM) Cell Culture and 
Osteogenic Induction 
 
Primary MEPM cells were isolated from micro-dissected palatal shelves 
of wild-type and Hoxa2
−/−
 mouse embryos at E13.5. The palatal shelves 
were treated with 0.25% trypsin-EDTA for 15 min, passed through a 70 
µm cell strainer and cultured as monolayer cells (Iwata et al., 2012) in 
DMEM: Ham’s F12 (1:1) media containing 10% FBS, 1% antibiotic-
antimycotic solution (Sigma). Osteogenic differentiation was carried out 
as described previously (Kwong et al., 2008) with minor modifications. 
Briefly, MEPM cells were seeded on 0.1% gelatin or poly-D-lysine 
coated plates at a cell density of 5 × 10
4
 cells per well in 24 well plates 
and cultured until they reached confluence. Osteogenic differentiation 
was induced with differentiation media (DMEM, 10% FBS, 2 mM L-
glutamine and 1% antibiotic-antimycotic solution) supplemented with 
osteogenic inducing agents, including 50 µg/ml L-ascorbic acid 2-
phosphate sesquimagnesium salt (Sigma), 10 mM β-glycerophosphate 
(Sigma), and 100 nM dexamethasone (Sigma). Cells were differentiated 
for up to 21 days (d) and samples were collected at d8, d15, or d21. To 
assess the impact of BMP signaling, MEPM cells were treated with 
dorsomorphin (5 µM) or DMSO and were harvested at d8 for further 
experiments. 
 
Alkaline Phosphatase I (ALPI) Staining 
 
ALPI staining in the palatal shelves in vivo was carried out as previously 
described (Baek et al., 2011). Embryonic mouse heads were fixed 
overnight in freshly prepared 4% paraformaldehyde at 4
◦
C and 
rehydrated in 30% sucrose at 4 
◦
C. Frozen coronal sections (10 µm) were 
prepared on slides coated with 0.5% gelatin. The sections were air dried 
for at least 2 h and then rehydrated with TBS with 0.08% tween-20 two 
times for 10 min each. Subsequently, the sections were treated with 
alkaline phosphatase buffer (100 mM NaCl, 100 mM Tris-HCl pH 9.5, 
50 mM MgCl2, 0.1% Tween-20) for 20 min and stained with alkaline 
phosphatase buffer containing 4.5 µl/ml of 5-bromo-4-chloro-3-indolyl 
phosphate (Roche) and 3.5 µl/ml of nitro blue tetrazolium (Roche) for 
10 min. The reaction was stopped with PBS containing 20 mM EDTA 
buffer and counter stained with nuclear fast red. The stained sections 
were dehydrated in 
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a series of PBS/ethanol, ethanol/xylene and finally mounted in 
DPX mounting media (Sigma). For osteoblast differentiation in 
primary MEPM cells, ALPI staining was carried out following 
the aforementioned protocol after fixing the cells with 4% 
paraformaldehyde for 15 min. 
 
Alizarin Red S (ARS) Staining and 
Quantification  
ARS staining and quantification was carried out as previously described 
(Gregory et al., 2004) with minor modifications. Briefly, monolayer 
MEPM cells were fixed with 4% paraformaldehyde for 15 min and 
stained with 250 µl of 40 mM ARS (Sigma) solution (pH 4.1) at room 
temperature for 20 min with gentle shaking. Excess dye was aspirated 
and washed with deionized water before imaging. ARS quantification 
was carried using an acid extraction method (Gregory et al., 2004). 
Standard plot of ARS concentration was constructed by serially diluting 
the 40 mM ARS in the buffer containing 10% (v/v) acetic acid and 10% 
(v/v) ammonium hydroxide. The absorbance values of the standard 
concentrations were used to interpolate the concentrations of the test 
samples. 
 
Quantitative Real-Time Polymerase Chain 
Reaction (qRT-PCR)  
Total RNA was isolated from the micro-dissected palatal shelves using 
RNA mini spin column (Bio-Rad) as per the manufacturer’s protocol. 
First strand complementary DNA synthesis (reverse transcription) was 
performed in 20 µl reactions with 500 ng of total RNA using High-
Capacity complementary DNA Reverse Transcription Kit (Invitrogen). 
qRT-PCR was carried out as described in our previous study (Thangaraj 
et al., 2017) using SYBR green assay (Applied Biosystems) in 7300-real 
time PCR system (Applied Biosystems) with primers listed in Table 1. 
 
Western Blotting 
 
Western bot analyses were carried out as previously described (Brown 
and Nazarali, 2010). Briefly, palatal tissues were homogenized in RIPA 
buffer. Total protein content was quantified using the Bradford assay and 
proteins were separated in 10% SDS-PAGE. Primary antibodies used 
were: RUNX2 (1:500; Abcam ab102711), SP7 (1:1500; Abcam 
ab22552), phosphorylated SMAD 1/5/8 (pSMAD 1/5/8) (1:500; Cell 
signaling 9511S), SMAD 1/5/8 (1:500; Santa Cruz Biotechnology sc-
6031-R), and β-ACTIN (1:2,000; Developmental Studies Hybridoma 
JLA20). Densitometric analyses were carried out using AlphaView 
software. 
 
 
 
TABLE 1 | Primer sequences used for the relative quantification of the transcripts by 
qRT-PCR.  
 
Transcript Primer sequences Length Amplicon 
 
  (bases) size (bp) 
 
     
 
Alkaline CCTTGACTGTGGTTACTGCT 20 216  
 
phosphatase (AlpI) CCTGGTAGTTGTTGTGAGCG 20    
   
 
Bone CAGTAGTTTCCAGCACCGAA 20 199  
 
morphogenic CACTTCCACCACAAACCCAT 20   
 
protein 2 (Bmp2)     
 
Bone AGGAAGGAGTAGATGTGAGAG 21 158  
 
morphogenic AGGGACGGAGACCAGATAC 19   
 
protein 4 (Bmp4)     
 
Bone GCAGGAGGGCAATAAGGTAG 20 159  
 
carboxy-glutamic 
ATGCGTTTGTAGGCGGTC 18 
  
 
acid containing        
 
protein (Bglap)     
 
CyclinD1 (Ccnd1) ACCCTGACACCAATCTCCTC 20 214  
 
 AAGCGGTCCAGGTAGTTCAT 20   
 
Sp7 transcription CACAAAGAAGCCATACGCTG 20 165  
 
factor (Sp7) CCAGGAAATGAGTGAGGGAAG 21    
   
 
Runt-related TGCCTCCGCTGTTATGAAAA 20 187  
 
transcription factor CTGTCTGTGCCTTCTTGGTT 20   
 
2 (Runx2)     
 
     
 
 
 
out by co-incubating: Ki67 (1:100; eBioscience 14569882) and RUNX2 
(1:200; Abcam ab23981) overnight at 4
◦
C. Sections were then washed 
three times and treated with secondary antibodies conjugated with Alexa 
Fluor R 488 (1:200) or Alexa Fluor R 594 (1:400) in 1X PBS with 0.1% 
Triton X-100 at room temperature for 1.5 h. Cell counting analyses were 
carried out manually using ImageJ software platform (NIH). 
 
Cell Proliferation Assay 
 
Cell proliferation assay was carried out in MEPM cells using cell-
counting kit-8 (Dojindo) as previously described (Iwata et al., 2010). 
MEPM cells were incubated with CCK-8 reagent for 1 h and the 
absorbance measured at 450 nm was plotted to calculate the relative 
cell proliferation rate. 
 
Statistical Analyses 
 
Statistical analyses were carried out using unpaired t-test in the 
case of two groups. One-way ANOVA or two-way ANOVA with 
Bonferroni multiple comparison test was used for one or two 
variate analyses, respectively. A p-value of <0.05 was considered 
significant. 
  
Immunohistochemistry 
 
Embryonic mouse heads were fixed overnight with freshly-prepared 4% 
paraformaldehyde and rehydrated in 30% sucrose at 4
◦
C. Frozen coronal 
sections (10 µm) were rehydrated with PBS for 45 min, permeabilized 
with 0.1% Triton X-100 and blocked with 3% skim milk containing 0.1% 
Triton X-100 in 1X PBS for 1 h at room temperature. Sections were then 
incubated overnight with the following primary antibodies: RUNX2 
(1:200; Abcam ab23981) or SP7 (1:800; Abcam ab22552) in 1X PBS 
with 0.1% Triton X-100 at 4
◦
C. Double labeling was carried 
 
 
RESULTS 
 
Hoxa2−
/
− Mice Exhibit Increased Expression 
of Osteoblast Markers during Palate 
Development in Vivo  
To investigate the role of Hoxa2 in osteogenesis of the palatal 
mesenchyme, we first examined changes in osteogenic differentiation in 
the embryonic palatal shelves of Hoxa2
−/−
 mice at E16.5, a stage when 
both the prospective palatal process of the maxilla and the palatal process 
of the palatine 
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bone evidently ossify (Baek et al., 2011). Staining for ALPI, a marker of 
osteoblast differentiation showed an expansion in ALPI expression 
domain in the Hoxa2
−/
 
−
 palatal mesenchyme compared to wild-type 
(Figures 1A–H). At the anterior region of the hard palate, ALPI staining 
was restricted to the nasal half in two condensations of the prospective 
palatal process of the maxilla on either side of the degraded midline 
epithelial seam in wild-type embryos (Figures 1A,E). In contrast, the 
domain of ALPI positive preosteoblast area was increased and expanded 
toward the oral side covering oral-nasal axis in 
 
 
 
 
Hoxa2
−/−
 palatal shelves (Figures 1B,F). In the posterior region of the 
hard palate, ALPI staining was present in the ossifying centers of the 
palatal process of the palatine bone in wild-type embryos (Figures 
1C,G), whereas there was an expansion in the expression domain of 
ALPI positive preosteoblasts toward the oral side in Hoxa2
−/−
 embryos 
(Figures 1D,H). 
 Two  well-known  regulators  of  osteogenic  differentiation 
RUNX2 (Komori et al., 1997) and SP7 (previously known 
as Osterix;  Nakashima et  al.,  2002)  have  been  implicated 
in the patterning of the palatal bones (Baek et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 | Loss of Hoxa2 leads to increased osteogenic differentiation of the palatal mesenchyme at E16.5. Position matched coronal sections of wild-type and Hoxa2
−/−
 
embryos at E16.5 were stained for ALPI (A–H), RUNX2 (I–L), and SP7 (M–P). Sections in the anterior region (A,B,E,F,I,J,M,N) were through the middle of the first molar 
tooth bud to detect osteogenic condensation of the palatal process of the maxilla. Sections in the posterior region (C,D,G,H,K,L,O,P) were through the osteogenic centers of the 
developing palatal process of the palatine bone. (A–D) ALPI staining (blue) counterstained with nuclear fast red. Scale bar, 100 µm. Boxed regions in (A–D) highlighting the 
palate are enlarged (E–H). Scale bar, 50 µm. (E,F) In the anterior hard palate, ALPI staining in the two condensations of the palatal process of the maxilla (marked in black 
dotted lines) was evidently increased in the Hoxa2
−/−
 embryos (F) compared to wild-type (E). (G,H) In the posterior hard palate, ALPI stained developing palatal process of the 
palatine bone (marked in black dotted lines) in the Hoxa2
−/−
 embryos (H) was increased compared to the wild-type (G), n = 5 biological replicates. (I–P) Immunohistochemical 
analyses of RUNX2 (green; I–L) and SP7 (red; M–P) in wild-type and Hoxa2
−/−
 palate at E16.5. RUNX2 was increased in both anterior (J) and posterior regions (L) of the 
Hoxa2 null hard palate, whereas SP7 was increased only in the anterior hard palate (N), n = 4 biological replicates. Scale bar, 50 µm. M1, first molar; Mb, mandible; Mx, maxilla; 
NS, nasal septum; pppb, the palatal process of the palatine bone; ppmx, the palatal process of the maxilla; T, tongue.  
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To elucidate the spatial mis-regulation of palatal bone formation in 
Hoxa2
−/
 
−
 mice, expression pattern of these two osteoblast-specific 
transcription factors were assessed at E16.5. Immunohistochemical 
analyses revealed that RUNX2 (Figure 1I) and SP7 (Figure 1M) 
expressions were confined to the condensations of the palatal process of 
the maxilla at the anterior hard palate in wild-type embryos at E16.5, 
whereas RUNX2 (Figure 1J) and SP7 (Figure 1N) expression domains 
were increased in Hoxa2
−/−
 embryos. In the posterior region, along the 
developing palatal process of the palatine bone, the expression of 
RUNX2 (Figure 1L) was increased in Hoxa2
−/−
 embryos compared to 
wild-type (Figure 1K). In this region, the expression of SP7, a 
downstream target of RUNX2 and a marker of mature osteoblasts, was 
not evidently increased in the Hoxa2
−/−
 palate (Figure 1P) compared to 
wild-type (Figure 1O). This suggests that cells toward the oral side of 
the palatal process of the palatine bone are at immature osteoblast stage 
and may not have developed bone matrix by E16.5. Collectively, these 
data indicate that Hoxa2 could be a potential inhibitor of osteogenic 
differentiation in the palatal mesenchyme, which may serve to spatially 
restrict the expression of osteoblast-specific proteins during palate 
development in vivo. 
 
Furthermore, gene expression profiles of osteoblast markers were 
evaluated during the initiation of ossification of the palatal process of the 
palatal bone and the palatal process of the maxilla at E13.5 and E15.5, 
respectively. The loss of Hoxa2 in the developing palate resulted in an 
increase in mRNA expression of osteoblast markers such as Runx2, AlpI 
and Sp7 at both E13.5 (Figures 2A–D) and E15.5 (Figures 2E–H). At 
E13.5, mRNA expression of Runx2, AlpI and Sp7 were increased to 
∼6.36-, ∼9.65-, and ∼2.62-fold, respectively, in Hoxa2
−/−
 palate 
compared to wild-type (Figures 2A–C). At E13.5, mRNA expression of 
Bglap (previously known as Ocn) was not significantly altered (Figure 
2D). At E15.5, mRNA expression of Runx2, AlpI, Sp7, and Bglap were 
upregulated ∼1.86-, ∼2.29-, ∼1.42-, ∼3.27-folds, respectively, in 
Hoxa2
−/−
 palate compared to wild-type (Figures 2E–H). Consistent 
with this, protein expression of RUNX2 was upregulated at E13.5 and 
E15.5 to ∼1.4-fold (Figures 2I,J). SP7 protein expression, both long 
(Figures 2I,K) and short isoforms (Figures 2I,L) were upregulated at 
E15.5 to ∼1.4-fold. These data reveal that along with regulating the 
spatial patterning of osteogenic differentiation, Hoxa2 also regulates the 
expression of osteogenic markers at the molecular level in the developing 
palate. 
 
Hoxa2 Inhibits Osteoblast Differentiation of 
Mouse Embryonic Palatal Mesenchymal 
(MEPM) Cells in Vitro 
 
To evaluate the potential of Hoxa2 in regulating the temporal pattern of 
osteogenesis, the primary mesenchyme cells from the wild-type and 
Hoxa2
−/
 
−
 palatal shelves were differentiated in vitro for up to 21 days 
(d). Osteogenesis of mesenchymal cells involves sequential stages of 
proliferation, osteogenic commitment around day8 (∼d8) followed by 
matrix deposition (∼d15) and mineralization (∼d21) (Gordon et al., 
2010). Differentiating cells were stained for ALPI at d8 and Alizarin  
 
 
 
Red S (ARS) at d15 and d21. ALPI staining showed an increased 
osteoblast differentiation at d8 in Hoxa2
−/−
 MEPM cells 
compared to the wild-type MEPM cells (Figures 3A,B). In 
addition, ARS staining followed by quantification of ARS 
extracted matrix showed that Hoxa2
−/−
 MEPM cells exhibited 
increased extracellular matrix deposition ∼2-fold at d15 
(Figures 3C,D,G) and increased mineralization ∼1.5-fold at d21 
(Figures 3E,F,H) compared to the wild-type MEPM cells. 
 
Next, the gene expression profiles of osteogenic markers were examined 
in wild-type and Hoxa2
−/−
 MEPM cells during osteogenic 
differentiation in vitro. Runx2 mRNA expression was increased to ∼1.9-
fold in the Hoxa2
−/−
 MEPM cells compared to the wild-type during 
osteoblast commitment stage at d8 (Figure 3I). AlpI and Sp7 mRNA 
expression were increased ∼2.85 and ∼3.37-fold, respectively, during 
matrix deposition stage at d15 in the Hoxa2
−/−
 MEPM cells (Figures 
3J,K). Bglap mRNA expression was increased ∼6.37-fold during matrix 
deposition at d15 and ∼8.09-fold during matrix mineralization at d21 in 
the Hoxa2
−/−
 MEPM cells (Figure 3L). Thus, loss of Hoxa2 results in 
upregulation of osteogenic marker expression in a stage-specific manner 
as early as d8 (osteogenic commitment stage). These data indicate that 
Hoxa2 may play a role in early osteoblast differentiation by inhibiting 
the transcription factors regulating osteogenic fate specification. 
 
 
Increased Osteoprogenitor Proliferation and 
Commitment in the Hoxa2−
/
− Palatal  
Mesenchyme during Early Palate 
Development 
 
Hoxa2 peaks in its expression in the developing palate at E13.5 (Smith 
et al., 2009), a stage when the mesenchymal cells simultaneously 
proliferate and commit to form preosteoblasts of the prospective palatal 
process of the palatine bone. This suggests that the cleft palate phenotype 
in Hoxa2
−/−
 mice, due to the failure of palatal shelves to elevate and 
reorient horizontally above the tongue after E13.5 (Barrow and 
Capecchi, 1999), may be a consequence of abnormal cell proliferation 
(Smith et al., 2013) and osteogenic differentiation (Wu et al., 2008; Fu et 
al., 2017; Jia et al., 2017a,b). To gain further insight into the role of 
Hoxa2 during this early stage of palate development, the rate of 
mesenchymal cell proliferation and the commitment of mesenchymal 
cells to osteoprogenitor fate was investigated in vivo at E13.5. 
Immunohistochemical staining of RUNX2 (Figures 4A,B) was used to 
evaluate osteoprogenitor commitment in the wild-type and Hoxa2
−/−
 
palatal shelves at E13.5. RUNX2 (Figure 4A) expression in the wild-
type was restricted to the bend region in the nasal side of the palatal 
shelves, whereas the expression domain of RUNX2 (Figure 4B) was 
increased spatially toward the medial edge of the palate as well as to the 
oral side of the palate in the Hoxa2
−/−
 mutants. This is similar to the 
aberrant expression patterns of RUNX2 observed at E16.5 in the 
Hoxa2
−/−
 palatal shelves. In addition, the number of RUNX2-positive 
osteoprogenitor cells on the nasal side of the palatal shelves were 
significantly higher in 
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FIGURE 2 | Loss of Hoxa2 leads to increased expression of osteogenic markers in the developing palate at E13.5 and E15.5. Quantitative real-time PCR (qRT-PCR) analyses 
indicate that the gene expression profile of osteogenic markers such as Runx2 (A,E), AlpI (B,F), and Sp7 (C,G) were upregulated in the developing Hoxa2
−/−
 palatal shelves at 
E13.5 (A–C) and E15.5 (E–G). Gene expression of Bglap was upregulated at E15.5 (H) but not at E13.5 (D). qRT-PCR data (n = 5 biological replicates) were normalized to β -
actin and represented relative to wild-type (mean ± S.E.M; unpaired t-test, *p < 0.05; **p < 0.01; ***p < 0.001). Western blot analyses of RUNX2 (I,J) and SP7 (I,K,L) were 
carried out using the microdissected palatal shelves from wild-type and Hoxa2
−/−
 mice at E13.5 and E15.5. RUNX2 protein expression was upregulated in the Hoxa2
−/−
 palate 
at E13.5 and E15.5 (I,J), whereas SP7 isoforms were upregulated at E15.5 (I,K,L). Densitometric analyses (n = 4 biological replicates) were normalized to β-ACTIN and 
represented relative to wild-type (mean ± S.E.M; unpaired t-test, **p < 0.01).  
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FIGURE 3 | Hoxa2 inhibits osteoblast differentiation of MEPM cells in vitro. Wild-type and Hoxa2
−/−
 MEPM cells were subjected to osteogenic differentiation in vitro for up 
to 21 days (d). The differentiated cells were stained for ALPI at d8 (A,B), ARS at d15 (C,D), and d21 (E,F). ARS stained osteocyte matrices from wild-type and Hoxa2
−/−
 
MEPM cells were extracted and quantified at d15 (G) and d21 (H). Experiment was carried out three times and the data shown here are from a representative experiment with n = 
3 biological replicates; mean ± S.E.M; unpaired t-test, *p < 0.05; ***p < 0.001). Hoxa2
−/−
 MEPM cells displayed increased matrix deposition and mineralization at d15 (G) and 
d21 (H), respectively. (I–L) qRT-PCR analyses revealed that gene expression profile of osteogenic markers such as Runx2 (I), AlpI (J), Sp7 (K), and Bglap (L) were upregulated 
in the Hoxa2
−/−
 MEPM cells in a stage-specific manner during osteoblast differentiation. Data was normalized to β -actin and represented relative to wild-type at d0 (n = 3 
biological replicates; mean ± S.E.M; two-way ANOVA with Bonferroni post-hoc test, *p < 0.05; **p < 0.01; ***p < 0.001).  
 
 
 
the Hoxa2
−/−
 mutants (∼64%) compared to wild-type (∼33%; 
Figure 4C).  
Next, the rate of cell proliferation was assessed at E13.5 using Ki67 
immunostaining. The percentage of Ki67-positive cells was significantly 
increased in the Hoxa2
−/−
 palatal mesenchyme (∼50%) compared to wild-
type (∼26%; Figures 4D–F). In the nasal side of the palatal shelves, the 
percentage of Ki67-positive cells was ∼53% in Hoxa2
−/−
 embryos compared 
to ∼26% in the wild-type (Figure 4F). Interestingly, the nasal side 
mesenchyme displayed a higher proliferation rate of ∼53% compared to the 
oral side of ∼23% in Hoxa2
−/−
 palatal shelves (Figure 4F). In addition, the 
percentage of proliferating osteoprogenitor cells (RUNX2-positive/Ki67-
positive) in the nasal side of the Hoxa2
−/−
 palatal shelves was higher (∼20%) 
compared to ∼11% in wild-type (Figures 4G–I). Furthermore, mRNA 
expression of cyclin D1 (Ccnd1), a critical G1 phase cell cycle regulator was 
also upregulated in the Hoxa2
−/−
 palatal shelves from E12.5 to E14.5 (Figure 
4J). These results indicate that Hoxa2 plays a critical role  
 
 
 
 
by inhibiting osteoprogenitor commitment and osteoprogenitor 
proliferation prior to the elevation and fusion of the palatal 
shelves. 
 
Increased Canonical BMP Signaling 
Pathway in the Hoxa2−
/
− Palatal Shelves  
To understand the molecular signaling pathways underlying the aberrant 
cell proliferation and osteogenic differentiation in the Hoxa2
−/−
 palatal 
shelves, BMP signaling was investigated as it is critical for cell 
proliferation (Zhang et al., 2002) and expression of osteogenic markers 
in the developing palate (Baek et al., 2011). First, the mRNA expression 
of BMP ligands critical for osteoblast differentiation such as Bmp2 and 
Bmp4 in the developing palatal shelves was examined. Bmp2 expression 
was upregulated to ∼3.57-fold at E13.5 and ∼1.96-fold at E15.5 in 
Hoxa2
−/−
 palatal shelves compared to wild-type (Figure 5A). Similarly, 
Bmp4 expression was upregulated to ∼3.42-fold at E13.5 and to ∼1.81-
fold at E15.5 
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FIGURE 4 | Hoxa2
−/−
 palatal shelves exhibit increased osteoprogenitor proliferation and commitment at E13.5. Osteoprogenitor cells in the developing palatal shelves of wild-
type and Hoxa2
−/−
 embryos were evaluated using RUNX2 immunostaining (A,B) and RUNX2-positive cells were counted manually using ImageJ platform (C). Proliferation 
rate was assessed using Ki67 immunostaining (D–F) at E13.5. Scale bar, 50 µm; N, nasal; O, oral. Proliferating osteoprogenitor cells (cellspositive for both RUNX2 and Ki67) 
(Runx2 /Ki67) (G,H) relative to the total number of mesenchymal cells (DAPI-positive) from wild-type and Hoxa2
−/−
 palatal shelves were counted in the nasal side (I). 
Hoxa2
−/−
 embryos exhibited increased RUNX2-positive (C), Ki67-positive (F) and RUNX2/Ki67-double positive (I) cells in the nasal side of the palatal shelves (n = 5 
biological replicates; mean ± S.E.M; unpaired t-test, *p < 0.05; **p < 0.01; ***p < 0.001). Expression of cell cycle regulator Cyclin D1 (Ccnd1) mRNA was upregulated in the 
Hoxa2
−/−
 palatal shelves (J) from E12.5 to E14.5. qRT-PCR data was normalized to β -actin and represented relative to wild-type at respective embryonic stages (n = 6 
biological replicates; mean ± S.E.M; unpaired t-test, *p < 0.05; ***p < 0.001).  
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FIGURE 5 | Hoxa2 regulates canonical BMP signaling in the developing palate. Gene expression of BMP ligands, Bmp2 (A) and Bmp4 (B) were upregulated in 
 
palatal shelves at E13.5 and E15.5. qRT-PCR data (n = 4 biological replicates) were normalized to β -actin (mean ± S.E.M; unpaired t-test, *p < 0.05; ***p 
 
< 0.001). Representative immunoblot (C) of pSMAD 1/5/8 from the developing palate of wild-type and Hoxa2
−/−
 embryos at E15.5. (D) 
Densitometric analysis represents the relative expression of pSMAD 1/5/8 normalized to SMAD 1/5/8 and represented relative to wild-type (n = 4 biological replicates; 
mean ± S.E.M; unpaired t-test, *p < 0.05). 
 
 
 
(Figure 5B). Immunoblotting analyses revealed that canonical 
BMP signaling mediated by pSMAD 1/5/8 was also upregulated 
to ∼1.5-fold in the Hoxa2
−/−
 palate at E15.5 (Figures 5C,D). 
These results indicate that canonical BMP signaling pathway 
may be downstream of the Hoxa2 gene network in palate 
development. 
 
Blocking Canonical BMP Signaling Rescues the 
Aberrant Cell Proliferation and Osteogenic 
Differentiation in Hoxa2−
/
− MEPM Cells 
 
To determine if the upregulated canonical BMP signaling is functionally 
responsible for the increased mesenchymal cell proliferation and 
osteogenic differentiation observed in the Hoxa2
−/−
 palate, 
dorsomorphin was used to inhibit BMP signaling during osteogenic 
differentiation of MEPM cells in vitro. Although at higher doses 
dorsomorphin (10–20 µM) inhibits AMPK signaling (Zhou et al., 2001) 
and mTOR signaling (Vucicevic et al., 2011), it selectively inhibits BMP 
signaling at lower doses (Yu et al., 2008). Upon 5 µM dorsomorphin 
treatment, upregulated mRNA expressions of Bmp2 (Figure 6A), Bmp4 
(Figure 6B) and Runx2 (Figure 6C) in the Hoxa2
−/−
 MEPM cells were 
restored to the wild-type levels. Moreover,  
 
 
 
increased protein expression of RUNX2 and pSMAD 1/5/8 (Figure 
6D) in the Hoxa2
−/−
 MEPM cells were reduced after dorsomorphin 
treatment. The increased cell proliferation (Figure 6E) and 
osteogenic differentiation (Figure 6F) in the Hoxa2
−/−
 MEPM cells 
were also reduced after dorsomorphin treatment. These results 
indicate that the upregulated canonical BMP signaling is functionally 
responsible for the increased cell proliferation and osteogenic 
differentiation during palate development in Hoxa2
−/−
 embryos. 
Altogether, the findings reveal that Hoxa2 inhibits osteoprogenitor 
proliferation and commitment, via BMP signaling, to control the 
spatial and temporal expression of osteoblast markers for proper 
palatogenesis. 
 
 
DISCUSSION 
 
Mice lacking Hoxa2 exhibit cleft palate (Gendron-Maguire et al., 1993; 
Rijli et al., 1993; Barrow and Capecchi, 1999) and microtia (Minoux et 
al., 2013), which are consistent with Hoxa2 mutations in humans (Alasti 
et al., 2008). We have previously shown that Hoxa2 is expressed in the 
palatal shelves during development (Nazarali et al., 2000) reaching a 
maximal expression at E13.5 and regulates cell proliferation in the 
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FIGURE 6 | Blocking canonical BMP signaling with dorsomorphin rescues the aberrant osteoprogenitor cell proliferation and osteogenic differentiation in the  
Hoxa2
−/−
 MEPM cells. Dorsomorphin treatment restored gene expressions of Bmp2 (A), Bmp4 (B), and Runx2 (C) in the Hoxa2
−/−
 MEPM cells close to wild-type levels 
during osteogenic differentiation in vitro at d8. Data represented relative to wild-type MEPM cells treated with DMSO (n = 4 biological replicates; mean ± S.E.M; one-way 
ANOVA followed by Bonferroni post-hoc test, *p < 0.05; ***p < 0.001; ns, not significant). (D) Representative immunoblots showing restoration of RUNX2 and pSMAD 1/5/8 
in Hoxa2
−/−
 MEPM cells treated with dorsomorphin during osteogenic differentiation in vitro at d8 (n = 3 biological replicates). (E) Cell proliferation analysis in the wild-type 
and Hoxa2
−/−
 MEPM cells treated with DMSO or dorsomorphin during osteogenic differentiation at d3 (n = 5 biological replicates; mean ± S.E.M; one-way ANOVA followed 
by Bonferroni post-hoc test, ***p < 0.001; ns, not significant). (F) ALPI staining revealed that treatment with dorsomorphin nullified the aberrant osteogenic differentiation in 
Hoxa2
−/−
 MEPM cells in vitro at d8.  
 
 
developing palate (Smith et al., 2009). There are several lines of evidence 
that Hoxa2 regulates palate development intrinsically (Smith et al., 
2009), yet the mechanism is largely unknown. In this study, we have 
found that Hoxa2 inhibits BMP signaling dependent osteogenic 
differentiation spatially and temporally to regulate palate formation. The 
present study deepens the current understanding of the role of Hoxa2 in 
palate formation and the mechanisms underlying the cleft palate 
phenotype in Hoxa2
−/−
 mice linking Hoxa2, BMP signaling and 
osteogenesis.  
Our findings here reveal that Hoxa2 controls the temporal and spatial 
expression pattern of osteoblast markers in the developing palatal 
mesenchyme. Ossifying domains characterized by RUNX2 and ALPI were 
increased in the palatal process of the maxilla and in the palatal process of 
the palatine bone in Hoxa2
−/−
 mice. In contrast, SP7 a marker of mature 
osteoblasts was expanded only in the palatal process of the maxilla and not 
in the palatal process of the palatine bone at E16.5. This suggests that cells 
toward the oral side of the palatal process of the palatine bone are at immature 
osteoblast stage and may not have developed bone matrix by E16.5. 
Patterning of the palatal 
 
 
 
 
process of the palatine bone and of the maxilla are through independent 
skeletogenic processes (Baek et al., 2011). The palatal process of the 
palatine bone ossifies at E13.5, whereas the ossification of the palatal 
process of the maxilla begins only at E15.5. Consistent with this, qRT-
PCR and immunoblot analyses revealed a corresponding upregulation of 
osteogenic markers in the Hoxa2
−/−
 palate at these two critical stages 
E13.5 and E15.5. In addition, primary Hoxa2
−/−
 MEPM cells displayed 
an increase in osteogenic differentiation and a stage-specific increase in 
the expressions of the osteoblast-specific transcripts indicating that 
Hoxa2 regulates temporal differentiation of mesenchyme cells to 
osteoblasts in the palate. Together, our results reveal that Hoxa2 
functions as an inhibitor of osteogenic differentiation in the palatal 
mesenchyme during development. Our findings are in agreement with 
previous studies showing the role of Hoxa2 as an inhibitor of bone 
formation in other craniofacial regions (Kanzler et al., 1998; Dobreva et 
al., 2006). 
 
Very little is known about the signaling network downstream of Hoxa2 
during palatogenesis. Here, we have demonstrated that Hoxa2
−/−
 palatal 
shelves exhibit upregulated canonical 
 
 
Frontiers in Physiology | www.frontiersin.org  November 2017 | Volume 8 | Article 929 
149 
 
Iyyanar and Nazarali Hoxa2 Inhibits Osteogenesis in Palate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 | Schematic diagram depicting the role of Hoxa2 in proliferation and osteogenic differentiation of the palatal mesenchyme. (A) Hoxa2 inhibits canonical BMP 
signaling in the developing palate, which in turn restricts the expression domain of osteogenic markers such as Runx2, AlpI, and Sp7. (B) In wild-type, Hoxa2 expression 
peaks during early palatogenesis to control cell proliferation and to maintain mesenchymal cells in an undifferentiated stage by regulating BMP signaling pathway. (C) Loss of 
Hoxa2 leads to upregulation of BMP signaling resulting in increased osteoprogenitor cell proliferation and osteogenic differentiation, possibly accounting for the failure in the 
elevation of palatal shelves resulting in manifestation of cleft palate.  
 
 
BMP signaling mediated by pSMAD 1/5/8. In addition, the expression 
of BMP ligands such as Bmp2 and Bmp4 are upregulated in Hoxa2
−/−
 
palatal shelves in vivo and in Hoxa2
−/−
 MEPM cells in vitro. BMP 
signaling plays a critical role in proliferation (Zhang et al., 2002; Baek 
et al., 2011) and osteogenic differentiation of the palatal mesenchyme 
(Wu et al., 2008; Han et al., 2009; Baek et al., 2011). Importantly, 
abnormal BMP signaling in the palatal mesenchyme leads to cleft palate 
manifestation (Zhang et al., 2002; He et al., 2008). Inactivation of 
Bmpr1a in the palatal mesenchyme (Osr2-IresCre; Bmpr1a
f
 
/f
 ) results 
in submucous cleft palate, absence in the patterning of the palatal process 
of the maxilla and defective palatal process of the palatine bone (Baek et 
al., 2011). Genome-wide mapping revealed that Bmp2, Bmp4 and 
Bmpr1a are possible targets of Hoxa2 (Donaldson et al., 2012) and 
HOXA2 protein binds to the intronic region of Bmp4 (Minoux et al., 
2013) in the developing pharyngeal arch2. In this study, dorsomorphin 
was used to inhibit BMP signaling in the wild-type and Hoxa2
−/−
 
primary palatal mesenchymal cells during osteogenic differentiation. 
Dorsomorphin selectively inhibits BMP signaling at lower doses (Yu et 
al., 2008) and at higher doses dorsomorphin (10–20 µM) also inhibits 
AMPK signaling (Zhou et al., 2001) and mTOR signaling (Vucicevic et 
al., 2011). In our study, dorsomorphin treatment not only rescued the 
upregulated gene expression of osteogenic factors such as Bmp2, Bmp4, 
and Runx2 but also the aberrant cell proliferation and osteogenic 
differentiation in the Hoxa2
−/−
 MEPM cells. These experiments 
highlight the involvement of BMP signaling in the abnormal 
osteoprogenitor cell proliferation and osteogenic differentiation in the 
Hoxa2
−/−
 palate, which could attribute to the cleft palate phenotype in 
these mutants.  
 
 
 
To our knowledge, there is no report available on the characterization of 
osteoprogenitor cell proliferation and commitment in the palatal mesenchyme 
during development. In this study, we have unraveled the role of Hoxa2 in 
maintaining the palatal mesenchymal cells in an undifferentiated stage by 
inhibiting osteoprogenitor proliferation and commitment preventing 
abnormal ossification in the developing palate. Palatal mesenchymal cells 
derived from CNCC undergo osteogenic proliferation and commit to form 
osteoblasts (Iwata et al., 2010). Double immunolabeling analyses of RUNX2 
and Ki67 at E13.5 revealed that among the total population of mesenchyme 
cells, there was a significantly higher number of (i) proliferating cells (Ki67-
positive cells), (ii) osteoprogenitor cells (RUNX2-positive cells), and (iii) 
proliferating osteoprogenitor cells (RUNX2-positive /Ki67-positive cells) in 
the nasal side of the Hoxa2
−/−
 palatal shelves compared to the wild-type. In 
the palatal mesenchyme, increased or decreased cell proliferation could result 
in failure of the palatal shelves to elevate and reorient above the tongue 
leading to cleft palate (Bush and Jiang, 2012; Smith et al., 2013). Recent 
studies show evidence for abnormal osteogenic signaling prior to the 
elevation of palatal shelves in several well-studied cleft palate mutant mice 
models including Pax9
−/−
 mice (Jia et al., 2017a,b) and Osr2
−/−
 mice (Fu et 
al., 2017). Consistent with our findings here in the Hoxa2
−/−
 mice, Osr2
−/−
 
exhibit increased osteogenic centers of the palatal process of the palatine bone 
prior to the elevation of the palatal shelves at E13.5 and in addition to 
defective cell proliferation, enhanced osteogenesis could contribute to cleft 
palate phenotype in Osr2
−/−
 mice (Fu et al., 2017). In addition, RNA-Seq 
data from Osr2
−/−
 palatal shelves revealed upregulation of several positive 
regulators of osteogenesis including Runx2, Runx3, 
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Sp7, and Bmp ligands- Bmp3, Bmp5, and Bmp7. Furthermore, Pax9
−/
 
−
 
mice exhibit reduced cell proliferation and osteogenesis in the 
developing palate (Jia et al., 2017a). Restoration of reduced cell 
proliferation and osteogenesis by Wnt agonists (Dkk inhibitors) rescued 
the cleft palate phenotype in Pax9
−/−
 mice (Jia et al., 2017a). The 
increase in cell proliferation in the nasal side of the Hoxa2
−/−
palate 
indicates a strong role for Hoxa2 in the spatial maintenance of 
mesenchymal cells in an undifferentiated state for temporal coordination 
of osteoblast differentiation (Figure 7). Our findings here exemplify the 
regional heterogeneity in proliferation and osteogenic differentiation by 
Hoxa2 along the oral-nasal axis in the palatal mesenchyme prior to the 
elevation of palatal shelves. Our data argue that improper BMP signaling 
leading to the increased osteoprogenitor cell proliferation and 
commitment could be a reason for the cleft palate pathogenesis in the 
Hoxa2
−/−
 mice. Further studies are needed to address if the cleft palate 
phenotype in the Hoxa2
−/−
 mice could be rescued using other mutant 
mice with impaired osteogenesis. 
 
Our data demonstrate that Hoxa2 inhibits osteoprogenitor cell 
proliferation and osteogenic commitment via modulating BMP signaling 
in the mouse embryonic palatal mesenchyme. Hoxa2 regulates spatial 
and temporal programs of osteogenesis by maintaining mesenchymal 
cells in an undifferentiated stage until osteogenic clues arrive. In 
conclusion, our findings provide new insights into the signaling 
mechanism underlying the role of Hoxa2 during embryonic palate 
development. 
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Cleft palate is a common congenital abnormality that results from defective secondary palate 
(SP) formation. The Sine oculis-related homeobox 2 (Six2) gene has been linked to 
abnormalities of craniofacial and kidney development. Our current study examined, for the 
first time, the specific role of Six2 in embryonic mouse SP development. Six2 mRNA and 
protein expression were identified in the palatal shelves from embryonic days (E)12.5 to 
E15.5, with peak levels during early stages of palatal shelf outgrowth. Immunohistochemical 
staining (IHC) showed that Six2 protein is abundant throughout the mesenchyme in the oral 
half of each palatal shelf, whereas there is a pronounced decline in Six2 expression by 
mesenchyme cells in the nasal half of the palatal shelf by stages E14.5–15.5. An opposite 
pattern was observed in the surface epithelium of the palatal shelf. Six2 expression was 
prominent at all stages in the epithelial cell layer located on the nasal side of each palatal shelf 
but absent from the epithelium located on the oral side of the palatal shelf. Six2 is a putative 
downstream target of transcription factor Hoxa2 and we previously demonstrated that Hoxa2 
plays an intrinsic role in embryonic palate formation. We therefore investigated whether Six2 
expression was altered in the developing SP of Hoxa2 null mice. Reverse transcriptase PCR 
and Western blot analyses revealed that Six2 mRNA and protein levels were upregulated in 
Hoxa2
−/−
 palatal shelves at stages E12.5–14.5. Moreover, the domain of Six2 protein 
expression in the palatal mesenchyme of Hoxa2
−/−
 embryos was expanded to include the 
entire nasal half of the palatal shelf in addition to the oral half. The palatal shelves of Hoxa2
−/−
 
embryos displayed a higher density of proliferating, Ki-67 positive palatal mesenchyme cells, 
as well as a higher density of Six2/Ki-67 double-positive cells. Furthermore, Hoxa2
−/−
 palatal 
mesenchyme cells in culture displayed both increased proliferation and elevated Cyclin D1 
expression relative to wild-type cultures. Conversely, siRNA-mediated Six2 knockdown 
restored proliferation and Cyclin D1 expression in Hoxa2
−/−
 palatal mesenchyme cultures to 
near wild-type levels. Our findings demonstrate that Six2 functions downstream of Hoxa2 as 
a positive regulator of mesenchymal cell proliferation during SP development. 
 
 
Keywords: Six2, palate, Hoxa2, craniofacial development, cell proliferation, Cyclin D1  
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INTRODUCTION 
 
Cleft palate is a common congenital malformation in humans, with a 
complex etiology (Vanderas, 1987). The palate separates the nasal and 
oral cavities, allowing for proper respiration, feeding and phonation. 
Both genetic and environmental factors have been implicated in the 
causation of cleft palate (Dixon et al., 2011). However, the molecular 
mechanisms involved in the pathogenesis of cleft palate are poorly 
understood.  
Mouse secondary palate (SP) development begins around embryonic day (E) 
11.5, with the emergence of paired palatal shelf outgrowths from the 
maxillary prominences. From E12.0–13.5, the palatal shelves grow vertically 
downwards on either side of the developing tongue. At E14.0, the tongue 
depresses, allowing the two palatal shelves to re-orient horizontally above the 
tongue. The elevated palatal shelves grow horizontally toward each other, 
establishing contact to form the midline epithelial seam (MES) at E14.5. The 
MES degrades by E15.5, creating a confluent SP. The SP then fuses anteriorly 
with the primary palate, a derivative of the converged medial nasal processes, 
to complete the formation of the roof of the oral cavity by E16.5 (Ferguson, 
1988; Kaufman, 1992). In addition, mesenchymal cells located in the anterior 
portion of the SP ossify to form the palatine bone. Disruptions in the growth, 
elevation or fusion of the palatal shelves can lead to congenital cleft palate 
defects (Ferguson, 1988; Gritli-Linde, 2007; Smith et al., 2013). 
 
Sine oculis-related homeobox 2 (Six2) is a member of the vertebrate Six 
gene family which encode homeobox transcription factors homologous 
to the Drosophila Sine oculis protein (Kawakami et al., 2000). Six family 
genes have been reported to promote cell proliferation and survival 
during embryogenesis (Kawakami et al., 2000). Six2 is expressed 
primarily in the cranial base, midface, facial prominences, first 
pharyngeal arch, and in the urogenital region of the developing embryo 
(Fogelgren et al., 2008). Six2 null mice die at birth exhibiting renal 
hypoplasia (Self et al., 2006) and a shorter cranial base (He et al., 2010). 
In these mice, chondrocyte differentiation in the cranial base is abnormal, 
with decreased cell proliferation and increased terminal differentiation 
leading to premature fusion of the cranial base (He et al., 2010). 
 
Downregulation of Six2 by microRNAs miR-181b or miR-181c 
inhibits cell proliferation and promotes apoptosis in metanephric 
kidney mesenchymal cells in vitro (Lyu et al., 2013; Lv et al., 2014). 
Transcription factor Zeb1, a marker of epithelial-mesenchymal 
transitions during embryogenesis and cancer metastasis, regulates 
cell proliferation in metanephric mesenchymal cells by binding to 
the Six2 promoter and upregulating its expression (Gu et al., 2016). 
Additionally, Six2 promotes metastasis of breast cancer cells by 
repressing E-cadherin expression via mechanisms involving miR-
200b downregulation, Zeb 2 upregulation, and E-cadherin promoter 
methylation (Wang et al., 2014).  
 
 
Abbreviations: ddPCR, digital droplet PCR; E, embryonic day; IHC, 
immunohistochemical; MEE, medial edge epithelium; MEPM, mouse embryonic 
palatal mesenchyme; MES, midline epithelial seam; O-N, oro-nasal, qRT-PCR, 
quantitative real-time PCR; SP, secondary palate.  
 
 
 
In the radiation-induced mouse mutant brachyrrhine (Br/Br), 
prenatal deficiency of Six2 leads to frontonasal dysplasia, cleft palate 
(Singh et al., 1998; McBratney et al., 2003) and renal hypoplasia 
(McBratney et al., 2003; Fogelgren et al., 2008, 2009). Moreover, 
investigations have linked Six2 deletion in humans to an autosomal 
dominant frontonasal dysplasia syndrome that has similarities to the 
murine Br mutant phenotype (Hufnagel et al., 2016). 
 
Deletions of the Hoxa2 gene in mice also lead to cleft palate defects, 
together with altered morphogenesis of second pharyngeal arch 
structures (Rijli et al., 1993 and Gendron-Maguire et al., 1993). 
Investigations in our laboratory have previously demonstrated that 
Hoxa2 is expressed intrinsically within the palatal shelves of wild-type 
mouse embryos (Nazarali et al., 2000), where it inhibits proliferation of 
the palatal mesenchyme cells (Smith et al., 2009). The possibility that 
Six2 plays a specific role in SP development has not been previously 
examined. In our present study we demonstrate, for the first time, that 
Six2 is expressed intrinsically in both the palatal shelf mesenchyme and 
palatal shelf epithelium of wild-type mouse embryos, and further show 
that Six2 mRNA and protein are upregulated in the palatal shelves of 
Hoxa2
−/−
 mice. In addition, we provide evidence that Six2 functions 
downstream of Hoxa2 to regulate mesenchymal cell proliferation within 
the developing secondary palate. 
 
MATERIALS AND METHODS 
Hoxa2 Transgenic Mice 
 
Hoxa2
+/−
 mice were maintained by backcrossing to C57BL/6J wild-type 
mice and the heterozygous mice were intercrossed to generate Hoxa2
+/+
 
and Hoxa2
−/−
 embryos for analysis in this study (Smith et al., 2009). 
Pregnant mice were sacrificed by isoflurane inhalation followed by 
cervical dislocation. Embryos were staged according to Kaufman (1992) 
and were considered E0 on the day the vaginal plug was found. 
Genotypes were confirmed by PCR analyses as described in Gendron-
Maguire et al. ( 1993). The protocol for the use of animals was approved 
by the University of Saskatchewan’s Animal Research Ethics Board and 
adhered to Canadian Council on Animal Care guidelines for humane 
animal use. 
 
Immunohistochemistry 
 
Embryos were harvested from timed-pregnant mice and the heads were fixed 
with 4% paraformaldehyde in phosphate buffered saline, pH 7.4 (PBS) for 24 
h. Embryo heads were placed in 30% sucrose in PBS for at least 24 h, 
followed by embedding in optimal cutting temperature compound (OCT; 
Tissue-Tek R ) and serially sectioned at 10 µm thickness. Histological 
sections taken anterior or posterior to the first molar tooth bud were 
designated as anterior and posterior palate sections, respectively, and sections 
taken at the plane of the first molar tooth bud were designated as middle 
palate sections (Welsh and O’Brien, 2009; Smith et al., 2013). Tissue sections 
were placed on 0.5% gelatin-coated glass slides, air-dried at room 
temperature for at least 2 h, rehydrated for 30 min in PBS, and blocked for 
30 min at room temperature in PBS containing 4% skim milk and 0.1% 
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Triton X-100. Sections were then incubated overnight at 4
◦
C with 
primary antibody diluted in PBS. The antibodies used were: Six2 rabbit 
polyclonal antibody (Proteintech R ; 1:500 dilution), E-cadherin rat 
monoclonal antibody (Sigma; 1:200 dilution) and Ki-67 rat monoclonal 
antibody (Affymetrix eBioscience R ; 1:100 dilution). Sections were 
rinsed twice for 5 min in PBS followed by incubation with secondary 
antibody for 1 h at room temperature (anti-IgG Alexa fluor 488 antibody, 
1:200 dilution or anti-IgG Alexa fluor 594, 1:400 dilution; Molecular 
Probes R ). Finally, sections were rinsed twice in PBS and mounted in 
ProLong R Gold antifade reagent with DAPI (Molecular Probes R ). 
 
RNA Isolation and Reverse Transcription 
 
Total RNA was isolated from excised palatal shelves of wild-
type and Hoxa2
−/−
 embryos at stages E12.5, E13.5, E14.5, and 
E15.5 using Aurum Total RNA mini kit (BioRad R ) as per the 
manufacturer’s protocol. First-strand cDNA synthesis was 
performed using SuperScript reverse transcriptase (Invitrogen R 
) with 1 µg of total RNA as per the manufacturer’s protocol 
(Smith et al., 2009). 
 
Quantitative Real Time PCR (qRT-PCR) 
 
Gene expression analysis was performed on palatal shelf cDNA samples 
as described in our previous study (Thangaraj et al., 2017). Briefly, a 
TaqMan R gene expression assay was used for qRT-PCR analysis of 
relative Six2 mRNA expression levels. All qRT-PCR reactions were 
performed using 25 ng of template cDNA, TaqMan Universal Master 
Mix, FAM-labeled TaqMan Gene Expression assay Mm03003557_S1 
for Six2 (Applied Biosystems R ), and VIC-labeled endogenous control 
TaqMan assay for β -actin (Applied Biosystems R assay 4352341E). 
Cyclin D1 expression was quantified by SYBR Green assay using 
forward primer 5
′
-ACCCTGACACCAATCTCCTC-3
′
 and reverse 
primer 5
′
-AAGCGGTCCAGGTAGTTCAT-3
′
. All reactions were run in 
biological replicates of 5. Thermocycling parameters were: 2 min at 
50
◦
C, 10 min at 95
◦
C, followed by 40 cycles of 95
◦
C for 15 s and 60
◦
C 
for 70 s. The CT values obtained were analyzed using the 2
−11CT
 
method to determine the relative expression of target genes in wild-type 
and Hoxa2 null samples. 
 
 
Droplet Digital PCR (ddPCR) 
 
To independently confirm the results of our qRT-PCR analyses, we also 
performed ddPCR gene expression analyses on palatal shelf cDNA 
samples, following established protocols (Hindson et al., 2013). Briefly, 
oil-emulsified PCR reaction mixtures containing palatal shelf cDNA 
were amplified in 96-well plates on a Bio-Rad Tetrad 2 Peltier Thermal 
Cycler under the following conditions: 95
◦
C for 10 min then 40 cycles 
of 95 
◦
C for 15 s and 60
◦
C for 1 min (2.5
◦
C/s ramp rate) with a final 10 
min hold at 98
◦
C. After amplification, the plates were transferred to a 
Bio-Rad QX 100 Droplet Reader, which aspirated oil-emulsified PCR 
products from each well and counted numbers of FAM-positive and 
VIC-positive droplets, sampling at 100 kHz. Discrimination between 
droplets containing amplified target (positives) from those which did not 
(negatives) was achieved by applying a global fluorescence amplitude 
threshold. Gene transcript  
 
 
 
concentrations for each palatal RNA sample were calculated using dedicated 
ddPCR Poisson distribution computational modeling software (Bio-Rad R ). 
We employed the same Six2 and  
β -actin TaqMan assays for our ddPCR analyses as described in 
our qRT-PCR protocol. 
 
Western Blot Analysis  
Palatal shelves were dissected from wild-type or Hoxa2
−/−
 embryos and 
homogenized in RIPA Buffer (150 mM NaCl, 10 mM Tris, 0.1%-SDS, 1% 
Triton X-100, 1% deoxycholate, 5 mM EDTA) supplemented with a protease 
inhibitor cocktail (Sigma R ) as previously described (Brown and Nazarali, 
2010). Sample aliquots containing equal total protein were loaded onto 10% 
polyacrylamide-SDS gels. Following electrophoresis, the proteins were 
transferred to Immunoblot PVDF membranes (Bio-Rad R ). The membranes 
were blocked overnight at 4
◦
C in PBS containing 4% skim milk, followed by 
incubation for 1 h at room temperature with rabbit polyclonal Six2 primary 
antibody (Proteintech R ; diluted 1:2,000 in PBS containing 4% skim milk). 
This was followed by four 15 min washes in PBST (PBS containing 0.08% 
Tween-20) and incubation for 1 h at room temperature with horseradish 
peroxidase-conjugated anti-rabbit secondary antibody (Bio-Rad R ; diluted 
1:3,000 in PBS containing 4% skim milk). After four 15 min washes in PBST, 
the membranes were incubated with Clarity R Western ECL substrate (Bio-
Rad R ) and the signal detected using a SYNGENE R image analyzer. As a 
control for equal protein loading, the membranes were subsequently washed 
overnight at 4
◦
C in PBS, followed by incubation with anti-β-tubulin 
(Developmental Studies Hybridoma Bank) at 1:2,000 dilution for 1 h at room 
temperature. Subsequently, membranes were washed with PBST, incubated 
with anti-mouse IgG horseradish peroxidase conjugate (Bio-Rad R ; 1:2,000 
dilution), and processed for chemiluminescence protein detection as 
described above. After imaging, semi-quantitative densitometry was 
performed using AlphaView R software to generate an integrated density 
value for each Six2 protein band, which was normalized to the β-tubulin 
density value from the same sample. Four separate Western blots, each 
having both wild-type and Hoxa2
−/−
 samples from E12.5, E13.5, E14.5, 
E15.5 palatal shelves, were performed. For each blot, the normalized Six2 
expression values in the various samples (wild-type and Hoxa2
−/−
 palates at 
E12.5, E13.5, E14.5, E15.5 stages) were compared to the value of the E12.5 
wild-type sample on the same blot, which was arbitrarily assigned a relative 
expression level of 
 
 
1. A total of four blots (n = 4) were analyzed using two-way 
 
ANOVA to compare Six2 protein expression in wild-type and 
Hoxa2
−/−
 samples. 
 
Culture of Mouse Embryonic Palate 
Mesenchymal (MEPM) Cells  
Primary cultures of MEPM cells were established as previously 
described (Iwata et al., 2012; Iyyanar and Nazarali, 2017). Briefly, 
palatal shelves from E13.5 embryos were aseptically micro-dissected 
and placed in Hank’s balanced salt solution. The palatal shelves were 
then incubated with 0.25% trypsin/EDTA in Ca
+
/Mg
++
-free PBS for 20 
min at 37
◦
C, briefly triturated, 
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and passed through a 70 µm cell strainer (BD Falcon R ) to generate a 
dissociated mesenchymal cell suspension. Trypsin action was terminated 
by adding complete DMEM/F-12 medium (Dulbecco’s Modified 
Eagle’s Medium/Ham’s medium F12 [1:1] supplemented with 10% fetal 
bovine serum, 1% antibiotic/antimycotic solution [Sigma R ], and L-
glutamate) to the cell suspension. The cells were plated on poly-D-lysine 
coated plates and cultured at 37
◦
C in 5% CO2 incubator. 
 
 
 
Cell Density Determination 
 
Following IHC staining of histological sections, the number of Ki-
67 positive mesenchymal cells in the palatal shelf were counted 
manually using Image J software and this number was divided by the 
total cross-sectional area (mm
2
) of the palatal mesenchyme. 
Additionally, the numbers of Ki-67 positive mesenchyme cells in the 
nasal vs. oral halves of the sectioned palatal shelves were counted 
and divided by their respective areas (mm
2
); n = 4. 
 
siRNA Treatment and Cell Proliferation 
Analysis  
A pre-designed Six2 siRNA (Invitrogen R Silencer Select assay s73795) 
and a negative control siRNA (Invitrogen R ) were utilized. MEPM cells 
(5 × 10
3
) were plated in a 96-well plate until they reached 60–80% 
confluency. Aliquots of 50 nM siRNA were mixed with Lipofectamine 
3000 (Invitrogen R ) according to the manufacturer’s protocol. The 
siRNA-Lipofectamine complex (10 µl) was added to each well of 
MEPM cells containing 100 µl of serum free medium. Following 
incubation at 37
◦
C for 12 h, the transfection medium was replaced with 
fresh medium. MEPM cells were analyzed for cellular DNA content after 
48 h from the time of transfection using the CyQUANT NF cell 
proliferation assay kit (Life Technologies R ) following the 
manufacturer’s protocol. Briefly, the transfected MEPM cells were 
incubated with 1X dye binding solution at 37
◦
C for 45 min in the dark. 
Fluorescence was measured with a BioTek R microplate reader at 485 
nm excitation and 530 nm emission wavelengths.  
  
Statistical Analyses 
 
All statistical analyses and graph construction were performed 
using GraphPad R Prism 5.0 software. The Western blot, gene 
expression, and cell count data were evaluated using two-way 
analysis of variance (ANOVA) followed by Bonferroni post-hoc 
tests. 
 
RESULTS 
 
Six2 mRNA and Protein Are Expressed in  
the Developing Palate and Upregulated in 
Hoxa2−
/
− Mice  
Our qRT-PCR analyses revealed that Six2 mRNA is expressed in the 
developing palatal shelves of wild-type mouse embryos from E12.5 to 
E15.5, with highest expression at E12.5 and E13.5 (Figure 1A). The 
palatal shelves of Hoxa2
−/−
 null embryos showed a significant 
upregulation of Six2 mRNA levels relative to wild-type palates at stages 
E12.5 to E14.5 (Figure 1A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 | Temporal changes in Six2 mRNA (A,B) and Six2 protein (C,D) levels in the palatal shelves of wild-type and Hoxa2
−/−
 mouse embryos at developmental stages 
E12.5-E15.5. (A) qRT-PCR analysis of relative levels of Six2 mRNA expression in the palatal shelves of wild-type and Hoxa2
−/−
 mouse embryos at developmental stages 
E12.5-E15.5. The Six2 mRNA expression values are normalized against expression levels of the β -actin reference gene (n = 5 biological replicates). Note that Six2 mRNA levels 
were significantly higher in Hoxa2
−/−
 palatal shelves compared to wild-type from stages E12.5 to E14.5. (B) Droplet digital PCR (ddPCR) quantification of relative Six2 mRNA 
levels in palatal shelves of wild-type and Hoxa2
−/−
 embryos at stages E12.5–E15.5 (n = 5 biological replicates). Western blots (C) and corresponding densitometric 
measurements (D) of temporal changes in Six2 protein levels in wild-type and Hoxa2
−/−
 palatal shelves during palatogenesis (n = 4 biological replicates). Note that Six2 protein 
is significantly upregulated in palatal shelves of Hoxa2
−/−
 embryos from E12.5 to E14.5. Two-way ANOVA followed by Bonferroni post-hoc test was performed for each 
analysis. Bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p <0.001.  
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These trends were confirmed on independent biological samples 
using the ddPCR technique as an alternate method to quantify Six2 
gene transcript levels (Figure 1B). Consistent with the Six2 mRNA 
expression profiles, Western blot analysis revealed that Six2 protein 
is present in the developing palatal shelves from E12.5 to E15.5, with 
peak expression at E13.5 in wild-type embryos (Figures 1C,D). At 
stages E12.5 to E14.5, Six2 protein levels were significantly higher 
in Hoxa2
−/−
 palatal shelves compared to wild-type palatal shelves 
(Figure 1D). These results demonstrate that Six2 is expressed 
intrinsically in the developing palate and is negatively regulated by 
Hoxa2 during palatogenesis. 
 
Six2 Protein Distribution in the Developing 
Secondary Palate Exhibits Temporal and 
Spatial Variations 
 
We next examined the spatial distribution of Six2 protein in the 
developing SP. IHC analyses of mid-coronal sections of heads from 
wild-type mouse embryos revealed abundant Six2 protein expression in 
the mesenchyme of the palatal shelves from stages E12.5 to E15.5 
(Figures 2A–D). The intensity of Six2 immunostaining in the palatal 
shelf mesenchyme of wild-type embryos appeared higher at earlier 
stages of palatogenesis (E12.5–E13.5) (Figures 2A,B) compared to later 
stages (E14.5– E15.5) (Figures 2C,D). At stages E12.5 and E13.5, prior 
to palatal shelf elevation, Six2 protein was observed throughout the 
palatal mesenchyme in both the prospective “nasal half ” of the palatal 
shelf (located nearest the tongue at these pre-elevation stages) as well as 
in the “oral half ” of the 
 
 
 
 
palatal shelf (located furthest from the tongue) (Figures 2A,B). 
However, by E14.5 to E15.5, after the wild-type palatal shelves 
have reoriented to a horizontal position above the tongue, there 
was a conspicuous loss of Six2 immunostaining within a layer of 
palatal mesenchyme located in the nasal half of the palatal shelf, 
immediately subjacent to the surface palatal epithelium (Figures 
2C,D). In contrast, Six2 protein expression persisted throughout 
the palatal mesenchyme in the oral half of the palatal shelf in wild 
type embryos (Figures 2C,D). 
 
The palatal shelves of Hoxa2 null embryos, unlike those of wild-type 
embryos, fail to elevate and instead remain oriented vertically 
downward on either side of the developing tongue (Figures 2E–H). 
Within these Hoxa2
−/−
 palatal shelves, Six2 protein expression 
persisted through stage E15.5 in  
palatal mesenchyme cells of both  the  nasal  half  of  the 
palatal shelf (positioned nearest the  tongue)  as well as 
the oral half of  the  palatal shelf  (located furthest  from 
the tongue) (Figures 2E–H). Therefore, in comparison to 
wild-type embryos, the loss of Hoxa2 function expands  
the spatial domain of Six2 expression within the palatal 
mesenchyme at stages E14.5–E15.5 (compare Figures 2A–D to 
Figures 2E–H).  
The outer epithelial cell layer that coats the nasal and oral surfaces of the 
palatal shelf displayed a strikingly different pattern of Six2 protein 
distribution. In wild-type palatal shelves, Six2 immunostaining was 
prominent in the surface epithelium located on the nasal side of the palatal 
shelf at both pre-elevation and post-elevation stages (Figures 2A–D; Figures 
3A,B). Conversely, Six2 protein was undetectable in the surface epithelium 
located 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2 | Immunohistochemical (IHC) analysis of Six2 localization in the palatal shelves of wild-type (A–D) and Hoxa2 null embryos (E–H) at developmental stages E12.5 
(A,E), E13.5 (B,F), E14.5 (C,G), and E15.5 (D,H). Photomicrographs are mid-coronal sections, and are representative of a minimum of 5 biological replicates per stage. In each 
photograph, the asterisk indicates the nasal half of the palatal shelf and the arrow head indicates the oral half of the palatal shelf. T, identifies the developing tongue. Six2 
immunostaining in the mesenchyme of wild-type palatal shelves appeared most intense at stages E12.5 (A) and E13.5 (B), and was uniformly distributed throughout the palatal 
shelf at these early stages. However, by stages E14.5 (C) to E15.5 (D) there was a pronounced decline in Six2 expression by a layer of mesenchyme cells in the nasal half of the 
palatal shelf lying immediately beneath the palatal epithelium. In Hoxa2
−/−
 embryos (E–H), Six2 immunostaining persisted throughout the palatal mesenchyme within the nasal 
half as well as the oral half of the palatal shelf at all stages from E12.5-15.5 (E–H). Note that the palatal shelves of Hoxa2 null embryos fail to elevate and remain oriented 
vertically alongside the tongue (G,H). Scale bar, 50 µm.  
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FIGURE 3 | Six2 protein is differentially expressed by epithelium on the nasal side vs. the oral side of the palatal shelf in wild-type mice. IHC staining of mid-coronal sections of 
wild-type palatal shelves at E14.5 for Six2 (A–D) and E-Cadherin (E–H). Panels I-L are the Six2 immunofluorescence images overlaid with the E-Cadherin immunofluorescence 
images to identify cells co-expressing the two proteins. Six2 protein expression is prominent in epithelial cells located on nasal side of the palatal shelf (marked by the white 
rectangle in panel (A), and by the white arrow in panel (B), where it is co-expressed with the epithelial marker E-cadherin (E,F,I,J). Six2 is also expressed in epithelial cells of 
the MES (marked by yellow rectangle in panel A, and by yellow arrows in panel (C), which is the point of contact between the apical tips of the two elevated palatal shelves. In 
contrast, Six2 protein is absent from the epithelium on the oral side of the palatal shelf [marked by the blue rectangle in panel (A) and by position of the arrowhead in panel (D)], 
which expresses E-cadherin alone (E,H,I,L). MES, midline epithelial seam; T, tongue. Scale bars, 50 µm. The IHC staining images shown are representative of palatal sections 
from a minimum of 5 embryos.  
 
 
 
on the oral side of the palatal shelf (Figures 2A–D, 3A,D). The pattern 
of Six2 expression within the palatal epithelium was largely unaffected 
by loss of Hoxa2 function. In Hoxa2
−/−
 embryos, like wild-type 
embryos, Six2 expression was prominent in epithelial cells located on 
the nasal side of the palatal shelf (facing the tongue), with little or no 
Six2 protein detectable in the epithelium covering the oral side of the 
palatal shelf (located furthest from the tongue) (Figures 2E–H, 4A,B,D). 
These findings were confirmed by co-staining palatal sections from wild-
type (Figure 3) and Hoxa2
−/−
 embryos (Figure 4) with an antibody for 
E-cadherin, a characteristic epithelial marker (Figures 3E–L, 4E–L). 
Examination of the palatal sections at high magnification revealed that 
the surface epithelium on the nasal side of the palatal shelf co-expressed 
both Six2 and E-cadherin proteins in wild-type embryos (Figures 
3B,F,J) as well as in Hoxa2
−/−
 mutants (Figures 4B,F,J). By contrast, 
epithelial cells on the oral side of the palatal shelf were positive for E-
cadherin alone in both wild-type (Figures 3D,H,L) and Hoxa2
−/−
 
embryos (Figures 4D,H,L).  
Interestingly, in the palatal shelves of E14.5 wild-type embryos, we also 
observed prominent expression of Six2 together with E-cadherin within 
cells of the MES, the point of contact/adhesion between the apical tips 
of the two horizontally elevated palatal shelves (Figures 3C,G,K). 
However, Six2 immunostaining was only faintly visible in medial edge 
 
 
 
 
epithelium (MEE) cells located at the apical tips of the Hoxa2
−/−
 
palatal shelves, which fail to elevate and make midline contact 
(Figures 4C,G,K). 
 
Expression of the Ki-67 Cell Proliferation 
Marker Is Enhanced in the Hoxa2−
/
− Palatal 
Shelves 
 
To explore the relationships between Six2, Hoxa2 and cell 
proliferation during SP development, we performed double 
immunofluorescence staining on histological sections from the 
anterior, middle, and posterior regions of E13.5 wild-type and Hoxa2 
null palatal shelves using Six2 antibody in combination with an 
antibody for Ki-67, a nuclear protein expressed exclusively in 
proliferating cells (Figure 5). 
 
We observed that the mesenchyme of both wild-type and Hoxa2
−/−
 
palatal shelves contained large numbers of proliferating, Ki-67 positive 
cells (Figures 5C,D). Cell counts performed on the immunostained 
sections revealed that the number of Ki-67 positive palatal mesenchyme 
cells per unit area was significantly higher in Hoxa2
−/−
 palatal shelves 
compared to wild-type in both the anterior and posterior regions of the 
palate (Figure 6A). This trend was also observed in the middle region of 
the palate, although the difference there was not statistically significant. 
Interestingly, in all three regions along the A-P axis 
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FIGURE 4 | Six2 protein is exclusively expressed in epithelium on the nasal side of the palatal shelf in Hoxa2
−/−
 mice. IHC staining of mid-coronal sections of Hoxa2 null 
palatal shelves at E14.5 for Six2 (A–D), E-Cadherin (E–H), and overlays of the Six2 and E-Cadherin immunofluorescence images (I–L). Expression of Six2 protein within the 
palatal epithelium is restricted to epithelial cells located on the nasal side of the palatal shelf (marked by white rectangle in panel (A), and by white arrow in the higher 
magnification image (B). Six2 is absent from epithelial cells located on the oral side of the palatal shelf (marked by blue rectangle in A, and by position of arrowhead in higher 
magnification image D). Within Hoxa2
−/−
 embryos, Six2 is also absent from cells of the medial edge epithelium (MEE) which is located at the apical tip of the palatal shelf 
(marked by yellow rectangle in (A), and by yellow arrow in higher magnification image (C). Because palatal shelves of Hoxa2−
/
− fail to elevate and make contact, they do not 
form an MES. The entire surface epithelium of Hoxa2
−/−
 palatal shelves (on both its nasal and oral sides, as well as within the MEE) expresses E-cadherin (E–H, I–L). MEE, 
medial edge epithelium; T, tongue. Scale bars, 50 µm. The IHC staining images shown are representative of palatal sections from a minimum of 5 embryos.  
 
 
of the palate (anterior, middle, and posterior), the density of 
proliferating Ki-67 positive mesenchyme cells was significantly 
higher in the nasal half of the palatal shelf compared to its oral half 
(Figure 6B). This was the case for both wild-type as well as Hoxa2 
null embryos (Figure 6B).  
Many Six2-expressing palatal mesenchyme cells in both wild-type 
and Hoxa2 null embryos were actively proliferating, as evidenced by 
Ki-67 co-expression (Figures 5E, F). Cell counts revealed that the 
numbers of these Six2/Ki-67 double-positive palatal mesenchyme 
cells per unit area were significantly higher in Hoxa2
−/−
 mice 
compared to wild-type in all three regions along the A-P axis of the 
palate (anterior, middle, and posterior) (Figure 6C). 
 
 
 
treatment with Six2 siRNA resulted in ∼90% reduction in Six2 mRNA 
expression in MEPM cultures when compared to cultures administered 
either siRNA delivery vehicle alone (mock treatment) or a non-targeting 
negative control siRNA. Importantly, siRNA-mediated Six2 knockdown 
decreased cell proliferation in both wild-type and Hoxa2
−/−
 MEPM 
cultures (Figure 7B) and also reduced mRNA levels of Cyclin D1, a cell 
cycle regulator (Figure 7C). In the Hoxa2
−/−
 MEPM cultures, Six2 
knockdown restored both cell proliferation and Cyclin D1 expression 
down to levels approximating those of wild-type control MEPM cultures 
treated with either siRNA delivery vehicle alone or the negative control 
siRNA (Figures 7B,C). 
 
 
Six2 Knockdown Reduces Cell Proliferation 
and Cyclin D1 Expression in MEPM Palatal 
Mesenchyme Cell Cultures 
 
We next investigated whether Six2 is a positive regulator of cell proliferation 
in the palatal mesenchyme and whether upregulation of Six2 is responsible 
for the increased cell proliferation in Hoxa2
−/−
 palatal mesenchyme. Primary 
cultures of MEPM cells were transfected with siRNA targeting Six2 mRNA 
to determine the effects of Six2 knockdown on proliferation of palatal 
mesenchyme cells in vitro. As shown in Figure 7A, 
 
 
DISCUSSION 
 
Previous studies have established that the Six2 gene is expressed within 
multiple regions and tissues of vertebrate embryos, including the 
developing head, pharyngeal arches, and kidneys (Oliver et al., 1995; 
Kutejova et al., 2005; Fogelgren et al., 2008). Furthermore, Six2 
mutations are linked to embryonic craniofacial and renal malformations 
(Singh et al., 1998; McBratney et al., 2003; Self et al., 2006; Fogelgren 
et al., 2008, 2009), which appear to result in part from reduced cell 
proliferation during organogenesis (Self et al., 
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FIGURE 5 | Double IHC staining of wild-type and Hoxa2
−/−
 palatal shelves with 
antibodies for Six2 as well as Ki-67, a marker of proliferating cells. Representative 
coronal sections from the middle region of E13.5 wild-type palatal shelves (A,C,E) 
and Hoxa2
−/−
 palatal shelves (B,D,F). Green fluorescence in panels (A,B) identifies 
Six2 expressing cells, whereas red fluorescence in panels (C,D) identifies all cells 
expressing proliferation marker Ki-67. Panels (E,F) are overlays of the Six2 (A,B) 
and Ki-67 (C,D) immunofluorescence images to identify cells that co-expressed 
Six2 together with Ki-67. Both wild-type (E) and Hoxa2
−/−
 (F) palatal shelves 
contained numerous Six2/Ki-67 double-positive mesenchyme cells, which appear 
yellow in these image overlays. Six2/Ki-67 double-positive cells appear higher in 
the Hoxa2
−/−
 palate. Asterisk indicates the nasal half of the palatal shelf and the 
arrowhead indicates the oral half of the palatal shelf. Scale bars, 50 µm. The IHC 
staining images shown are representative of palatal sections from a minimum of four 
wild-type and four Hoxa2 null embryos.  
 
 
 
2006; He et al., 2010). Our present study demonstrates, for the 
first time, that Six2 transcripts and Six2 protein are expressed 
endogenously within the palatal shelves of wild-type mouse 
embryos throughout the period of normal SP formation. 
Moreover, we found that Six2 expression within the palatal 
primordia is both temporally modulated and spatially 
heterogeneous.  
Our gene expression and Western blot data indicate that Six2 mRNA and 
protein levels are quantitatively highest during the early stages of SP 
formation (E12.5–13.5), when the palatal shelves emerge as paired 
outgrowths of the two maxillary prominences and grow vertically downwards 
on either side of the developing tongue. Six2 mRNA and protein expression 
persist, albeit at quantitatively lower levels, within the palatal processes 
during the subsequent phases of palatal shelf elevation, contact, and fusion 
(at E14.5–E15.5) which culminate in the separation of the oral and nasal 
cavities. The lateral palatine processes undergo progressive enlargement 
during early phases of palatogenesis, suggesting the possibility that the Six2 
transcription factor may assist in promoting palatal shelf tissue growth. 
Supporting this possibility, we have demonstrated that siRNA-mediated 
knockdown of Six2 mRNA expression in cultures of palatal 
 
 
 
 
shelf mesenchyme cells resulted in reduced mesenchymal cell 
proliferation as well as reduced mRNA levels of the cell cycle 
regulator, Cyclin D1.  
In addition to the temporal variation in Six2 expression levels during SP 
development, our IHC analyses revealed intriguing heterogeneity in its 
spatial distribution within the mesenchyme and epithelium of the 
growing palatal shelves. Within the palatal mesenchyme of wild-type 
embryos, Six2 protein was expressed uniformly throughout 
mesenchymal cells located in the prospective oral half of the palate, at 
stages both prior to and following palatal shelf elevation. By contrast, 
palatal shelf elevation in wild-type embryos was accompanied by a 
marked loss of Six2 expression by a band of palatal mesenchyme cells 
located in the nasal half of the palatal shelf. Interestingly, a somewhat 
converse pattern of Six2 distribution was observed in the surface 
epithelium of the palatal shelves, such that Six2 expression was 
prominent within epithelial cells located on the nasal side of each palatal 
shelf, whereas little or no Six2 protein was detectable within epithelial 
cells on the oral side of the palatal shelves. Several other genes have been 
previously shown to exhibit differential expression along the oro-nasal 
(O-N) axis of the developing SP. Like Six2, the Fgf10 (Rice et al., 2004), 
Foxf1 (Lan and Jiang, 2009; Xu et al., 2016), Gli1 (Han et al., 2009; Lan 
and Jiang, 2009), Osr2 (Lan and Jiang, 2009), and Ptch1 (Lan and Jiang, 
2009) genes are all predominantly expressed in the oral half of the palatal 
mesenchyme (reviewed in Bush and Jiang, 2012). Conversely, Pax9 
exhibits higher expression in mesenchyme in the nasal half of palatal 
shelf (Lan et al., 2004; Zhou et al., 2013). It remains to be explored 
whether the localized expression of Six2 along the O-N axis in the palatal 
mesenchyme or the palatal epithelium either regulates or is regulated by, 
the domains of expression of any of these other genes. Alternatively, the 
loss of Six2 expression by a population of mesenchymal cells in the nasal 
half of the palatal shelf might be a consequence of the onset of osteogenic 
differentiation in this location, since bone formation during SP 
development is confined to the nasal half of the palatal shelves (Han et 
al., 2009; Baek et al., 2011). A number of transcription factors and 
signaling molecules also demonstrate gradations in their expression 
levels along the A-P (anterior-posterior) axis of the developing SP 
including Msx1, Bmp4, Bmp2, Shh, Spry2, Fgf10, Fgf7, Shox2, Meox2, 
Tbx22, and Barx1 (reviewed in Bush and Jiang, 2012; Smith et al., 2013). 
However, our study revealed no significant quantitative differences in 
Six2 expression levels between anterior, middle and posterior regions of 
the palate. 
 
Our study also examined the relationship between Hoxa2 function within 
the developing palatal shelves and the regulation of Six2 expression 
therein. Our gene expression and Western blot analyses revealed that 
Six2 mRNA and Six2 protein levels are significantly elevated in palatal 
shelves of Hoxa2
−/−
 mouse mutants, and our IHC data demonstrate that 
the domain of Six2 expression in Hoxa2-null palatal shelf mesenchyme 
is ectopically expanded to include the entire nasal half of the palatal shelf 
in addition to the oral half. These findings suggest that Hoxa2 acts as a 
negative regulator of Six2 expression within palatal shelf mesenchyme. 
Consistent with our observations, earlier studies by Kutejova et al. (2005, 
2008) showed that the Six2 gene is an 
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FIGURE 6 | The densities of proliferating, Ki-67 positive and Six2/Ki-67 double-positive mesenchyme cells are elevated in Hoxa2
−/−
 palatal shelves compared to wild-type. 
(A) Relative numbers of Ki-67 positive palatal mesenchyme cells per mm
2
 in coronal sections taken from anterior, middle and posterior regions of E13.5 wild-type and 
Hoxa2
−/−
 palatal shelves. In the anterior and posterior regions, the density of proliferating palatal mesenchyme cells was significantly higher in Hoxa2
−/−
 palatal shelves 
compared to wild-type. (B) In both wild-type and Hoxa2
−/−
 palatal shelves, the density of proliferating palatal mesenchyme cells was consistently higher in the nasal half vs. 
the oral half of the palatal shelf. (C) Relative numbers of Six2-positive mesenchyme cells that co-expressed Ki-67 (i.e., were actively proliferating) in the anterior, middle and 
posterior regions of Hoxa2
−/−
 palatal shelves compared to wild-type. Bar graphs represent mean ± SEM; n = 4 biological replicates. *p < 0.05, **p < 0.01.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 | Six2 knockdown in wild-type and Hoxa2
−/−
 mouse embryonic palate mesenchyme (MEPM) cultures reduces cell proliferation and Cyclin D1 expression. 
(A) Treatment of MEPM cultures with Six2 siRNA decreased Six2 mRNA expression by 90% compared to cultures administered either a negative control siRNA or  
siRNA delivery-vehicle alone (mock treatment). (B) Six2 siRNA treatment significantly decreased cell proliferation in both wild-type MEPM and Hoxa2
−/−
 MEPM cultures and 
also reduced expression of Cyclin D1 mRNA (C). Note that levels of cell proliferation (B) and Cyclin D1 expression (C) in Hoxa2
−/−
 MEPM cultures were consistently higher 
than those of parallel wild-type cultures in all three treatment groups. Also, Six2 knockdown restored cell proliferation and Cyclin D1 expression in  
Hoxa2
−/−
 MEPM cultures to levels approximating those of control wild-type MEPM cultures. Bars represent mean ± SEM; n = 4 biological replicates. *p < 0.05, **p <0.01, 
***p < 0.001.  
 
immediate downstream target of transcription factor Hoxa2 in the second 
pharyngeal arch which, through negative regulation, confines Six2 
expression to the more anterior first pharyngeal arch. Previous investigations 
in our own laboratory have shown that the Hoxa2 gene is expressed 
endogenously in the epithelium and mesenchyme of the developing palatal 
shelves (Nazarali et al., 2000; Smith et al., 2009). However, unlike Six2, we 
have observed no conspicuous difference in Hoxa2 expression levels between 
the oral and nasal halves of the palate. Therefore, other genes in addition to 
Hoxa2 must regulate Six2 expression domains within the palatal mesenchyme 
of wild-type embryos to account for the greater Six2 protein abundance in the 
oral half of the palatal shelf vs. the nasal half. Moreover, within the outer 
epithelium layer of the palate, the spatial expression pattern of Six2 must 
 
 
 
be independent of Hoxa2 function, since Six2 protein remains confined 
to epithelial cells on the nasal side of the palatal shelf in Hoxa2
−/−
 
mutants, as it is in wild-type embryos.  
The palatal shelves originate from outgrowths of the maxillary 
prominence derivatives of pharyngeal arch 1. However, somewhat 
paradoxically, Hoxa2 expression is normally absent from tissue of the 
first pharyngeal arch itself, and the loss of Hoxa2 function in Hoxa2
−/−
 
mutant mice leads to ectopic formation of arch 1 skeletal structures in 
place of arch 2 elements (Gendron-Maguire et al., 1993; Rijli et al., 
1993). Studies from several labs have shown that Hoxa2 null mice 
develop cleft palate defects in vivo (Gendron-Maguire et al.,  
1993; Rijli et al., 1993; Barrow and Capecchi, 1999). We have 
previously demonstrated that Hoxa2 knockdown in whole 
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palatal organ culture explants resulted in failure of the palatal shelves to 
fuse ex vivo (Smith et al., 2009). We have now extended those findings 
by showing that the cleft palate defects in Hoxa2
−/−
 palatal shelves are 
accompanied by elevated levels and spatially expanded expression of 
Six2 protein, as well as increased proliferation of the palatal 
mesenchyme cells. This suggests the possibility that Six2 expression 
within the normally developing SP may positively regulate palatal 
mesenchyme cell proliferation and, furthermore, that the increased 
mesenchymal cell proliferation observed in Hoxa2 null palatal 
mesenchyme may result from increased expression of endogenous Six2. 
This is supported by our observation that, in vivo, the numbers of palatal 
mesenchyme cells that co-express Six2 together with the cell 
proliferation marker Ki-67 are higher in Hoxa2
−/−
 palatal shelves than 
wild-type palatal shelves. Moreover, we demonstrated that treatment of 
wild-type palate mesenchymal cell cultures with Six2 siRNA to 
knockdown Six2 expression led to significant reductions in both cell 
proliferation and Cyclin D1 mRNA levels. Indeed, whereas Hoxa2
−/−
 
MEPM cultures otherwise displayed enhanced cell proliferation, Six2 
knockdown in the Hoxa2 null cultures restored mesenchymal 
proliferation to wild-type levels. 
 
From our findings, it appears likely that increased Six2 expression 
leading to a rise in the level of palatal mesenchyme proliferation is 
responsible, at least in part, for the generation of cleft palate defects in 
Hoxa2
−/−
 embryos. This is consistent with studies from other 
laboratories that have implicated increased mesenchymal proliferation as 
contributing to cleft palate formation in Wnt5a
−/−
 (He et al., 2008) and 
Sprouty2
−/−
 mice (Welsh et al., 2007; Matsumura et al., 2011), as well 
as in embryos expressing Fgf8 ectopically in palatal mesenchyme (Wu 
et al., 2015). Apparently, rates of mesenchymal cell proliferation must 
be tightly regulated for normal growth, morphogenesis and elevation of 
the palatal shelves, with either increased or decreased proliferation of 
palatal mesenchyme potentially leading to cleft palate defects (reviewed 
in Smith et al., 2013). 
 
In summary, our study is the first to specifically investigate the 
expression and cell proliferation function of Six2 in the developing SP. 
We have demonstrated that Six2 mRNA and protein exhibit dynamic 
temporal and spatial expression profiles within the mouse SP from 
embryonic stages E12.5 through to E15.5. We observed that Six2 protein 
is present within both the mesenchyme and epithelium of the developing 
SP; however, its 
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Cleft palate is a common congenital birth defect in humans. In mammals, the palatal tissue can be 
distinguished into anterior bony hard palate and posterior muscular soft palate that have specialized 
functions in occlusion, speech or swallowing. Regulation of palate development appears to be the 
result of distinct signaling and genetic networks in the anterior and posterior regions of the palate. 
Development and maintenance of expression of these region-specific genes is crucial for normal 
palate development. Numerous transcription factors and signaling pathways are now recognized as 
either anterior- (e.g., Msx1, Bmp4, Bmp2, Shh, Spry2, Fgf10, Fgf7, and Shox2) or posterior-specific 
(e.g., Meox2, Tbx22, and Barx1). Localized expression and function clearly highlight the importance 
of regional patterning and differentiation within the palate at the molecular level. Here, we review 
how these molecular pathways and networks regulate the anterior–posterior patterning and 
development of secondary palate. We hypothesize that the anterior palate acts as a signaling center 
in setting up development of the secondary palate. 
 
Keywords: anterior–posterior axis, secondary palate, development, signaling, migration, growth factors 
 
 
INTRODUCTION  
Cleft palate is one of the most common congenital birth defects 
in humans, occurring with a frequency of 1:700 to 1:1000 live 
births (Gorlin et al., 2001). A cleft secondary palate can occur as 
an iso-lated birth defect (non-syndromic), in conjunction with a 
cleft lip, or as a part of another syndrome. Both genetic and 
environ-mental factors play roles in the development of cleft 
palate (Dixon et al., 2011).  
During mammalian embryogenesis, the development of the 
secondary palate is regulated by a number of complex networks of 
growth factors and transcription factors. These molecular networks 
and pathways work together to tightly regulate criti-cal cellular 
processes in the palate including cell proliferation, apoptosis, 
migration, and epithelial-mesenchymal transdifferen-tiation. The 
secondary palate originates from first branchial arch neural-crest 
derived mesenchymal cells covered by a multi-layer sheet of cells 
derived from the facial ectoderm (Noden, 1983). In the mouse, 
bilateral palate shelves first develop as outgrowths from the maxillary 
processes at embryonic day 11.5 (E11.5). The shelves then grow 
vertically down either side of the tongue until E14.0 (Ferguson, 
1988), after which the shelves undergo a rapid elevation to become 
horizontally oriented toward one another above the tongue. Growth 
of the stomodeum as well as jaw joint activity and neuromuscular 
function make it possible for the embryo to have mouth-opening 
reflexes. These movements allow the tongue to flatten and depress, 
and the downward positioned palate shelves to reorient (Humphrey, 
1969; Diewert, 1980). A number of changes occur within the palate 
shelves to facilitate the rapid movement of the shelves from a vertical 
to a horizontal  
 
 
position starting at the anterior end and proceeding posteriorly, 
however, a clear understanding of how elevation occurs has yet to be 
achieved. Ultimately, the elevated palatal shelves then grow toward 
one another until the medial edge epithelium from each shelf contacts 
to form the midline epithelial seam (MES) at E14.5. In addition to 
growth of the palate shelves, a change in the relative dimensions of 
the head (vertical dimensions of the head increase while the lateral 
maxillary width remains constant) allows the palate shelves to 
contact one another at the midline (Diewert, 1978, 1983). Epithelial 
cells from opposing palate shelves adhere to one another through 
glycoproteins on their surface (Greene and Kochhar, 1974; Pratt and 
Hassell, 1975; Souchon, 1975; Greene and Pratt, 1977) as well as 
through desmosomes (De Angelis and Nalbandian, 1968; Morgan 
and Pratt, 1977). Contact and subsequent fusion begins in the anterior 
mid-palate regions and proceeds in both the anterior and posterior 
directions like a zipper (Morgan and Pratt, 1977; Ferguson, 1988). 
The MES then undergoes a rapid degradation to form a secondary 
palate with complete mesenchymal confluence (Ferguson, 1988; 
Berkovitz et al., 2009). Numerous mechanisms for the degradation of 
the MES have been proposed, including epithelial apoptosis 
(Pourtois, 1966; Saunders, 1966; Farbman, 1968; Shuler, 1995; 
Martínez-Álvarez et al., 2000a; Xu et al., 2006), migration (Carette 
and Ferguson, 1992; Shuler et al., 1992; Martínez-Álvarez et al., 
2000a), and epithelial-mesenchymal transformation (Fitchett and 
Hay, 1989; Griffith and Hay, 1992; Shuler et al., 1992; Kaartinen et 
al., 1995; Proetzel et al., 1995; Sun et al., 1998; Cui et al., 2005). 
Epithelial-mesenchymal transformation has been ruled out based on 
fate-maps (Vaziri Sani et al., 2005), but this theory is still 
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unsettled. Mesenchymal confluence signals the end of palatoge-nesis 
at E15.5 (Ferguson, 1988). Finally, the anterior secondary palate 
fuses to the primary palate and the dorsal portions of the secondary 
palate fuse with the nasal septum marking the comple-tion of proper 
palatal development. Distinct pathways/networks regulate 
development at each stage of palatogenesis, with defects at any stage 
capable of resulting in cleft palate. In addition to problems with 
development of the palate proper, defects in the development of other 
craniofacial elements including the tongue and mandible can result in 
a cleft palate (Ferguson, 1987).  
Analysis of the literature on regionally expressed genes can be 
difficult since a standardized method of determining the anterior, 
medial, and posterior regions of the palate is not in place. Many 
authors fail to indicate how they define the region of the palate that 
they are examining making comparison difficult between articles. It 
is important for the field to adopt a standard con-vention for defining 
the anterior, medial, and posterior palate to ensure that these 
comparisons can be made. In the past, the anterior and posterior have 
been described in a number of ways. We propose that the convention 
can be followed such that the tissue anterior or posterior to the first 
molar tooth bud be con-sidered the anterior or posterior palate, 
respectively. The medial palate would be considered palate tissue in 
the plane of the molar tooth bud (Figure 1). The rationale is that the 
first formed palatal rugae (R1) demarcates the expression boundary 
of anterior (e.g., Msx1, Shox2, and Fgf10) and posterior (e.g., Meox2, 
Tbx22) spe-cific genes (Zhang et al., 2002; Yu et al., 2005; Li and 
Ding, 2007; Pantalacci et al., 2008; Welsh and O’Brien, 2009; Bush 
and Jiang, 2012). The first molar tooth bud lies immediately ante-rior 
to the R1, which forms the posterior boundary for anterior Fgf10 
expression (Welsh et al., 2007). On the structural basis, the anterior 
two-thirds of the palate is the future hard palate. During  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 | Schematic representation for defining anterior, medial, and 
posterior regions of palatal shelves. Tissue anterior or posterior to first molar tooth 
is considered anterior or posterior palate, respectively. The palatal tissue in the 
region of first molar tooth bud is considered medial. Abbreviations: PP, primary 
palate; PS, palatal shelves; M1, first molar tooth bud.  
 
 
 
rostral extension of the anterior palate from E11.5 to E14.5, the 
spatial relationship between R1 and the developing molar tooth 
bud remains unchanged (Welsh et al., 2007; Welsh and O’Brien, 
2009), making the molar tooth bud an ideal convention to 
delineate the two structurally distinct regions of palate.  
This review will provide an in depth look at the molecular 
processes involved in regulating the patterning and early devel-
opment of the secondary palate. Genes known to be involved in 
the fusion of the palate processes will not be discussed in detail; 
see Nawshad (2008) for a comprehensive review. The major 
focus here will be to summarize both current information and 
devel-oping new connections between the factors and genes 
involved in specifying and maintaining the A–P axis. We 
hypothesize that the anterior palate acts as a signaling center for 
secondary palate patterning and development. 
 
ANTERIOR-SPECIFIC GENE EXPRESSION  
A large number of anterior-specific genes specifically expressed 
and active within the anterior palate (Figure 2) compared to the 
posterior palate highlights the importance of the anterior region 
during secondary palate development (Zhang et al., 2002; Rice et 
al., 2004; Alappat et al., 2005; Yu et al., 2005; Levi et al., 2006; 
Lee et al., 2007, 2008; Welsh et al., 2007; He et al., 2008; Liu et 
al., 2008). 
 
Msx1 NETWORK  
The first network described to play an anterior-specific role in the 
developing palate involves the homeobox transcription fac-tor 
Msx1. Mutations in the human MSX1 gene have been linked  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2 | Schematic representation of the key regulators in the anterior 
palate. Msx1 and Bmp4 function in an autoregulatory loop mechanism in the 
mesenchyme. Bmp4 induces Shh expression in the epithelium which signals backs to 
the mesenchyme to positively regulate Bmp2 to enhance cell proliferation in the 
mesenchyme. Msx1 expression is controlled by Hoxa2 in early palatal development. 
Fgfs and their receptors are regulated by Spry2 for proper balance of proliferation 
and prevention of premature apoptosis in the epithelium. Fgf10 induces Shh whereas 
Fgf 7 acts as an antagonist. Msx1 also maintains proliferation by inducing Bmp7 in 
the mesenchyme along the nasal epithelium. Genes represented in red are restricted 
to either oral or nasal side of the palate, whereas those represented in blue are present 
across the shelf.  
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to isolated non-syndromic cleft palate (Vastardis et al., 1996; 
Lidral et al., 1998; Van den Boogaard et al., 2000; Suzuki et al., 
2004; Tongkobpetch et al., 2006; Otero et al., 2007). Msx1-
deficient mice display neonatal lethality due to a wide open cleft 
secondary palate (Satokata and Maas, 1994; Houzelstein et al., 
1997). Expression of Msx1 is localized exclusively to the ante-
rior mesenchyme during the early stages of palate development 
from E12.5 to E13.5 (Zhang et al., 2002; Alappat et al., 2003) and 
functions through regulating the expression of Bmp4, Shh, and 
Bmp2 at E12.5–E13.5 in the anterior palate (Zhang et al., 2002). 
Msx1 appears to regulate Bmp4 expression in the ante-rior 
mesenchyme, which subsequently signals to the epithelium and 
regulates Shh expression; from the epithelium Shh then sig-nals 
back to the mesenchyme and regulates Bmp2 expression (Zhang 
et al., 2002). In addition to this linear network, Bmp4 is involved 
in a reciprocal regulatory cycle controlling the expres-sion of 
Msx1. The main function of Msx1 and its subsequent network 
appears to be regulation of cell proliferation within the anterior 
mesenchyme (Zhang et al., 2002). It has been demon-strated that 
although exogenous BMP is capable of inducing Msx1 expression 
and increasing cell proliferation in the anterior palate it has no 
effect on the posterior palate (Zhang et al., 2002; Hilliard et al., 
2005). Since first reported, numerous studies have investigated 
the expression and function of the genes in this net-work. All 
studies performed to date (see below) confirm that this network is 
important in anterior mesenchyme proliferation; how-ever, the 
regulation of each of these genes is far more complex than 
suggested originally. 
 
The regulation of Msx1 expression has been linked to many other 
factors in the palate. Msx1 was shown to be downstream of the Foxe1 
gene with Foxe1 null mice having very low expression of palatal 
Msx1 and Tgf-β3 at E14 (Venza et al., 2011). Loss of the Fgf 
antagonist Spry2 in the piebald deletion animal model (discussed in 
more details in the section “Fgf Signaling Pathway”) results in 
increased Msx1 expression as well as a posterior expansion of its 
expression border at E13.5 and E14.5; this increased expres-sion 
leads to an increase in proliferation within the palate (Welsh et al., 
2007). Msx1 is Fgf-responsive in other regions of cranio-facial 
development (Bei and Maas, 1998; Alappat et al., 2003), although 
Fgf10 null palates do not exhibit altered Msx1 expres-sion (Alappat 
et al., 2005). These data suggest other Fgfs may be acting in the palate 
to regulate Msx1 expression (other pos-sible explanations are 
discussed in subsequent sections below). Fgf9 may play an active role 
in palate development (Colvin et al., 1999, 2001) and loss of Spry2 
may relieve the antagonism of Fgf9 resulting in the observed 
upregulated and expanded Msx1 expres-sion (Welsh et al., 2007). 
Recently, Fgf9 was shown to regulate cell proliferation in palatal 
mesenchyme via Pitx2-dependent induc-tion of cyclin D1 and cyclin 
D3 in the Tgfbr2
fl/fl
; Wnt1-Cre mice (Iwata et al., 2012a), however, 
expression of Msx1 was not exam-ined in this study. Fgf7 is 
expressed within the palate mesenchyme (Rice et al., 2004) and may 
also be involved in regulating Msx1 expression and affected by loss 
of Spry2, although this has not been investigated. 
 
Hoxa2, another homeobox gene, has recently been shown to regulate 
palatal Msx1 expression (Smith et al., 2009). Hoxa2 null mice exhibit 
an 81% penetrance of cleft palate (Gendron-Maguire et al., 1993; 
Rijli et al., 1993; Barrow and Capecchi, 1999), which  
 
 
 
appears to result from increased cell proliferation where expres-
sion levels of both Msx1 and its known down-stream target Bmp4 
are up-regulated during the early stages of palate development 
(Smith et al., 2009). Genetic studies in humans have also linked 
mutations in the HOXA2 gene with a cleft secondary palate 
(Alasti et al., 2008). Hoxa2 acts upstream of Msx1 in the second 
branchial arch neural crest cells (Santagati et al., 2005). This new 
gene tar-get provides additional insight, as Hoxa2 is known to be 
absent from the migrating first branchial arch from which the 
palate shelves arise (Prince and Lumsden, 1994). Clearly 
expression in the branchial arches prior to overt palate growth is 
not a pre-requisite of genes that are important in regulating 
palatogenesis. Whether Hoxa2 and Fgfs represent distinct 
regulatory network of Msx1 or are part of the same regulatory 
network remains to be determined. Strict regulation of Msx1 
expression in the palate is probably due to its importance in 
regulating proliferation in the anterior palate.  
The transcriptional activity of Msx1 can also be altered by other 
proteins in the palate. Msx1 undergoes post-translation 
modification by sumoylation in vivo in a region of the protein that 
is responsible for regulating Msx1 interactions with other proteins 
(Gupta and Bei, 2006). Thus, sumoylation of Msx1 may help 
facilitate its ability to interact with other transcription fac-tors and 
therefore control its ability to regulate the expression of other 
genes. Haploinsufficiency of the SUMO1 gene has been reported 
to lead to cleft palate through altering the sumoyla-tion status of 
various proteins (Eya1, Pax9, and Msx1) in the palate (Alkuraya 
et al., 2006). However, it has also been sug-gested that SUMO1 
expression is not necessary for normal mouse development 
(Zhang et al., 2008). Debates also exist on whether 
polymorphisms of the SUMO1 gene in humans are linked to cleft 
palate (Song et al., 2008; Almeida de Assis et al., 2011). What 
role SUMO1 plays in palate development is therefore unclear at 
this time.  
In addition to regulating Bmp4 and Bmp2, Msx1 regulates the 
expression of Bmp7 and its antagonist Follistatin (Levi et al., 
2006). Loss of Msx1 leads to a decrease in the anterior palatal 
expression of Bmp7 but an increase in its expression in the pos-
terior palate (Levi et al., 2006). The Bmp antagonist Follistatin is 
expressed throughout the palatal epithelium; in the anterior palate 
it is primarily expressed in a restricted dorsal domain that does 
not overlap the regions of Bmp4 and Bmp2 expression (Levi et al., 
2006). Msx1 null mice also exhibit a decrease in the level of 
anterior palatal Follistatin expression (Levi et al., 2006). 
Together, these data highlight the important role of Msx1 in the 
regula-tion of the Bmp family and their antagonists in the palate, 
and provide another mechanism by which it may regulate the 
level of proliferation in the anterior palate.  
Dlx5 is expressed in the anterior mesenchyme of the palate and 
mutations in the Dlx5 gene result in a cleft secondary palate (Levi et 
al., 2006; Han et al., 2009). Furthermore, loss of the transcription 
factor MEF2C consequently leads to loss of Dlx5 expression in the 
branchial arches resulting in a cleft palate (Verzi et al., 2007). 
Although Dlx5 and Msx1 share similar expres-sion domains it is 
unlikely that they are involved in regulating each others expression 
as Msx1 expression is not altered in Dlx5 null palates and vice versa 
(Han et al., 2009). Dlx5/Msx1 double knockouts show a rescue of the 
Msx1 null cleft palate phenotype 
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(Levi et al., 2006; Han et al., 2009). Loss of Dlx5 in Msx1 null 
embryos alters the expression of Shh, Bmp7, and Follistatin in the 
palate. Bmp7 expression in these double knockouts is increased 
throughout the palate, while expression of Follistatin is decreased 
(Levi et al., 2006; Han et al., 2009). Shh expression is decreased in 
Msx1 null palates but its domain is expanded in the double knockouts 
suggesting that both Msx1 and Dlx5 are involved in determining the 
area of Shh expression (Han et al., 2009). Dlx5 and Fgf7 share the 
same expression region in the anterior palate mesenchyme on the 
nasal side. Fgf7 region of expression is lim-ited in Dlx5 null mutants 
as well as in the Msx1/Dlx5 double knockouts (Han et al., 2009). 
These data point toward a sys-tem where Dlx5 regulates the 
expression of Fgf7, which in turn represses Shh. It has also been 
demonstrated that a feedback loop and cross talk exists between 
Bmp7 and Shh, which plays a role in refining the expression domain 
of both genes (Han et al., 2009). Therefore, in the Msx1/Dlx5 double 
knockouts the limited Bmp7 expression allows an increase in Shh 
expression, which likely leads to the observed increase in cell 
proliferation and rescues the Msx1-induced cleft palate. 
 
BONE MORPHOGENIC PROTEIN SIGNALING 
PATHWAYS 
 
Bmp4 is known to be downstream of Msx1 in the palate (Zhang et al., 
2002). However, similar to Msx1, many alternative regula-tory 
pathways for Bmp4 have been described in recent years. The 
transcription factor Tbx3 shows an overlapping expression pat-tern 
with Bmp4 in the developing anterior palate mesenchyme (Lee et al., 
2007). These two genes regulate each other’s expression in the palate 
whereby Tbx3 inhibits the expression of Bmp4 while Bmp4 induces 
Tbx3 expression (Lee et al., 2007). As expected and based on the 
previously reported role of Bmp4 in the palate, this regulatory loop 
acts by regulating the levels of cell prolifer-ation in the anterior 
palatal mesenchyme (Lee et al., 2007). In the limb, Tbx3 expression 
is dependent on Bmp4 (Tümpel et al., 2002) and plays an important 
role in maintaining normal prolif-eration in the region (Davenport et 
al., 2003). Tbx3 null embryos however, do not exhibit a cleft palate 
(Davenport et al., 2003) and therefore the ability of Tbx3 to regulate 
Bmp4 expression and subsequently proliferation may be redundant 
with another regulatory mechanism in the palate. 
 
At the onset of palate development, the transcription factor Tp63 
regulates the expression of Bmp4 in the anterior palate. Loss of 
the Tp63 gene leads to cleft palate through altering the expression 
of a variety of genes (including Bmp4) in the max-illary processes 
from which the palatal shelves emanate. This altered gene 
expression results in defects of the A–P axis as well as the onset 
of palate development (Thomason et al., 2008). These 
observations indicate regulation of gene expression during and 
prior to the overt growth of the palate shelves can influence palate 
development and patterning.  
Bmp4 acts upstream of Shh and Bmp2 within the palate (Zhang et al., 
2002). New studies detail the importance of the Wnt5a sig-naling 
molecule in regulating the A–P axis in the palate including the 
expression of Bmp4 (He et al., 2008). In the absence of Wnt5a 
signaling, Bmp4 expression is down-regulated in the anterior palate 
at E13.5, while being ectopically up-regulated in the pos-terior palate 
(He et al., 2008). As predicted, Shh expression in 
 
 
 
 
the anterior palate and posterior palate correspondingly decreases and 
increases, respectively. Surprisingly, Bmp2 expression was unaltered 
in the Wnt5a null mutants (He et al., 2008), imply-ing Bmp2 
expression in the palate is regulated by an additional mechanism. 
Despite a decrease in Bmp4 and Shh expression, pro-liferation was 
increased in the anterior mesenchyme, which is contrary to what 
would normally be expected (He et al., 2008).  
Noggin is a polypeptide that binds to members of the Bmp family 
preventing them from signaling. Noggin null mice show that without 
Noggin’s repression of Bmp signaling, palate devel-opment does not 
proceed normally, with fusion between the palate and mandible 
ultimately leading to a cleft palate pheno-type. Although Noggin null 
mice did not have changes in the expression of Msx1, Bmp4, or Shh 
they did have reduced Shox2 and Bmp2 expression in the anterior 
palate and an ectopic exten-sion of Bmp2 expression into the 
posterior region of the palate. In addition, decreased proliferation 
rates were seen exclusively in the anterior mesenchyme of Noggin 
null palate which suggests that loss of Bmp2 in the anterior palate 
effects proliferation and sup-ports the theory that posterior cells are 
not receptive to ectopic Bmp expression (Hilliard et al., 2005; He et 
al., 2010).  
The Bmp family plays an important role in maintaining the A–P axis 
of the palate shelves as well as regulating proliferation (Nie, 2005). 
Bmp ligands regulate down-stream gene expres-sion and cell 
processes through activation of cellular receptors. Bmpr1a and 
Bmpr1b are expressed in an overlapping pattern in the anterior palate. 
The Bmp receptor Bmpr1a is essential in the regulation of 
proliferation and patterning in the palate; a total loss of the Bmpr1a 
gene in all craniofacial cells leads to decreased proliferation as well 
as an anterior shift in the expression pat-terns of the posterior-specific 
genes Pax9 and Barx1 (Liu et al., 2005). Conditional loss of Bmpr1a 
in the neural crest and deriva-tives (Wnt1-Cre; Bmpr1a 
f
 
/−
 mice) 
leads to an anterior clefting of the secondary palate resulting from 
decreased mesenchymal pro-liferation (Li et al., 2011). The 
significantly reduced expression of Msx1, Bmp4, Pax9, and Shox2 
may be responsible for the defective cell proliferation. These results 
indicate that although Bmpr1b has a common expression pattern it is 
not able to compensate for the loss of epithelial Bmpr1a expression 
(Li et al., 2011). Interestingly when Bmpr1a is deleted from all 
craniofacial tissue the expres-sion of Msx1 is unaltered (Liu et al., 
2005). Together these data show that the role and number of Bmp 
receptors in the palate is complex and yet to be fully understood. This 
could also imply a novel role for Bmp4 and potentially other Bmps 
acting through the Bmpr1a receptor in regulation of the spatial 
expression of posterior-specific genes. 
 
 
SONIC HEDGEHOG SIGNALING  
Sonic hedgehog (Shh) is expressed in the epithelium through-out 
palatogenesis (Paiva et al., 2010) and proper regulation of the Shh 
signal is crucial for normal palate development to occur. Expression 
is restricted to a striped pattern that corresponds to the rugae (Rice et 
al., 2006). Rugae develop through the thick-ening of the epithelium 
and condensation of the underlying mesenchyme. These rugae are 
suggested to act as centers that coordinate patterning within the palate 
implying an important role for Shh in the patterning of the developing 
palate (Rice et al., 
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2004; Lin et al., 2011). The epithelial cells expressing Shh are not 
actively proliferating, whereas the mesenchymal cells underly-ing 
these regions are more highly proliferative than mesenchymal cells 
in other areas of the palate (Han et al., 2009). Loss of rugae and rugae-
specific morphogens has been suggested to hamper the molecular 
guidance necessary to regulate the growth of the palate. For example, 
loss of Wnt signaling in the palate epithelium blocks the formation of 
the rugae and altered Shh expression which in turn results in abnormal 
extension along the A–P axis and a unique anterior only cleft palate 
phenotype (Lin et al., 2011). Shh is also a down-stream target of the 
Msx1 network that regulates cell proliferation in the anterior palate 
(Zhang et al., 2002). Loss of the Spry2 gene also leads to a 
disorganization in the expres-sion pattern of Shh, which ultimately 
leads to deformities in the rugae in the palate of these knockout 
animals (Welsh et al., 2007). Double null mutants of Fgf intracellular 
antagonists Spry2
−/−
 act as Fgf gain-of-function mutant with highly 
disorganized palatal rugae. Similar rugae disorganization was also 
observed in the con-ditional deletion of Shh (K14-Cre; Shh
fl
 
/fl
 mice) 
(Economou et al., 2012). Their analyses suggests that Fgf acts as an 
activating factor and Shh acts like Spry, functioning as an inhibitor of 
Fgf signaling and of rugae development.  
Gli3, a protein expressed in the epithelium and mesenchyme along 
the entire A–P axis of the palate, is capable of acting as both an 
activator and repressor of Shh signaling (Huang et al., 2008). In the 
absence of the Shh signal, the Gli3 protein is processed by protein 
kinase A allowing it to enter the nucleus and repress the expression 
of Shh target genes. Presence of the Shh signal pre-vents the 
processing of the Gli3 protein, and therefore prevents Gli3 from 
repressing the expression of the Shh target genes (Wang et al., 2000; 
Litingtung et al., 2002). In the limb, an antagonis-tic relationship 
between Shh and Gli3 is crucial in setting up the A–P axis. Gli3 is 
expressed in the anterior region of the devel-oping limb, where it 
represses the expression of Shh. dHAND is a posterior-specific 
protein in the limb that is also repressed by Gli3 but is a known 
activator of Shh expression. Together, this pathway sets up an A–P 
axis in the limb that ensures proper development (Niswander, 2003). 
This important interaction between Gli3 and Shh in the limb in 
combination with the expression of both genes in the palate suggests 
a role for Gli3 in the palate. Not surpris-ingly, Gli3 null mice display 
a cleft secondary palate; however, the cleft palate phenotype was not 
due to changes within the palate itself, but rather due to defective 
growth of the tongue (Huang et al., 2008). These results demonstrate 
that regional differences and signaling pathways are not conserved 
between areas of the developing embryos. Hence, simply lining up 
the expression of all of the players in a pathway within the palate does 
not necessar-ily imply they function by a similar mechanism as 
described for other areas of the developing embryo. 
 
Fgf SIGNALING PATHWAY 
 
Mutations in numerous members of the Fgf family have been 
linked to cleft palate in the human population (Riley et al., 2007). 
The best understood Fgf-dependent pathway in the palate 
involves Fgf10 and its receptor Fgf2rb. Fgf10 null mice exhibit a 
wide open cleft palate that is due to abnormal palate shelf 
morphology and size, preventing the shelves from contacting  
 
 
 
at the MES (Rice et al., 2004; Alappat et al., 2005). In addi-tion, 
ectopic fusion of the palate shelves to the oral epithelium is observed 
in some animals, preventing normal shelf eleva-tion (Alappat et al., 
2005). Similar to Msx1 expression, Fgf10 is expressed primarily in 
the anterior palate mesenchyme at the early stages (E12–E13) of 
palatogenesis (Rice et al., 2004). The Fgf10 ligand acts through the 
receptor Fgfr2b, which also shows an anterior-specific expression 
pattern in areas of epithelium adjacent to mesenchyme expressing 
Fgf10 (Rice et al., 2004). Shh expression is down-regulated in the 
epithelium of both Fgf10 and Fgfr2b null embryos, leading directly 
to a severe reduction in epithelial cell proliferation and a 
consequently thin epithelial layer. Mesenchymal cell proliferation 
also significantly decreases due to a lack of reciprocal Shh signaling 
through its receptor Ptc1 (Rice et al., 2004). As discussed above, 
Msx1 expression is not altered in Fgf10 null mutants (Alappat et al., 
2005), nor is Bmp4 expression. However, the Bmp antagonist 
Sostdc1 does have reduced expression levels in Fgf10 null palates 
(Welsh and O’Brien, 2009). Therefore the altered Shh expression in 
the Fgf10 or Fgfr2b null mice may be due to the decreased 
antagonism on Bmp signaling or directly due to loss of Fgf signaling 
and not through alterations in the Msx1 network. Conditionally 
knocking out all Fgfr2 isoforms exclusively in the epithelium also 
lead to a cleft palate. Once again Shh expression is disordered and 
there is a lack of clearly defined rugae during the time palatogenesis 
nor-mally occurs. In this instance however, cell proliferation is only 
decreased within the epithelium, suggesting that Fgfr2 receptors must 
exist in mesenchymal cells, and be responsible for regulat-ing cell 
proliferation in these cells (Hosokawa et al., 2009). Loss of Fgf 10 
signaling alters cellular processes including apoptosis, suggesting it 
plays a role in cell survival. Fgf10 null mice exhibit premature and 
ectopic fusion indicating that Fgf10 also has a role in ensuring proper 
fusion (Rice et al., 2004).  
While Fgf10 regulates cell proliferation within the anterior palate, 
ectopic exposure to Fgf10 does not bring about a notice-able 
effect on the level of proliferation in the posterior palate (Yu et 
al., 2005), implying the down-stream effectors of Fgf10 
expression must not be present within the posterior region of the 
palate. This provides further evidence the anterior and pos-terior 
regions of the palate are distinct cell populations with very 
different regulatory mechanisms for the same cellular processes.  
In addition to regulating proliferation, apoptosis, and fusion, 
Fgf10 can also induce cell migration within the anterior palate. 
Fgf10 expression is not only localized to the anterior 
mesenchyme but is also higher in the oral region of the anterior 
mesenchyme (Rice et al., 2004). Fgf10 acts as a chemoattractant 
and induces the migration of anterior mesenchyme cells from the 
nasal to the oral side of the palate (He et al., 2008). The loss of 
Fgf10 causes palate shelves to assume an abnormal shape 
(Alappat et al., 2005), which could in part be explained by the loss 
of oral cell migration.  
The Fgf receptor Fgfr1b has also been described as having an anterior 
and nasal specific expression pattern within the devel-oping palate 
(Lee et al., 2008). As with other members of the Fgf family, its 
expression is linked to the regulation of prolifer-ation within the 
anterior palate. Expression of Fgfr1b is negatively regulated by the 
Wnt11 signaling molecule. In return, Fgfr1b 
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negatively regulates the expression of Wnt11 (Lee et al., 2008). At 
early stages (E13.5) of palate development, the balance is tilted 
toward Fgfr1b allowing the palate to undergo cell proliferation. 
However, as palate development proceeds (E14), the expression 
balance is shifted away from Fgfr1b. At this stage proliferation must 
temporarily halt in order for the individual palate shelves to fuse and 
form a complete palate (Lee et al., 2008). Thus, although the most 
obvious role for the Fgf family is in regulating the level of 
proliferation within the palate, the Fgf family also plays a role in 
regulating events such as fusion by maintaining minimal expression 
of certain genes until the appropriate time.  
As discussed above, one specific animal model showed that loss of 
the Fgf antagonist Spry2 leads to a cleft palate due to alterations in 
the level of cell proliferation within the palate as well as the 
expression profiles of numerous genes including Msx1 (Welsh et al., 
2007; Matsumura et al., 2011). Spry2 is expressed in the epithelium 
and mesenchyme at consistent levels through-out palatogenesis 
(Matsumura et al., 2011). The animal model discussed above has a 
piebald deletion, which is a collection of overlapping Mb-scale 
chromosomal deficiencies which includes the Spry2 gene (Welsh et 
al., 2007), while another is a single specific knockout of the Spry2 
gene (Matsumura et al., 2011). Earlier reports from the group that 
developed the animal model lacking exclusively Spry2 indicated that 
animals were not shown to have a cleft palate (Shim et al., 2005; 
Taketomi et al., 2005), however more recent reports have shown a 
prevalence for cleft palate (Matsumura et al., 2011). The piebald 
deletion led to a high incidence of cleft palate while the targeted 
deletion of Spry2 only displayed the cleft palate phenotype in 
approximately 20% of animals. The differences in incidence rates are 
likely due to other defects resulting from the Mb-scale of the piebald 
deletion. Both mutants showed that a loss of Spry2 expression leads 
to an increase in the level of cell proliferation in the palate (Welsh et 
al., 2007; Matsumura et al., 2011) which could be expected since its 
absence relieves inhibition on Fgf signaling which has been reported 
to control proliferation rates (Rice et al., 2004; Alappat et al., 2005). 
Also seen in both mutant animal models was altered Msx1 
expression. The true knockout model showed an increase in the level 
of Msx1 expression, although region specific expression was not 
investigated (Matsumura et al., 2011). The piebald muta-tion initiates 
a posterior expansion of Msx1 coinciding with a loss of the anterior 
expansion of the posterior-specific transcription factor Tbx22. While 
Tbx22 expression fails to reach its normal anterior expression 
boundary, Etv5 and Barx1, which are primar-ily expressed in the 
posterior palate, expand their domains to the anterior (Welsh et al., 
2007). These results suggest antagonism of Fgfs by Spry2 affects a 
number of networks in the palate lead-ing to gross changes in their 
expression patterns. Further analysis will be required to determine, 
which other factors are involved with the high rate of cleft palate in 
the piebald deletion mice. Although Fgf signaling is necessary for 
palate development, its action appears to require fine-tuning by 
repressors for normal palatogenesis to occur. 
 
 
 
Shox2 NETWORK 
 
Fgf10 expression is down-stream of the homeobox transcrip-tion 
factor Shox2 (Yu et al., 2005). The Shox2 gene is expressed  
 
 
 
exclusively in the anterior mesenchyme region of the developing 
secondary palate, with its highest expression occurring during the 
early stages of palate development. Mice deficient in the Shox2 
gene exhibit a rare form of cleft palate where the cleft only occurs 
in the anterior part of the secondary palate. Expression of a 
number of genes critical for palatogenesis such as Jag2, Lhx8, 
Osr2, Pax9, Tgfb3, and Msx1 and its down-stream target Bmp4 
do not change in the Shox2
−/−
 palatal shelves (Yu et al., 2005). 
However, expression domains of both Fgf10 and Fgfr2c are 
altered, which corresponds with altered proliferation and apop-
tosis within the anterior palate in the Shox2 null mice (Yu et al., 
2005). These data indicate altering the expression of genes only 
in one area of the palate can lead to clefting only in that spe-cific 
area. However, Msx1 is also expressed in the very anterior region 
of the palatal shelves and yet in Msx1 null mice a com-plete cleft 
of the secondary palate is observed (Zhang et al., 2002) as it is in 
the Fgf10 
−/−
 mice (Rice et al., 2004; Alappat et al., 2005). It is 
not known precisely why Shox2 exhibits this unusual anterior 
cleft. It may be that increased Fgf10 expres-sion is sending a 
signal to the posterior palate to fuse (Yu et al., 2005).  
While regulation of the Shox2 gene has been the subject of recent 
investigations in palate development, a complete under-standing 
of Shox2 regulation remains elusive (Yu et al., 2005). Blocking 
of Bmp signaling with the antagonist Noggin results in a down-
regulation of Shox2 expression within the exposed anterior 
mesenchyme at E12.5. Exposure of palatal mesenchyme to 
Bmp4, Bmp2, and Shh in culture is not sufficient to induce Shox2 
expres-sion. These data suggest Bmp signaling is not capable of 
inducing Shox2 expression on its own but is necessary for normal 
Shox2 gene expression (Yu et al., 2005). 
 
EPHRIN SIGNALING  
Ephrin-B1 belongs to the transmembrane B-type subfamily of 
Eph/Ephrin signaling molecules (Davy and Soriano, 2005). These 
signaling molecules have the ability to carry out bidirectional sig-
naling. Hence, cells expressing the Eph receptor tyrosine kinase can 
receive a forward signal whereas cells expressing ephrin (Efn) can be 
transduced to receive the reverse signal (Bush and Jiang, 2012). The 
Efnb1 gene is expressed in the mesenchyme of the anterior palate 
throughout the secondary palate devel-opment. Efnb1 forward signals 
to regulate anterior palatal shelf outgrowth by promoting cell 
proliferation through the activa-tion of ERK/MAP pathway (Bush 
and Soriano, 2010). Both Efnb1 null mice and Efnb1
+/−
 
heterozygous female mice develop cleft palate with decreased cell 
proliferation in the anterior palatal mes-enchyme (Bush and Soriano, 
2010). The Efnb1 gene is X-linked and the Efnb1
+/−
 heterozygous 
embryos exhibit mosaic pattern of Efnb1 expression in the palate that 
correlates with a mosaic pat-tern of proliferation and hence a more 
severe dysmorphogenesis of the palatal shelves compared to Efnb
−/−
 
null mice. Efnb1 is pri-marily expressed in the anterior mesenchyme, 
although the cleft palate phenotype was along the entire axis (Bush 
and Soriano, 2010). In contrast, loss of Shox2 (described above) 
which is also anteriorly restricted in the palate, induces a unique 
anterior-delimited cleft palate (Yu et al., 2005). Hence, reduced 
Efnb1 signaling in the anterior palatal mesenchyme in Efnb
−/−
 null 
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or Efnb1
+/−
 heterozygous embryos may cross a threshold A–P 
position at which initiation of fusion is required (Bush and 
Soriano, 2010). 
 
Tgf-β PATHWAY  
The role of Tgf -β family members in palatal shelf growth and fusion 
is an area that has been well-studied. Loss ofxd func-tion of Tgf-β2 
(Sanford et al., 1997), Tgf-β3 (Kaartinen et al., 1995; Proetzel et al., 
1995; Martínez-Álvarez et al., 2000b), and Tgf-β receptors Tgfbr1 
(Dudas et al., 2006), Tgfbr2 (Ito et al., 2003; Xu et al., 2006) are 
known to cause cleft palate. More detailed information on this 
pathway was reviewed recently in Bush and Jiang (2012). In the 
context of this review, we will only highlight the anterior and 
posterior-specific roles of these pathway members. The Tgf type I 
receptor Alk5 is expressed exclusively in the anterior palatal 
epithelium and its activation in Tgf -β3
−/−
 palatal epithelium rescues 
palatal fusion, whereas loss of Alk5 function in epithelium of wild-
type palatal shelves prevents palatal fusion (Dudas et al., 2004). 
Interestingly, fusion of the posterior parts of palates is predominant 
following acti-vation of Alk5 at E14 whereas its activation at E13.5 
also facil-itates fusion in the anterior region (Dudas et al., 2004). 
Thus, there appears to be an anterior to posterior direction of palatal 
fusion (Taya et al., 1999) with Tgf -β3 signaling mediated by Alk5 in 
the anterior epithelium (Dudas et al., 2004). The homozy-gous knock-
in of Tgf-β1 in the Tgf-β3 locus partially rescues the cleft palate 
phenotype of Tgf-β3
−/−
 mice in the anterior palate (Yang and 
Kaartinen, 2007). Since Tgf-β1 is expressed in the palatal epithelium 
along the A–P axis (Yang and Kaartinen, 2007), its partial rescue of 
anterior palatal fusion may also be mediated via Alk5 signaling in 
Tgf-β3
−/−
 mice. Recent find-ings show that craniofacial 
abnormalities in Tgfbr2 
−/−
 mice is prevented following genetic 
manipulation of an alternative non-canonical TGF-β signaling 
pathway through Alk5/Tgf type 
 
III receptor complex and SMAD-independent TRAF6/TAK1/p38 
signaling (Iwata et al., 2012b). The role of Tgf-β3 in apoptosis of 
medial edge epithelium (MEE) is well-established (Martínez-
Álvarez et al., 2000a,b) and Tgf-β3 synthesized at the MEE 
facilitates accumulation of chondroitin sulfate proteoglycans at 
apical surface of MEE (Gato et al., 2002). Loss of Tgf-β3 dis-
rupts the normal distribution of E-cadherin, α-, and β-catenins in 
MEE and impairs cell-cell adhesion (Tudela et al., 2002). 
Conditional deletion of β-catenin in the epithelium in K14-Cre 
transgenic mice suppresses canonical Wnt signaling giving rise to 
an abnormal and persistent MES. Loss of β-catenin also induces 
down-regulation of Tgf-β3 and inhibition of apoptosis in MEE 
that subsequently leads to a cleft palate phenotype (He et al., 
2011). Hence, region specific expression of Tgf-β3 is essen-tial 
for proper palate development and these findings highlight the 
interplay between the various pathways that govern palate 
development. 
 
POSTERIOR-SPECIFIC GENE EXPRESSION  
Although many genes important in palate development have 
regional specific expression and are expressed predominantly in 
the anterior palate, several genes are also important in the 
posterior region (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3 | Schematic representation of the key regulators in the posterior 
palate. Barx1 and Tbx22 induce cell proliferation in the posterior palate. Hoxa2 
also controls the expression of Barx1 in the early stage of palatogenesis. Mn1 
positively regulates Tbx22 and represents the first network determined to 
specifically regulate the level of proliferation in the posterior palate. Meox2 plays 
role in fusion of the posterior palate.  
 
Meox2 NETWORK  
Meox2 is a homeobox transcription factor with a posterior-specific 
expression pattern that becomes increasingly localized to the extreme 
posterior region of the palate as development pro-ceeds (Jin and 
Ding, 2006; Li and Ding, 2007). Mice lacking the Meox2 gene exhibit 
a low penetrance of cleft palate that results from a novel mechanism. 
Palate shelves grow, elevate and fuse; however, fusion is weak and 
as the craniofacial region expands the palate shelves pull apart from 
one another leading to a cleft palate specifically in the posterior 
region. Histological analysis of the cleft palates clearly show the 
palate shelves were completely absent of the medial epithelial edge 
and were composed solely of mes-enchyme. The mechanism 
responsible for the post-fusion cleft palate is not completely clear, but 
may involve a palatal growth defect in the posterior palate that 
prevents the palates from being able to keep up with the rest of 
craniofacial development (Jin and Ding, 2006). Alternatively, the 
loss of Meox2 may lead to improper palatal fusion and a weak seam 
that does not stand up to the mechanical forces of craniofacial 
development (Jin and Ding, 2006). Meox2 has been reported to be 
Tgf-β responsive in the mammary epithelial cells by inhibiting 
epithelial cell proliferation by binding to the promoter of p21 through 
Tgf- β/Smad signal-ing pathway (Valcourt et al., 2007). Interestingly, 
Xu et al. (2008) showed that p21 is required for Smad4 mediated p38 
MAPK path-way for apoptosis and MES degeneration. These works 
suggest that Meox2 could play a role in Tgf-β3 mediated fusion. 
However, these mechanisms need to be investigated further. 
 
Tbx22 NETWORK 
 
Tbx22 also has a posterior-specific expression profile within the 
developing palate (Herr et al., 2003). The Tbx22 gene is a T-box 
protein that acts as a transcription factor regulating the expres-
sion of down-stream genes. Alterations in the Tbx22 gene are a 
common single cause of cleft palate in humans (Marçano et al., 
2004). A missense mutation in the Tbx22 gene is responsible for 
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X-linked cleft palate (Marçano et al., 2004), whereby the mis-sense 
mutation affects the ability of Tbx22 to bind DNA and subsequently 
act as a transcriptional repressor (Andreou et al., 2007). This 
mutation is believed to prevent the SUMO-1 enzyme from 
sumoylating the Tbx22 protein. In the absence of this post-
translational modification, Tbx22 has a much lower affinity for its 
DNA binding sequence (Andreou et al., 2007), cannot recognize the 
DNA sequence and bind appropriately, and does not per-form its 
normal repressor functions. Notably, SUMO-1 is again implicated in 
regulating palatogenesis. Based on the number of important genes 
known to require sumoylation to function prop-erly, 
haploinsufficiency of SUMO-1 is not surprisingly linked to cleft 
palate phenotype (Alkuraya et al., 2006).  
Tbx22 expression in Spry2 piebald mutants is affected as dis-cussed 
above. In the absence of this Fgf antagonist, the expression of Tbx22 
fails to expand from the most posterior regions of the palate at E14.5. 
This altered expression profile coincides with a posterior shift in the 
expression of Msx1 as well as an increase in proliferation throughout 
the palate shelves (Welsh et al., 2007). The 5 regulatory region of the 
Tbx22 gene contains putative Msx1 binding sites (Herr et al., 2003), 
however, Msx1 null mice do not show an expansion of the Tbx22 
expression domain (Fuchs et al., 2010), and Tbx22 null mice are not 
reported to have increased Msx1 expression (Pauws et al., 2009). 
Palatal Tbx22 expression has been demonstrated to be independent of 
Fgf signaling, but was reported to be repressed in culture by 
exogenous Bmp4 (Fuchs et al., 2010). Taken together this suggests a 
system whereby Msx1 is involved in regulating Bmp4 expression 
which subsequently plays a role in the repression of Tbx22 
expression, leading to a posterior-specific expression pattern.  
Liu et al. describe a novel molecular network involving the Tbx22 
(Liu et al., 2008). The transcription factor Mn1 has a medial-
posterior-specific expression profile that generally over-laps the 
Tbx22 expression profile. Loss of one or more copies of Mn1 
leads to craniofacial abnormalities including a cleft secondary 
palate. In the Mn1 null embryos, Tbx22 expression decreases in 
the posterior region of the palate, and Mn1 directly regulates the 
expression of Tbx22 in the palate (Liu et al., 2008). A marked 
decrease in proliferation in the medial and posterior palate shelves 
also occurs, and is believed to be due in part to the regulation of 
a separate gene target (Ccnd2) by Mn1 (Liu et al., 2008). This 
represents the first network determined to specifically regulate the 
level of proliferation in the posterior palate. Tbx22 expression 
appears to be regulated by at least two factors; Msx1 acts as a 
repressor, while Mn1 acts as an activator, and together they 
determine the specific expression domain of Tbx22 in the 
posterior region of the palate. 
 
Barx1 NETWORK  
Barx1 expression has a predominantly posterior expression pro-
file that is complementary to the anterior expression of Msx1 
(Barlow et al., 1999; Welsh and O’Brien, 2009). This region-
specific expression is initially set up in the branchial arches where 
Msx1 expression is localized to the distal regions of the first 
brachial arch and Barx1 expression is localized proximally 
(Barlow et al., 1999). The A–P axis derived from the regional 
expression of Msx1 and Barx1 is believed to result from the  
 
 
 
relative strength of Bmp and Fgf signaling (Welsh et al., 2007). The 
expression of Barx1 is altered in a number of knockout mouse lines. 
Loss of Spry2 via the piebald deletion not only affects Msx1 and 
Tbx22 expression, but also leads to an anterior expansion of Barx1 
expression that may be involved in the increased cell proliferation 
seen in these palates (Welsh et al., 2007). The loss of the Bmp 
receptor Bmpr1a also leads to an expansion of the region in the palate 
expressing Barx1 (Liu et al., 2005). Hoxa2 null embryos have 
increased Barx1 expression at the early stages of palate development. 
An increase in the level of cell proliferation in the posterior region of 
the palate is also observed in Hoxa2 null mice (Smith et al., 2009). 
The alterations in both Fgf and Bmp signaling causing altered Barx1 
expression support the view that regulation of the regional expression 
of Barx1 involves both fami-lies of signaling molecules. Evidence for 
this comes from Tp63
−/−
 mice where expression of Fgf8 at E11.5 in 
the anterior region of maxillary processes is down-regulated, which 
coincides with a reduced anterior expression of its target gene Barx1 
(Thomason et al., 2008). In contrast, the Tp63
−/−
 mice (which exhibit 
cleft lip and palate phenotype) show increased expression of Bmp4 in 
the anterior region of the maxillary processes at E10.5 and E11.5. 
Barx1 is also regulated by relative levels of Fgf8 and Bmp4 in 
developing chick facial primordia where BMPs reduce Barx1 
expression and antagonize Fgf-8 signaling (Barlow et al., 1999). 
 
AT WHAT STAGE DOES THE ANTERO-POSTERIOR 
MOLECULAR SIGNALING GET ESTABLISHED?  
An intriguing question during palatal development is when does the 
antero-posterior molecular signaling get established? Although 
answer to this remains elusive, available data indicates a much earlier 
time in development and prior to palatal shelf formation. The anterior 
localization of Msx1 and posterior local-ization of Barx1 is set to be 
determined in the first branchial arch where Msx1 is localized to distal 
and Barx1 to the proximal region (Barlow et al., 1999). In early mice 
palatal development, Barx1 expression is visible in the posterior 
region extending through almost three quarters of the developing 
palatal shelves, whereas Msx1 is restricted to a narrow anterior region 
of the developing palate (Welsh and O’Brien, 2009). Following 
rostral expansion, the anterior palate extends with the expression of 
Msx1 and the first molar tooth bud serves as the posterior boundary 
of this extended anterior expression (Welsh and O’Brien, 2009). 
Hence, genes expressed in the presumptive hard and soft palate 
appear to be set up earlier along an A–P axis in the branchial arches. 
Consistent with this expression along an A–P axis in the first arch, 
Msx1 plays a role in incisor development and Barx1 in molar tooth 
development (reviewed in Mitsiadis and Smith, 2006). Interestingly, 
Bmp-Fgf signaling also governs tooth development in a gradient 
manner along an A–P axis (Mitsiadis and Smith, 2006). It is likely 
these genes play a similar role in the orofacial structures. Indeed 
similar to its role in palate development where Bmp4 is required to 
prevent the premature apoptosis of palatal epithelium, Bmp4 is 
essential in blocking apoptosis in the dental epithelium in a Msx1-
dependent manner regulated by Tgf-β type I receptor Alk-5 (Zhao et 
al., 2008). 
 
The transcription factor Tp63 regulates the expression of Bmp4 in 
the anterior palate and loss of Tp63 in the maxillary 
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processes in the medial region from which the palatal shelves 
originate, results in improper Bmp signaling and a cleft palate 
phenotype (Thomason et al., 2008). However, conditional inac-
tivation of Bmp4 in the early maxillary mesenchyme using Nestin 
cre;Bmp4 
null
 
/flox
 (n/f) mice did not disrupt secondary palate 
development but resulted instead in isolated cleft lip (Liu et al., 
2005). Loss of Bmpr1a in facial primodia of Nestin cre;Bmpr1a n/f 
embryos, which did not impact Msx1 expression, resulted in reduced 
mesenchymal cell proliferation in maxillary process prior to the onset 
of secondary palate outgrowth resulting in smaller palatal shelves and 
subsequent cleft palate at birth (Liu et al., 2005). In contrast, tissue-
specific loss of Bmpr1a in palatal mesenchyme in Osr2-
IresCre;Bmpr1a
f
 
/f
 mutant mice results in reduced expression of 
Msx1 and an up-regulation in Bmp4 lead-ing to submucous cleft of 
the hard palate (Baek et al., 2011). Thus, the BMP family highlights 
the complexity of signaling involved in their early tissue specific role 
in orofacial development. Further early fate determination studies are 
needed using lineage specific animal models to characterize the 
complex signaling during early palate development to clearly 
determine the origins of the A–P molecular signaling. 
 
 
 
mesenchyme. Bmp4 induces Shh expression in the epithelium 
which signals backs to mesenchyme to positively regulate Bmp2 
to enhance cell proliferation in the mesenchyme (Zhang et al., 
2002). Cross talk also exists between Bmp7 and Shh, which plays 
a role in refining the expression domain of both genes (Han et al., 
2009). Tbx3 and Bmp4 regulate each other’s expression in the 
palate. Tbx3 inhibits the expression of Bmp4 while Bmp4 induces 
Tbx3 expression and regulates the levels of cell proliferation in 
the anterior palatal mesenchyme (Lee et al., 2007). Regulatory 
feedback loop exists between Fgfr1b and Wnt11. Fgfr1b 
represses expression of Wnt11 whereas Wnt11 signaling molecule 
nega-tively regulates Fgfr1b expression (Lee et al., 2008). 
Balance is titled toward or away from Fgfr1b, to respectively 
allow cell pro-liferation to proceed (at E13.5) or to recede (at E14) 
and fusion to occur (Lee et al., 2008). Unlike the anterior palate, 
molecular mechanisms of palatal outgrowth in the posterior 
palatal regions are not yet well established. Mn1 directly regulates 
the expres-sion of Tbx22 in the palate (Liu et al., 2008) and Msx1 
acts as a repressor of Tbx22 in the palate (Welsh et al., 2007) 
which together determines the posterior expression domain of 
Tbx22 in the palate. 
 
 
CROSSTALK BETWEEN NETWORKS/PATHWAYS  
Palatal elevation and fusion is governed by transcription fac-tors, 
various growth factors and their receptors forming inter-connected 
network of molecular pathways. Relative signals or gradients are 
strictly required to ensure proper development. The anterior and 
posterior palatal tissues being the future hard and soft palates differ 
in function and structure, show differ-ence in the expression patterns 
along the A–P axis. Numerous pathways/networks in the palate 
clearly display reciprocal signal-ing between the epithelium and 
mesenchyme. Genes expressed exclusively in the epithelium have 
been reported to regulate cel-lular processes and gene expression in 
the mesenchyme, and vice versa, such that reciprocal signaling 
occurs between the epithe-lium and mesenchyme (Zhang et al., 2002; 
Yamamoto et al., 2003; Rice et al., 2004; Nawshad et al., 2007). In 
recent years it has become increasingly evident that gene expression 
in the developing palate not only displays epithelial-mesenchymal 
speci-ficity, but also anterior–posterior (A–P) and oral-nasal 
specificity (reviewed in Murray and Schutte, 2004; Hilliard et al., 
2005; Bush and Jiang, 2012). Interestingly, Tp63 null mutants have 
abnormal outgrowth of the palate initially but by E12.5 the A–P 
specific expression patterns were normal despite abnormal shelf 
growth confirming the importance of setting up and maintaining the 
A–P axis (Thomason et al., 2008). In addition to their localized 
expression, genes have been reported to elicit different responses in 
different regions of the palate. For example, while exogenous Fgf10 
alters proliferation in the anterior palate, it has no effect on 
proliferation in the posterior region of the palate (Yu et al., 2005). 
Such localized expression and function phenomena clearly highlight 
the importance of regional patterning and differentia-tion within the 
palate at the molecular level. Overall, the number of genes involved 
in the development of the palate that dis-play strictly regulated 
domains of expression is clear evidence of regional differentiation 
within the palate. Msx1 and Bmp4 func-tion in an autoregulatory loop 
mechanism in the anterior palatal  
  
ANTERIOR PALATE-SIGNALING CENTER  
Critical events such as elevation, maturation and fusion of sec-
ondary palatal shelves follow an anterior to posterior sequence 
(Taya et al., 1999; Dudas et al., 2004) (Figure 4). During mouse 
palate development, at embryonic day E13.5–E14, the ante-rior 
palate orients horizontally above the tongue when the pos-terior 
palate is still lying vertically (Kaufman, 1992) providing a clear 
indication of the more dynamic growth in the anterior palate 
compared to the posterior palate. In addition, the initial site of 
apposition and subsequent fusion of the palatal shelves occur first 
in the anterior half of the palate and the sequence of palatal 
closure may be result of signaling activity along the A–P axis.  
Although Shox2 expression remains anterior-specific through-out 
palatogenesis, it displays a dynamic pattern of expression. At the 
initial stages of palate growth, Shox2 expression is only detected in 
the most extreme anterior regions of the palate (less than 25% of the 
length of the palate) (Yu et al., 2005; Li and Ding, 2007). As the 
palate shelves continue to grow, the expression of Shox2 expands 
until E14.5 when it covers the entire anterior palate and most of the 
medial palate (60% of the length of the palate shelf). Concurrent with 
the expansion of Shox2 expres-sion, the region of the palate 
expressing the posterior-specific gene Meox2 shrinks (Li and Ding, 
2007). This phenomenon demonstrates normal development of the 
anterior palate requires recruitment of cells from the posterior, which 
are converted into Shox2 anterior-specific cells. This has been 
suggested to be due to a repression of Meox2 by Shox2 or a down-
stream target of the Shox2 pathway (Li and Ding, 2007). 
 
The rugae have been suggested to play an important role in 
organizing and maintaining the A–P axis (Welsh et al., 2007; 
Pantalacci et al., 2008; Welsh and O’Brien, 2009). Rugae have been 
shown to form in the region between the last formed and rugae 8 (the 
first rugae to form) in a sequential order (Pantalacci et al., 2008; 
Welsh and O’Brien, 2009). Rugae 8 has been denoted the “boundary 
rugae” as it appears to act to separate the anterior 
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FIGURE 4 | At E13.5, the anterior palatal shelves first flip up to orient vertically when the 
posterior palatal shelves are still lying horizontal to each other (A). At E14, the posterior 
palatal shelves follow the anterior palatal shelves in orienting vertically, whereas the anterior 
palates begin to grow vertically toward each other to make contact (B). At E15, the anterior 
palatal shelves have made contact and fused, whereas the posterior shelves grow vertically 
(C). At E15.5, both the anterior and posterior palates have fused (D). At E16, the fusion 
between the primary and secondary palate occurs at the future secondary choana (E). Palatal 
shelves are divided into anterior (pink) Msx1 and posterior (aqua) Barx1 expression domains 
(A–E) representing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
future hard and soft palate, respectively. Fgf-Bmp gradients/thresholds maintain 
proper palatal growth and fusion through proliferation. Anterior Fgf10 and Bmps 
control proliferation via Shh expression. This directs anterior palate flip up and 
vertical growth at E13.5–E14 (A,B). Anterior Fgf-Bmp gradients along with 
posterior Fgf8 regulate proliferation and growth via Barx1 in the posterior palate at 
E14–E15 (B,C). Fusion is initiated at the anterior palate by Tgf-β3 through its 
receptor (C). Then the fusion extends posteriorly through Tgf-β-Meox2 (D). The 
fusion between the primary and secondary palate marks the completion of palatal 
fusion at E16 (D,E), via Bmpr1a mediated Shox2 and Tgf β signaling through its 
receptors.  
 
 
and posterior domains of the palate. Throughout palatal devel-
opment, expression of the anterior specific markers Shox2 and 
Msx1 remain anterior to rugae 8 and Meox2 and Tbx22 stay poste-
rior of this boundary (Pantalacci et al., 2008; Welsh and O’Brien, 
2009). This rapid expansion of the palate anterior to rugae 8 
provides an alternate explanation for the anterior growth of the 
palate to the one detailed above by Li and Ding (2007). The major 
difference is that Li and Ding did not detect differences in the 
proliferation rates of the anterior and posterior palate, while 
Pantalacci et al. (2008) did detect a higher level in the anterior 
palate. Which theory is deemed to be correct will require further 
investigations.  
Mice lacking expression of either Wnt5a or its noncanoni-cal 
receptor Ror2 were found to exhibit a cleft palate (Schwabe et al., 
2004; He et al., 2008). In addition, both genes were shown to 
exhibit an expression pattern whereby their expression was  
 
 
higher in the anterior palate than the posterior palate (He et al., 
2008), with Wnt5a detected exclusively in the mesenchyme 
(Paiva et al., 2010). The Wnt5a signal was consequently shown to 
act as a chemoattractant causing cells to migrate from the 
posterior region of the palate toward the anterior region. Evidence 
sug-gests that Ror2 mediates the role of Wnt5a in the 
palatogenesis (He et al., 2008). As discussed above, Wnt5a also 
regulates the expression of Bmp4 and Shh, both of which play 
important roles in the development and growth of the anterior 
palate (He et al., 2008). Hence, simple upregulation of Shox2 and 
downregulation of Meox2 may not result in the conversion of 
posterior cells to anterior cells if the cells are migrating toward 
the higher Wnt5a signal. As cells enter the anterior region of the 
palate, Wnt5a and potentially other factors may act to alter the 
expression pro-file of genes in the cells, causing them to 
transdifferentiate into anterior-specific palate cells. 
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Collectively, these recent discoveries, suggest that cells may 
migrate—first from the posterior region of the palate to the ante-rior 
region of the palate and then to the oral region of the anterior palate—
underscore the dynamic processes taking place during palate 
development. While at any given time cells display a spe-cific set of 
genes that determine how they react to external stimuli, this set of 
factors continually changes as development proceeds. In addition, the 
migration to the anterior region of the palate specifically lends further 
support to the theory the anterior palate plays a role as a signaling 
center acting to regulate palatogenesis as a whole. It also 
demonstrates the importance of maintaining a proper anterior to 
posterior axis in the palate development. 
 
CONCLUSION  
Regulation of palate development appears to be the result of dis-tinct 
pathways in the anterior and posterior regions of the palate. 
Development and maintenance of expression of these regional-
specific genes is crucial to normal palate development. Anterior-and 
posterior- specific genes appear to act in a mutually exclusive 
 
 
 
manner by either directly or indirectly inhibiting reciprocal 
expression.  
Recent findings show posterior palate cells maintain the abil-ity 
to transform into anterior specific cells upon migration. These 
data demonstrate the plasticity of these cell populations despite 
their differential responses to external stimuli.  
To date, researchers have often limited their investigations to 
determining levels of gene expression of putative targets. 
However, the future of palate research will need to consider the 
regional specificity of target genes. An important focus of new 
studies should be to examine the expression domains of potential 
targets along the A–P axis, as expansion or limitations of these 
domains can dramatically affect palate development. 
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